Effects of aspirin, ace-inhibitors/sartans and statins on neoplastic and pre- neoplastic lesions of the pancreas by Valente, Roberto
    PhD Doctoral Thesis 
1 
 
 
 
 
 
 
 
 
 
 
 
Effects of Aspirin, Ace-Inhibitors/Sartans and Statins on Neoplastic and Pre-
Neoplastic Lesions of the Pancreas 
 
 
 
PhD Candidate: Dott. Roberto Valente, MD, Gastroenterologist  
Main Supervisor: Dott. Gabriele Capurso, MD, Gastroenterologist, PhD 
 
                                                                                                    
PhD Course Director:  
Prof. Bruno Annibale, MD Gastroenterologist, Professor of Gastroenterology and Hepatology 
Chief of Gastroenterology Unit, Sant’Andrea University Hospital, Sapienza University of Rome, Rome, 
Italy 
Residency Director of Gastroenterology and Hepatology 
    PhD Doctoral Thesis 
2 
 
Background: ………………………………………………………………………………………………………………………………………………………….……..….3 
Aims: ……………………………………………………………………………………………………………………..………………………………………………………..7 
Materials and methods: ……………………………………………..……………………………………………..…………………………………………………….8 
Paper I…………………………………………………………………………………………………………….…………………………………………………8 
Study design and patients……………………………………………………………………..……….….……………………………………………....8 
Statistical analysis…………………………………………………………………………………………….………………………………………………10 
Results………………………………………………………………………………………………………..……………………………………………………10 
Paper II…………………………………………………………………………………………………………………………………………………………….18 
Study design and patients……………………………………………………………………..………………………………………………………….19 
Statistical analysis…………………………………………………………………………………………………………………………………………….20 
Results………………………………………………………………………………………………………………………..……………………………………21 
Paper III……………………………………………………………………………………………………………………………………………………………30 
Study design and patients……………………………………………………………………..……..…………………………………………………..30 
Statistical analysis…………………………………………………………………………………………………………………………………………….33 
Results……………………………………………………………………………………………………………………………………………………………..34 
Paper IV……………………………………………………………………………………………………………………………………………………………41 
Study design and patients…………………………………………………………………………………………………….…………..………………42 
Statistical analysis…………………………………………………………………………………………………………………………………………….43 
Results……………………………………………………………………………………………………………………………………………………………..44 
Discussion: …………………………………………………………………………………………………………………………………………………………………….51 
Conclusions: …………………………………………………………………………………………………………………………………………………………………..60 
References: ………………………………………………………………………………………………………………….………………………………………………..61 
Papers:……………………………………………………………………………………………………………………………………………………………………………65 
 
 
 
 
    PhD Doctoral Thesis 
3 
 
Background:  
Pancreatic cancer is expected to become the third cause of cancer related death within 2030.(1) In the 
last decades, the spread use of cross-sectional imaging and the progressive quality improvement of 
abdominal imaging, has led to a more frequent detection of pancreatic cystic neoplasm, whose actual 
prevalence is estimated to be around 45%. (2, 3)  
Intrapapillary mucinous neoplasms (IPMNs) represent circa half of these lesions and are increasingly 
considered as possible precursor lesions of pancreatic cancer. (4)  According to the isolated, combined 
or absent cystic involvement of the main pancreatic duct are divided into main duct (MD), mixed 
type(MT) and branch duct (BD) IPMNs. The increasing of pancreatic IPMNs detection, will probably 
represent in the next future, the only possibility to address pancreas cancer at early or ideally pre-
invasive stage. (5) 
If from an oncological point of view, MD-IPMNs and MT-IPMNs are the most challenging, harboring a 
risk of pancreatic cancer respectively in up to 91% (6-8) and 70% (9)of cases, from a decisional point 
of view, they are not. In fact, whenever the patient is fit for surgery, he/she encounter a surgical 
indication.(2, 5)  
The situation is more complex for BD-IPMNs, since they display 15% of progression at 3-5 years follow-
up(2) and 8-10% risk of pancreas cancer during lifetime. (10)  
For BD-IPMNs, which represent by far, the majority of IPMN lesions in the general population, a more 
conservative approach has been suggested, though lifelong follow up with MRI/MRCP and/or EUS until 
the patient is fit for surgery. (3, 4) 
The economic counterpart of such strategy, will unavoidably imply an excess health care costs that has 
still not been clearly quantified, but that probably will be unrealistically economical sustainable.  
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 In the next future therefore, two possible strategies can overcome the problem: an improvement in 
detection of the lesions at risk for progression, that will allow optimizing of resources, by 
continuing/intensifying follow up in a more targeted way and application of a chemoprevention, able 
to slow down and ideally stop the progression on IPMNs.  
While the first aspect has been addressed by several authors and guidelines and is still largely matter 
of debate, the second one has poorly been investigated.  
So far, no effective chemoprevention is available, to slow or prevent the progression of BD-IPMNs.  
In addition, IPMNs harboring high-grade dysplasia/cancer represent a target for surgery but long term 
prognosis is still impacted by rates of post-surgical locoregional and distant recurrences.(2)  
Although several authors have identified possible risk factors for recurrence after surgery such as 
family history for pancreas cancer and the grade of dysplasia in the resected specimen, (11, 12) even 
in this case, no specific study investigated the role of a possible chemoprevention able to prevent or 
slow down recurrence of pancreas cancer in operated patients.  
Beside the progressive increasing in incidence of pancreatic exocrine tumors, in the last decades even 
incidence of endocrine tumors has been continuously rising. Pancreatic neuroendocrine tumors 
(PNENs) are generally considered rare neoplasm, although represent 10% of pancreatic masses as 
prevalence.(13, 14) Few studies, with heterogenous results, have specifically investigated potential risk 
and protective factors for their occurrence, including the effect of possible pharmacological 
exposures.(14)  
Aspirin (ASA), Ace Inibitors/Sartans (ACEI/ARB) and Statins (STAT) are among the most used drugs for 
primary and secondary cardiovascular prevention have shown to inhibit cell growth in several cancers, 
including some clinical and preclinical models of pancreatic cancer. (15-20)  
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Aspirin, is a selective and irreversibly acetylator of prostaglandin (PG)G/H-synthases (COX-1 and COX-
2), that blocks the catalytic reaction that converts arachidonic acid into PGG2 and PGH2 and therefore 
thromboxane (TX)A2 resulting in anti-inflammatory, analgesic, antipyretic and antiplatelet effects. (21) 
COX-2 expression and platelets activation seems to contribute to development, progression and 
metastatic potential of cancer, through locoregional release of a variety of cell growth, pro angiogenic 
and pro inflammatory mediators,  while PGE2 seems to be implied into immunological escapes from 
Interferon and/or T-cell-dependent cancer killing.(22) Beside the well-known cardiovascular protective 
effect (23), aspirin has been recently proved to play a major role in inhibit cancerogenesis, acting on 
several pathways (mTOR, EGFR, 15-PGDH) (24) Observational studies support the idea that aspirin use 
is associated with a significant decrease in the risk of overall and site-specific cancers.(25) 
Angiotensin I-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are widely 
diffused antihypertensive drugs for their property to inhibit the activation of systemic renin–
angiotensin system (RAS).(26) Angiotensin II, which represents a cornerstone in such a cascade, has 
shown to harbor proangiogenic properties by acting on the vascular endothelial growth factor (VEGF), 
MAP Kinases and G-protein cascades with potential major implications on cancer management, as 
suggested for lung, breast and pancreas cancer.(26-28) 
Statins, are inhibitors of the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase and used 
as cholesterol lowering agents in the setting of both primary and secondary cardiovascular prophylaxis. 
Statins seem to act a regulation on several intracellular pathways such as Ras, MEK, mTOR, BCL-2 and 
Rho kinases, that also play a major role in cancer development. Recently their possible role in 
decreasing the incidence of cancer has been suggested in epidemiological studies and meta-analysis. 
(29-31) 
As a matter of facts, most meta-analysis on the possible role of aspirin and statins on pancreas cancer 
were based on cohort and case-control studies suffering from high heterogeneity.(32)  
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In addition, aspirin and statins are often co-prescribed, mostly for cardiovascular disease prevention 
or treatment. It is therefore difficult to exclude possible overlap phenomena.  As studies on the 
possible chemo-preventive activity of both aspirin and statins on PDAC gathered heterogeneous 
results, the analysis of their potential combined or confounding effect in this cancer type seems 
particularly important. So far, no study examined the association of both these two drugs at the same 
time with PDAC risk. 
In summary, during the last decades the incidence of pancreatic endocrine and exocrine tumors has 
been progressively increasing. The underlining reason is unknown, as it is unclear whether it might be 
the result of the exposure to common risk factors. Aspirin, ace inhibitors/sartans and statins, that have 
been suggested to act on molecular pathways involved in cancer in several types of tumor. 
Currently, no data is available on the possible effect that such drugs might have, on the progression of 
BD-IPMN, increasingly considered precursor lesions of pancreas cancer. So far it is also unknown 
whether aspirin ace inhibitors/sartans and statins might improve prognosis or prevent recurrences and 
cancer related death in operated IPMNs patients. 
Therefore, the current work has been divided into 4 papers with the aim of shed light on such aspects:  
Paper I: Effect of Aspirin, ACE Inhibitors/Sartans and Statins use on the progression of BD-IPMN in 
follow up: a multicenter study (main paper of PhD) 
Paper II: Clinical and pharmacological factors associated with cancer related death in operated IPMN 
patients  
Paper III: Risk and protective factors for the occurrence of sporadic pancreatic endocrine neoplasm 
Paper IV: Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-
Control Study 
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Aims: 
 
Paper I: to evaluate the possible effect of ASA, ACEI/ARB and STAT used for cardiovascular prevention 
on the progression of BD-IPMN in follow-up. (main paper) 
Paper II: to evaluate the effect of aspirin, ace inhibitors/sartans and statins alone or in association, on 
cancer related death in a cohort of operated IPMNs patients 
Paper III: to investigate the association between potential risk and protective factors, including 
pharmacological exposures, and the occurrence of sporadic PNENs across a European population from 
several institutions 
 
Paper IV: the primary aim of the study was to examine the association between overall and exclusive 
aspirin and statin use and their combined use with the risk of pancreas cancer. The secondary aim was 
to explore whether the association was stronger in specific subgroups. 
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Materials and Methods: 
 
Paper I (main paper) 
Study design:  
Multicenter, retrospective cohort study. Patients were collected at Sant’ Andrea University Hospital, 
Sapienza University of Rome, Rome Italy, Karolinska University Hospital in Stockholm Sweden and San 
Raffaele Hospital, Vita Salute University, Milan Italy between 2002 and 2017.  
Data collection: Prospectively collected data about medical history, family history of cancer and 
exposures were extracted by a specific created retrospective database at Sant ’Andrea Hospital and 
San Raffaele Hospital. Eventual missing data were filled as possible by re-contacting patients. A specific 
IT database (®Take Care) with in real time updated inpatient and outpatient clinic charts was consulted 
for data collection in Sweden. 
Patients and outcomes: 
Inclusion Criteria:  BD-IPMNs patients without “ab initio” surgical indications and undergoing 
radiological follow-up according to current guidelines at the participating centers. Clinical- and 
radiological characteristics as well as exposure to the target drugs were collected and analyzed in 
relation to the progression of BD-IPMN. 
Exclusion criteria at diagnosis:  
• presence of mural nodules 
• main pancreatic duct (MPD) diameter ≥5 mm  
• cyst diameter ≥40 mm  
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Exposures:The exposure to several potential risk factors for the development of pancreas cancer were 
considered: 
Smoking habit: participants were considered as being ever smokers when reporting to have smoked 
for a period above 6 months or a quantity superior to 100 cigarettes.  
Alcohol drinking: the cut-off to be considered a regular ever drinker was a daily intake of at least 12.5 
g of alcohol for at least one year. Such quantity is approximately equal to either one glass of wine, one 
shot of hard liquor or one pint of beer. Participants were then classified as ever drinkers or nondrinkers. 
General risk factors for pancreas cancer: A 1st degree family history of pancreatic cancer, the presence 
of symptoms, the cyst’s mean diameter and a diagnosis of diabetes were specifically recorded. Recent 
onset diabetes was defined as that which occurrence was in the 12 months prior to diagnosis of BD-
IPMN. 
Target drugs exposure: The previous use of drugs such as aspirin (ASA), ace inhibitors AND/OR Sartans 
(ACEI/ARB), exclusive ace inhibitors (ACEI), exclusive Sartans (ARB), statins (STAT), insulin and 
metformin has been recorded and analyzed. For STAT, ACEI and ARB a further distinct analysis was 
performed sub-dividing different drugs within the same class. For ASA a distinction between low and 
high dose was considered. Considering that many of these drugs are often prescribed together in 
patients displaying high cardiovascular risk profile, beside the evaluation of single class effect, we also 
considered the potential summative effect resulting from the simultaneous treatment with more than 
one drug. We therefore analyzed several possible combinations of the studied drugs. 
Definition of outcomes: progression during follow up defined as:  
-dimensional progression: increasing of cyst maximum diameter of at least 2 mm 
between two follow-up imaging 
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-clinical significant progression: appearance of mural nodules and/or increasing in MPD 
diameter ≥ 5 mm and/or the occurrence of cancer and/or increasing of cyst maximum 
diameter above 40 mm. 
-any-progression: indiscriminate appearance of either dimensional and/or clinical 
significant progression and increased number of cystic lesions.  
Statistical analysis:  
Patients exposed and non-exposed to the target drugs or displaying possible risk factors for pancreas 
cancer were compared by chi-square test and fisher test with Yates correction for categorical variables; 
Student’s t test or long Rank test for continuous ones. Significant variables were further analyzed by 
sex and age adjusted univariable and multivariable logistic regression analysis. The effect of the target 
drugs over the time was evaluated through univariable and multivariable Cox hazard regression 
analysis (by enter selection procedure). The 95% confidence interval (95% CI) was calculated where 
possible and all p-values were two-sided and considered statistically significant when p<0.05.  A 
dedicated statistical software (MedCald Mariakerke, Belgium) was used. 
 
Results: 
A total of 594 patients with BD-IPMN without mural nodules, suspect of main duct involvement and 
cyst dimension above 40 mm were recruited at the three participating centers (62.28% at Karolinska 
University Hospital, 23.73% at Sant ’Andrea Hospital and 13.9% at San Raffaele Hospital). The mean 
age 64.84 years (63.95-65.73; 95% CI), 38.38% were male. During a mean follow-up of 44.78 months 
(42.01-47.54; 95% CI), 46.86% of patients displayed progression (any), 41.32% displayed dimensional 
progression (mean size increasing: 7.77 mm), 7.74% displayed a clinically significant progression. 
Thirty-two-point forty-six percent of patients had a previous use of ASA, 31.9% of STAT and 43.39% of 
ACEI/ARB. Among this last group, 30.86% of patients were exclusive users of ACEI, while 45.67% were 
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exclusive users of ARB. Some of the patients were exposed to multiple drugs belonging to the same 
class and some to association of the different classes of drugs. Patients characteristics and a more 
detailed report of drug use are summarized in Table 1. 
Past medical history:  
Multifocal of BD IPMN (73.3% vs 56.8% p=0.03), a history of diabetes (31.8% vs 16.5%; p=0.01) and 
especially newly onset diabetes (18.2% vs 4.8% p=0.06) were all factors significantly associated to 
higher rates of clinically relevant progression Table 2. 
Drug exposures:  
Insulin use was significantly associated to higher rates of both dimensional and clinically significant 
progression (respectively: 12.3% vs 6.8%, p=0.02 and 22.7% vs 7.9%, p=0.0009). At sex and age 
adjusted univariable Cox proportional hazard regression analysis insulin was confirmed to be 
associated to an increased risk of clinically significant progression: HR= 3.07 (95%CI: 1.49 to 6.30; 
p=0.002). 
ACEI/ARB use was significantly associated to higher rates of both dimensional and clinically significant 
progression (62.8% vs 41.7%; p=0.007) Figure 1a.  
Exclusive use of ACEI and ARB were also associated with significantly higher rates of any progression 
(respectively 16.6% vs 23.6%; p=0.04 and 32.4% vs 22.6%; p=0.01). Additionally, ARB use was 
associated with higher rates of dimensional and clinically significant progression (respectively 33.6% 
vs 22.4%; p=0.0039 and 44.7% vs 25.7%; p=0.01). Among the same class of drugs Losartan use 
displayed an association to higher rates of (any) progression and dimensional progression 
(respectively: 44.3% vs 18.8%; p=0.0001 and 44.9% vs 19.3%; p=0.0001) Table 2. 
At sex and age adjusted univariable Cox proportional hazard regression analysis the exclusive use of 
ACEI was confirmed to be associated to a decreased risk of dimensional progression: HR= 0.65 (0.45-
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0.94; 95%CI; p=0.02) and any progression: HR= 0.64 (0.45-0.90; 95%CI; p= 0.01). The exclusive use of 
ARB was instead confirmed to be associated to an increased risk of clinically significant progression: 
HR= 1.94 (95%CI: 1.00-3.76; p=0.04) Figure 1b. 
The use of statins and, particularly simvastatin, were significantly associated to higher rates of clinically 
relevant progressions (respectively:  46.5% vs 30.6%, p=0.03 and 34.1% vs 19.4%, p=0.02). At sex and 
age adjusted univariable Cox proportional hazard regression analysis the use of statins was significantly 
associated to decreased risk of dimensional progression (HR= 0.72; 0.54-0.97 95%CI; p=0.03) Table 2. 
We performed several models of sex and age adjusted multivariable Cox proportional hazard 
regression analysis. In a first model the use of ACEI (HR=0.70; 95% CI 048.1.01; p=0.06) and STAT (HR= 
0.67; 95%CI 0.49-0.93; p=0.01) was associated to a decreased risk to display dimensional progression, 
while the use of Insulin was associated to a statistically significant higher risk of dimensional 
progression (HR 1.65; 95% CI 1.09-2.51; p=0.01.  
In a second model, the use of ACEI (HR=0,6937; 95%CI 0,4879 to 0,9862, p=0.04) and STAT (HR= 
0,7209=0,5316 to 0,9776; 95% CI, p=0.03) was associated to a decreased risk of (any) progression, 
while the use of Insulin was associated to an increased risk of (any) progression Insulin (HR= 1.49; 95% 
CI 0.99-2-24; p=0.05).  
In a third model the use of Insulin (HR=2.97; 95% CI 1.34-6.55; p=0.006) but not ARB (HR 1.41; 95% CI 
0.69-2.87; p=0.34) was statistically associated to clinically relevant progression Figure 1c.   
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Table 1 Characteristics of BD-IPMN patients in follow up. *ASA: Aspirin users (ever);** ACE: Ace Inhibitors only users 
(ever);§ ARB: Sartans only users (ever);§§ STAT: Statins users (ever);# ACEI/ARB: Ace Inhibitors AND/OR Sartans users 
(ever);## plus : concomitant use 
Characteristic N (%)- (95% CI) 
Patients 594 
Number of male 228/594 (38.38) 
Mean Age (years) 64.84 (63.95–65.73; 95% CI) 
Mean follow-up (months) 44.78 (42.01–47.54; 95% CI) 
Smoking 156/579 (26.94) 
1st degree family history of PDAC  27/582 (4.63) 
Diabetes  102/579 (17.61) 
Alcohol (ever) 136/579 (23.48) 
Recent onset diabetes 10/102 (9.80) 
Mean Cyst Diameter (mm) 15.1 (14.42-15.85; 95% CI) 
Multifocal Disease 344/592 (58.10) 
Symptomatic  104/592 (17.56) 
Progression (any) 277/591 (46.86) 
Dimensional Progression 243/588 (41.32) 
Mean dimensional increase (mm) 7.77 (6.82–8.72; 95% CI) 
Clinically significant progression 46/594 (7.74) 
ASA  
Low dose (<160mg/die) 
186/573 (32.46) 
170/186 (91.39) 
ACEI/ARB:  
ACEI:  
          -Enalapril 
          -Perindopril 
          -Captopril 
          -Lisinopril 
          -Ramipril 
          - Others 
ARB: 
        -Telmisartan 
        -Olmesartan 
        -Combisartan 
        -Valsartan 
        -Candesartan 
        -Irbesartan 
        -Losartan 
UNSPECIFIED: 
Multiple ARB 
ACE plus ARB 
243/560 (43.39) 
75/243 (30.86) 
70/110 (63.63) 
4/110 (3.63) 
1/110 (0.90) 
3/110 (2.72) 
30/110 (27.27) 
2/110 (1.81) 
              111/243 (45.67) 
6/156 (3–84) 
6/156 (3.84) 
2/156 (1.28) 
6/156 (3.84) 
56/156 (35.89) 
16/156 (10.25) 
64/156 (41.02) 
22/243 (9.05) 
10/243 (4.11) 
35/243 (14.40) 
ASA plus ACEI/ARB plus STAT 
ASA plus ACEI/ARB  
ASA plus STAT 
ASA plus ARB plus STAT 
ASA plus ARB  
ARB plus STAT 
82/558 (14.69) 
122/559 (21.82) 
114/571 (19.96) 
47/536 (8.76) 
71/537 (13.22) 
81/537 (15.08) 
STAT 
Simvastatin 
Atorvastatin 
Pravastatin 
Rosuvastatin 
Multiple 
Unknown  
183/594 (30.80) 
112/208 (53.84) 
56/208 (26.92) 
5/208(2.40) 
17/208 (8.17) 
25/208 (12.01) 
18/208 (8.65) 
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Features Progression (any): Yes/No Progression (dimension): 
Yes/No 
Significant progression:Yes/No 
Acute pancreatitis 13 (4.7) vs 14 (4.5) p=0.88  8 (3.3) vs 19 (5.5) p=0.21  2 (4.4) vs 25 (4.6) p=1.0 
1st degree FH PDAC 16 (5.9) vs 11 (3.6) p=0.20  15 (6.2) vs 12 (3.6) p=0.13  1 (2.3) vs 26 (4.8) p=0.71 
Multifocal  166 (60.4) vs 176 (56.2) p=0.31  151 (62.4) vs 188 (54.8) p=0.06  33 (73.3) vs 310 (56.8) p=0.03 
Smoking 67 (24.8) vs 88 (28.9) p=0.27  58 (24.2) vs 97 (29.0) p=0.22  13 (30.2) vs 142 (26.5) p=0.59 
Alcohol 59 (21.9) vs 76 (24.9) p=0.38  51 (21.4) vs 84 (25.1) p=0.31  11 (25.6) vs 124 (23.2) p=0.72 
Diabetes 49 (17.9) vs 52 (17.3) p=0.84  44 (18.2) vs 57 (17.2) p=0.76  14 (31.8) vs 88 (16.5) p=0.01 
New Onset Diabetes 6 (7.9) vs 4 (4.0) p=0.26  5 (7.7) vs 5 (4.5) p=0.50  2 (18.2) vs 8 (4.8) p=0.06 
Insulin  30 (11.2) vs 21 (7.1) p=0.09  29 (12.3) vs 22 (6.8) p=0.02  10 (22.7) vs 41 (7.9) p=0.0009 
Metformin  25 (9.3) vs 37 (12.5) p=0.21  22 (9.3) vs 41 (12.6) p=0.21  3 (6.8) vs 60 (11.5) p=0.34 
ASA  
Low dose ASA 
86 (32.2) vs 98 (32.5) p=0.95 
78 (92.9) vs 90 (96.8) p=0.23 
 75 (32.1) vs 108 (32.5) p=0.90 
68 (91.9) vs 100 (97.1) p=0.12 
 17 (39.5) vs 168 (31.8) p=0.29 
16 (100.0) vs 153 (94.4) p=0.33 
ACEI /ARB 116 (44.4) vs 124 (42.0) p=0.56  103 (44.8) vs 136 (42.0) p=0.51  27 (62.8) vs 215 (41.7) p=0.007 
ACEI  
Enalapril 
Perindopril 
Captopril 
Lisinopril 
Ramipril 
41 (16.6) vs 68 (23.6) p=0.04 
29 (29.0) vs 41 (36.0) p=0.27 
0 (0) vs 4 (3.4) p=0.12 
1 (1.0) vs 0 (0) p=0.46 
1(1.0) vs 3 (2.7) p=0.62 
10 (10.0) vs 19 (16.5) p=0.22 
37 (16.8) vs 72 (23.0) p=0.08 
 26 (28.6) vs 44 (36.1) p=0.25 
 0 (0) vs 4 (3.2) p=0.13 
 1 (1.1) vs 0 (0) p=0.42 
 1 (1.1) vs 3 (2.5) p=0.63 
 9 (9.9) vs 20 (16.3) p=0.17 
7 (18.4) vs 103 (20.6) p=0.74 
 4 (19.0) vs 66 (34.0) p=0.16 
 0 (0) vs 4 (2.0) p=1.0 
 0 (0) vs 1 (0.5) p=1.0 
 0 (0) vs 4 (2.1) p=1.0 
 2 (9.5) vs 28 (14.4) p=0.74 
ARB  
Telmisartan 
Olmesartan 
Combisartan 
Valsartan 
Candesartan 
Irbesartan 
Losartan 
80 (32.4) vs 65 (22.6) p=0.01 
4 (3.9) vs 2 (1.7) p=0.42 
1 (1.0) vs 5 (4.3) p=0.21 
2 (2.0) vs 0 (0) p=0.21 
5 (5.0) vs 1 (0.9) p= 0.10 
24 (24.0) vs 31 (27.7) p=0.54 
10 (10.1) vs 6 (5.3) p=0.18 
43 (44.3)vs 21 (18.8);p=0.0001 
 74 (33.6) vs 70 (22.4) p=0.0039 
 3 (3.2) vs 3 (2.4) p=0.70 
 1 (1.1) vs 5 (4.0) p=0.24 
 2 (2.2) vs 0 (0) p=0.17 
 5 (5.4) vs 1 (0.8) p=0.08 
 23 (25.3) vs 32 (26.7) p=0.82 
 9 (10.0) vs 7 (5.8) p=0.25 
 40 (44.9) vs 23 (19.3) p=0.0001 
 17 (44.7) vs 128 (25.7) p=0.01 
 0 (0) vs 6 (3.0) p=1.0 
 0 (0) vs 6 (3.0) p=1.0 
 0 (0) vs 2 (1.0) p=1.0 
 1 (4.8) vs 5 (2.6) p=0.46 
 4 (19.0) vs 51 (26.6) p=0.60 
 5 (23.8) vs 11 (5.7) p=0.01 
 9 (42.9) vs 55 (29.1) p=0.19 
STAT  
Simvastatine 
81 (30.3) vs 101 (33.4) p=0.42 
54 (21.3) vs 57 (19.9) p=0.68 
 67 (28.6) vs 114 (34.2) p=0.15 
 44 (19.7) vs 66 (21.0) p=0.71 
 20 (46.5) vs 162 (30.6) p=0.03 
 14 (34.1) vs 97 (19.4) p=0.02 
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Table 2: Association between patient’s features/exposure and the progression of the IPMN at Chi-square/ 
Fisher test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Atorvastatine 
Pravastatine 
Rosuvastatine 
19 (7.5) vs 36 (12.6) p=0.05 
4 (1.6) vs 1 (0.3) p=0.13 
6 (2.3) vs 11 (3.8) p=0.33 
 17 (7.6) vs 37 (11.8) p=0.11 
 3 (1.3) vs 2 (0.6) p=0.65 
 6 (2.6) vs 11 (3.4) p=0.60 
 5 (12.2) vs 50 (10.0) p=0.59 
 1 (2.4) vs 4 (0.8) p=0.32 
 1 (2.4) vs 16 (3.1) p=1.0 
ASA plus ACEI/ARB 57 (21.8) vs 63 (21.4) p=0.90  52 (22.6) vs 68 (21.1) p=0.66  14 (32.6) vs 107 (20.8) p=0.07 
  ASA plus STAT 46 (17.2) vs 67 (22.3) p=0.12  41 (17.5) vs 72 (21.8) p=0.21  13 (30.2) vs 100 (19.0) p=0.07 
ACEI/ARB plus STAT  61 (23.4) vs 66 (22.4) p=0.79  53 (23.0) vs 73 (22.6) p=0.90  17 (39.5) vs 110 (21.4) p=0.006 
ASA plus ACEI/ARB 
plus STAT 
35 (13.4) vs 46 (15.7) p=0.44  32 (13.9) vs 49 (15.2) p=0.66  11 (25.6) vs 70 (13.6) p=0.03 
ASA plus ARB plus 
STAT 
24 (9.7) vs 22 (7.7) p=0.40  22 (10) vs 24 (7.7) p=0.35  7 (18.4) vs 39 (7.8) p=0.02 
 
ASA plus ARB  39 (15.8) vs 31 (10.8) p=0.08  36 (16.4) vs 34 (10.9) p=0.06  9 (23.7) vs 61 (12.2) p=0.04 
ARB plus STAT 45 (18.2) vs 35 (12.2) p=0.05  40 (18.2) vs 39 (12.5) p=0.06  12 (31.6) vs 68 (13.7) p=0.002 
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Figure 1 a) Sex and age adjusted univariable Cox proportional hazard regression analysis for drug 
exposure 
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Figure 1 b) Sex and age adjusted univariable Cox proportional hazard regression analysis for the exclusive use of ACEI and  ARB
 
Figure 2 a) Sex and age adjusted multivariable Cox proportional hazard regression analysis for pharmacological exposure
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Paper II 
Study design 
A single-center hospital-based retrospective cohort study on prospectively collected patients surgically 
resected for pancreatic IPMNs. Patients were enrolled between 2007 and 2017 at Pancreatic Disease 
Unit, Karolinska University Hospital, Stockholm, Sweden. Ethical committee approval was obtained 
(EPN 2015/1544-31/4). Demographics, hereditary factors, clinical and pharmacological history were 
collected and analyzed.  
Cohort and Population’s Characteristics  
Consecutive cases of histologically verified IPMNs who had undergone surgery for radiological suspect 
of high grade IPMNs according to the European Guidelines for the management of cystic tumors of the 
pancreas (from October 2011). The date of surgery was considered as date of diagnosis. All patients 
were discussed in a multidisciplinary conference before surgery. 
 Definition of the exposure: Patients were investigated for ever use of aspirin, ace inhibitors, sartans 
and statins used alone or in combination as well as for exposure to known risk factors for pancreas 
cancer. Data regarding demographics, known risk factors for pancreatic cancer (hereditary, smoking, 
alcohol, overweight/obesity) as well as final pathological assessment (degree of dysplasia, presence of 
cancer, TNM, specific histological phenotype), and exposure to the target drugs was retrospectively 
collected. A specific Swedish electronic database (®Take Care) with in time updated inpatient and 
outpatient clinic charts was consulted for data collection. 
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Patients and outcomes: 
Outcome definition: Overall survival was defined as the interval of time between surgery and the date 
of analysis if patient was alive or between diagnosis and cancer related death in case he/she died 
during follow-up due to metastatic disease or locoregional recurrence.  
All patients in which death was not related to cancer, were excluded from survival analysis as a 
censored data, to specifically analyze the possible effect of investigated factors/drugs on cancer 
related survival.  
Inclusions criteria:  
Consecutive patients who have undergone surgery at Karolinska University Hospital because suspect 
malignified IPMN according to the European Guidelines for the Management of Pancreatic Cystic 
Neoplasms.  
Exclusion criteria:  
- The presence of a synchronous pancreatic cancer, cholangiocarcinoma or high grade 
neuroendocrine tumor that might influence the prognosis. 
- The presence of surgical margins at final histology showing cancer or high-grade dysplasia 
(Figure 1) 
 
 
 
 
 
    PhD Doctoral Thesis 
20 
 
 
Statistical analysis: 
Categorical variables were analyzed through chi-square, continuous variable through Students t-test. 
Statistically significant variables were further analyzed in sex and age adjusted univariate and 
multivariate logistic regression analysis. Sex and age adjusted univariable and multivariable logistic 
regression analysis was used to evaluate the possible association between cancer related death and 
known risk factors for pancreas cancer and sex and age adjusted univariable and multivariable cox 
hazard regression analysis was used to identify associations between pharmacological exposures and 
cancer related death. The 95% confidence interval (CI) was calculated. All p-values were two-sided and 
a p<0.05 was considered statistically significant. A statistical software package was used for data 
analysis (MedCalc Mariakerke, Belgium). 
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Results: 
Between 2008 and 2017, 274 IPMN patients were operated at Pancreatic Disease Unit, Karolinska 
University Hospital for suspect malignified IPMN. Two hundred ten, mean age 70.55 years (67.60-
73.50; 95% CI), 47.61% male, were included in the final analysis. Patients’ characteristics are 
summarized in Table1  
Clinical known risk factors for pancreas cancer: 
Fifty patients (23.80%) were smokers and among them 66% displayed active smoking. First-degree 
family history of pancreatic cancer was present in 3.8% of patients.  Diabetes was present in 19.52% 
of patients and in 2.43% diabetes was of early onset (diagnosed within the latest 12 months before 
surgery).  Multifocal disease was present in 43.8% of patients, preoperatively increased levels of 
Ca19.9 in 32.66%, while 34.05% of patients had a mean diameter of mean cyst above 40 mm. Mean 
MPD diameter was 7.64 (6.88-8.39; 95% CI). Significantly higher percentage of patients with 
preoperative jaundice, increased Ca19.9 and cyst diameter above 40 mm died for cancer (respectively: 
36.4 vs 9.8%, p=0.0005; 76.2% vs 27.6%, p<0.0001; 62.5% vs 30.0%, p=0.05). Table 2   
At sex and age adjusted univariable logistic regression analysis preoperative jaundice and preoperative 
increased level of Ca19.9 were associated with increased risk of cancer related death (respectively OR 
=4.99, 95% CI 1.80-13.87, p=0.02 and OR= 8.75, 95% CI 2.96-25.87, p=0.001. Table 3a   
At sex and age adjusted multivariable logistic regression analysis, preoperative increased level of 
Ca19.9 remained consistent with increased risk of cancer related death OR=7.31, 95% CI 2.40-22.21, 
p=0.0004. Table 3b  
A previous or current use (ever use) of aspirin, ace inhibitors/sartans and statins was present 
respectively in 29.18%, 51.90% and 36.84% of cases. ASA ever users displayed significantly higher rates 
of cancer related death 50.0% vs 27.4% p= 0.03. Sex and age adjusted univariable cox hazard regression 
analysis ASA users displayed a borderline significantly higher risk of cancer related death HR 2.11 (0.90-
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4.94, 95% CI, p=0.08). The risk of cancer related death was not statistically significant different among 
exclusive STAT and exclusive ACEI/ARB users (respectively HR= 0.77, 95% CI 0.32-1.89, p=0.58 and HR= 
1.18, 95% CI 0.49-2.82, p=0.69) or their combinations. (Table and Figure 2a)   
At multivariable cox hazard regression analysis adjusted for sex, age, clinical factors associated with 
both pancreas cancer and cardiovascular risk (such as smoking, diabetes, first degree family history, 
overweight/obesity and elevated Ca19.9) ASA users were confirmed to be associated with increased 
risk of cancer related death (HR=2.70, 95% CI 1.10-6.59, p=0.02). Figure 2b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    PhD Doctoral Thesis 
23 
 
 
Figure 1: Patients’ inclusion flow chart 
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Table 1 Patients demographic, disease morphology and operative characteristics 
Characteristic N/mean (%; 95%CI) 
Patients 210 
Male  100/210 (47.61) 
Age 70.55 (67.60-73.50; 95% CI) 
Mean OS (months) 37.60 (33.76-41.43; 95%CI) 
Dead 
Cancer related death 
51/210 (24.24) 
22/210 (10.47) 
Mean BMI 25.73 (25.12-26.38; 95% CI) 
Obesity 18/210 (8.57) 
Overweight  41/210 (19.52) 
Smokers 50/210 (23.80) 
Current smokers 33/50 (66.0) 
1st degree FH PDAC  8/210(3.80) 
Diabetes  41/210 (19.52) 
Recent Onset Diabetes                   1/41 (2.43) 
Jaundice                  26/210 (12.38) 
Abdominal pain 42/210 (20.0) 
Weight loss 32/210 (15.23) 
Acute pancreatitis 23/210 (10.95) 
Incidental diagnosis 100/209 (47.84) 
Multifocal  92/210 (43.80) 
Mean MPD diameter (mm) 7.64 (6.88-8.39; 95% CI) 
MPD diameter 5-9.9 mm 89/210 (42.38) 
    PhD Doctoral Thesis 
25 
 
MPD diameter ≥10 mm 50/210 (23.80) 
Max Cystic Size (mm) 33.93 (30.23-37.62; 95%CI) 
Cyst Size ≥4 cm in BD-IPMNs 47/138 (34.05) 
Mural nodules  16/209 (7.65)  
Increased Ca19.9 65/199 (32.66) 
Pancreaticoduodenectomy  97/210 (46.19) 
Distal Pancreatectomy 66/210 (31.42) 
Total Pancreatectomy 39/210 (18.57) 
Atypical resections 8/210 (3.80) 
Margin status: 
No dysplasia 
Low grade of dysplasia 
NA (total pancreatectomy) 
 
64/171 (37.42) 
107/171 (62.57) 
39/210 (18.57) 
ASA 
ACEI/ARB 
STAT 
ASA plus ACEI/ARB 
ASA plus STAT 
ACEI/ARB plus STAT 
ASA plus ACEI/ARB plus STAT 
61/209 (29.18) 
109/210 (51.90) 
77/209 (36.84) 
46/209 (22.00) 
42/208 (20.19) 
58/209 (27.75) 
32/208 (15.38) 
Final histology: 
Cancer 
IPMN with high grade dysplasia 
IPMN with low grade dysplasia 
 
60/210 (28.57) 
44/210 (20.95) 
106/210 (50.47) 
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Table 2 IPMNs features and patient’s exposure possibly associated to cancer relater death at fisher or chi square test 
Features/exposures Cancer related death vs alive patient p value 
Smoking 5 (22.7) vs 37 (22.6) 0.98 
1st degree FH PDAC      0 (0) vs 8 (4.9) 0.29 
Diabetes  4 (18.2) vs 32 (19.5) 0.88 
Preoperative Jaundice 8 (36.4) vs 16 (9.8) 0.0005 
Abdominal pain 4 (18.2) vs 35 (21.3) 0.73 
Weight loss 5 (22.7) vs 23 (14.0) 0.28 
Incidental diagnosis 7 (31.8) vs 79 (48.5) 0.14 
Head location 10 (45.5) vs 48 (29.3) 0.12 
Preoperative Increased Ca19.9 (≥37 UI/L) 16 (76.2) vs 43 (27.6)             <0.0001 
Multifocal IPMNs 6 (27.3) vs 76 (46.3) 0.09 
Positive Margin for dysplasia 12 (85.70) vs 87 (63.00) 0.09 
Preoperative presence of mural nodules 1 (4.5) vs 14 (8.6) 0.51 
maximum diameter 5-9.9 mm 10 (45.5) vs 71 (43.3) 0.84 
maximum diameter ≥10 mm 6 (27.3) vs 37 (22.6) 0.62 
Preoperative Cyst Size ≥4 cm  5 (62.5) vs 33 (30.0) 0.05 
ASA use (ever) 11 (50.0) vs 45 (27.4) 0.03  
STAT use (ever) 8 (36.4) vs 62 (38.0) 0.87 
ACEI use (ever) 7 (31.8) vs 33 (20.1) 0.21 
ARB use (ever) 4 (18.2) vs 41 (25.0) 0.48 
ACE/ARB use (ever) 13 (59.1) vs 82 (50.0) 0.42 
ASA plus STAT use (ever) 6 (27.3) vs 34 (20.9) 0.49 
ASA plus ACEI/ARB use (ever) 6 (27.3) vs 36 (22.0) 0.57 
ASA plus ACEI/ARB plus STAT use (ever) 5 (22.7) vs 26 (16.0) 0.42 
ACEI/ARB plus STAT use (ever) 6 (27.3) vs 47 (28.8) 0.87 
 
    PhD Doctoral Thesis 
27 
 
Table 3 Sex and age adjusted univariate and multivariable logistic regression analysis for the 
assessment of possible associations between clinical features and the occurrence of cancer related 
death. 
 
Clinical features Univariable OR (95%CI) Multivariable OR (95%CI) 
Jaundice 4.99 (1.80-13.87); p=0.02 2.57 (0.82-8.04); p=0.10 
Increased Ca19.9 (≥37 UI/L) 8.75 (2.96-25.87); p=0.001 7.31 (2.40-22.21); p=0.0004 
Preoperative Cyst Size ≥4 cm 4.43 (0.96-20.30); p=0.05  
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Figure 2a Sex and age adjusted univariable cox hazard regression analysis for the assessment of 
possible associations between pharmacological exposure and the occurrence of cancer related death 
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Figure 2b Multivariable cox hazard regression analysis for the assessment of possible associations between 
aspirin exposure and the occurrence of cancer related death, adjusted for sex, age, clinical factors associated 
with pancreas cancer (smoking, diabetes, first degree family history, overweight/obesity, elevated Ca19.9)  
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Paper III 
Study design 
A collaborative multicenter hospital-based case-control study was conducted in six European 
countries: Italy, Norway, Sweden, Slovenia, United Kingdom and Germany as part of the “Pancreas 
2000” educational project (www.pancreas2000.org), upon local hospital ethical committee approval. 
The cases were prevalent sporadic PNEN patients diagnosed within 24 months from the beginning of 
the study (January 2013) and new incident cases of sporadic PNENs diagnosed from January 2013 to 
December 2015 that were recruited at the participating centers. A standardized questionnaire, 
investigating demographics and potential risk factors, such as family history of cancer, environmental 
factors, previous use of drugs such aspirin and other medical history features was administered to 
patients, after gaining participant consent, by a trained medical doctor. The cases were prevalent 
sporadic PNEN patients diagnosed within 24 months from the beginning of the study and new incident 
cases of sporadic PNENs diagnosed afterwards and recruited at the participating centers.  
 
Patients and outcomes 
The inclusion criterion: histological or cytological diagnosis of PNEN. The date of the confirmatory 
pathological report was accepted as the date of diagnosis.  
Exclusion criteria:  
-inherited form of PNEN such as those associated with multiple endocrine neoplasia-type 1 (MEN1), 
von Hipple-Lindau disease (VHL), neurofibromatosis type 1 (NF-1), tuberous sclerosis (TSC) 
-inability to participate, such as dementia.  
According to the absence or presence of a clinical syndrome due to hormonal hypersecretion, cases 
were classified as non-functioning or functioning tumors (gastrinoma, insulinoma, glucagonoma).  
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Cases were classified according with the European Neuroendocrine Tumor Society (ENETs) and the 
2010 World Health Organization classifications.  
Eligible controls were either individuals seen in the participating hospitals’ outpatient clinic for a non-
specific, non-organic gastrointestinal disorder (bloating, aspecyfic dyspeptic symptoms, eructation) or 
visitors attending the same network of referring hospitals, matched by country, sex and age (+/- 5 
years). Visitors and hospital outpatients’ clinic belonged to the same catchment area of cases.  
Specific exclusion criteria for controls were the presence of:  
1) Genetic syndromes associated with the occurrence of PNENs 
2) History of active cancer (diagnosed within 5 years)  
3) any biological relation of a participating PNEN case in this study  
4) Previous medical history of any chronic inflammatory condition (e.g. chronic obstructive pulmonary 
disease, liver cirrhosis, inflammatory bowel disease, end stage kidney disease) 
5) Familial cancer syndromes  
Controls were included in the same country and interviewed within 6 months of the inclusion of the 
matched corresponding case.  
Exposure definitions  
Subjects were questioned about risk factors that were present at least 12 months before diagnosis or 
presentation of symptoms, to avoid potential bias due to lifestyle modifications, cancer symptoms or 
cancer treatments.   
Ever smokers were considered as subjects with cumulative lifetime smoking history greater than 6 
months or 100 cigarettes smoked. A quantification of the smoking habit was performed considering 
the number of pack-years (pack-year = number of packs per day x years of smoking), with 20 pack-
years being the lower limit to qualify a participant a heavy smoker.  
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A daily intake of at least 12.5 g of alcohol, equivalent to one glass of wine, one pint of beer or one shot 
of hard liquor, for at least one year, was considered the cut-off to be a regular ever alcohol 
drinker.(33)Because of possible different drinking habits within different European countries, the 
weekly alcohol amount was also sub-analyzed according to low (1-7 weekly units assumption), medium 
(8-14 weekly units), medium-high (14-20 weekly units) and heavy alcohol consumption (≥21 weekly 
units).  
Coffee drinking was also recorded as ever drinking (at least one cup per day) or heavy coffee drinking 
(>5 cups per day).  
Height and weight were recorded from which body mass index (BMI) (kg/m2) was calculated. A medical 
history of chronic pancreatitis, acute pancreatitis, peptic ulcer disease, biliary stones and previous 
surgery were specifically recorded as well as diagnosis of diabetes that was further subdivided for type 
and onset. For cases, recent onset diabetes was defined as that which was diagnosed in the 12 months 
prior to the PNEN diagnosis, and for controls a diagnosis of diabetes 12 months prior to the date of 
recruitment was required. Sensitivity analysis were also performed for different intervals of the onset 
of diabetes, (respectively inferior to 1 year, between 1 and 3 years, between 3 and 5 years and above 
5 years). Another sensitivity analysis was also conducted considering incident/prevalent cases and 
hospitals controls/visitors controls compared to respective cases.  
As atopy and allergy have been associated with a reduced risk of pancreatic cancer, cases and controls 
were interrogated about a history of allergy, with specific enquiry for eczema, hay fever and asthma.  
Subjects were interrogated about 1st and 2nd degree family history of cancer, and the total number 
of siblings and children was recorded. 
The use of drug exposures such as aspirin, proton pump inhibitors, metformin and insulin were 
recorded. 
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Statistical Analysis 
An a priori power calculation was performed. We estimated sample size based on the differences 
reported in the frequencies of exposure in cases and controls according to a previous study(34), and 
considering a ratio 1:3, with a statistical power equal to 80% and an alpha error equal to 0.05. 
According to the previous study (34), the reported prevalence in cases and controls was respectively 
53% vs. 32% for 1st degree family history of cancer, 10% vs. 2% for diabetes and 14% vs. 3% for heavy 
alcohol consumption. Therefore, the sample size’s estimate of cases and controls, to show true 
differences whether existing, were respectively 64 cases and 191 controls for 1st degree family history 
of cancer, 117 cases and 350 controls for diabetes, 85 cases and 253 controls for heavy alcohol 
consumption. We therefore estimated that a total of 200 cases and 600 controls across participating 
centers, to be an adequate sample size to reveal differences in the prevalence of most risk factors 
analyzed among cases and controls, where these exist. Characteristics of cases and controls were 
compared by chi-square test for categorical variables or Student’s t test for continuous variables. 
Significant variables were analyzed by logistic regression analysis adjusted for sex, age and enrolment 
center. A multivariable logistic regression analysis, adjusted for sex, age and enrolment center was also 
performed with an enter selection procedure for statistically significant risk factors. A dedicated 
statistical software package (MedCald Mariakerke, Belgium) was used for data analysis. The 95 % 
confidence interval (CI 95) was calculated where possible. All p-values were two-sided and p<0.05 was 
considered statistically significant. 
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Results 
Patients characteristics 
A total of 201 cases and 603 sex and age matched controls were enrolled among the six  centers (Italy, 
Norway, Sweden, United Kingdom, Slovenia and Germany) as shown in table 1. The mean age was 59.6 
years in cases (CI 57.7-61.4) and 59.5 years in controls (CI 58.4- 203 60.55), and 51% of cases and 
controls were male. Amongst the 201 PNEN cases, 154 (76.6%) had a non-functioning tumor. Of the 
47 functioning PNENs, 26 (55.3%) had an insulinoma, 9 (19.1%) a gastrinoma, 7 (14.9%) a glucagonoma 
and 5 (10.6%) other functioning tumors. The majority were G1 (44.8%) or G2 (43.3%) PNENs and were 
equally distributed among different disease stages (Table 1). Of the 201 PNEN cases, 80 (38%) cases 
were incident and 121 (62%) prevalent. Of the 603 controls, 422 (70%) were hospital outpatients 
controls and 181 (30%) visitors.    
Risk factors for the occurrence of PNEN  
The proportion of subjects who had a 1st degree family history of cancer was similar in cases and in 
controls (respectively 51.1% vs. 45.3% p=0.17), while 2nd degree family history was slightly more 
prevalent in cases (36.8% vs. 30.2% p=0.09). A 1st degree family history of specific cancer sites was 
also not significantly different (Table 2). No cases or controls reported a family history of neuro-
endocrine tumor (NET). At multiple regression analysis 2nd degree family history of any cancer was, 
however associated with an increased risk of PNEN (see Table 2 and 3).  
 
Body Mass Index  
Mean BMI was not significantly different amongst cases and controls (26.8 kg/m2 223 (CI 26.0- 27.5) 
and 26.4 kg/m2 (CI 26.4-26.8), p=0.10. Similarly, whilst the overall prevalence of obesity was more 
frequent in cases than controls (25.5% vs. 18.2%) this was not significant (p=0.44). At regression 
analysis after adjustment for matching variables, there remained no significant association with 
obesity (OR 1.36, 95% CI 0.88-2.08, p=0.15) (Table 3).  
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Cigarette smoking, alcohol intake and coffee drinking  
The proportion of smokers (55.5% vs. 53.5%, p=0.59), heavy smokers (25.5% vs. 24.0%, 231 p=0.59), 
alcohol drinkers (75.6% vs. 70.8%, p=0.33), heavy alcohol drinkers (3.4% vs. 4.2%, 232 p=0.33), coffee 
drinkers (84.8% vs. 87.8%, p=0.24) and heavy coffee drinkers (18.8% vs. 233 19.2%, p=0.24) did not 
significantly differ between cases and controls (Table 2).  
 
History of diabetes mellitus  
A history of diabetes mellitus was more prevalent in cases than in controls (18.4% vs. 12.3%, 237 
p=0.03). This difference was greater on analysis of non-recent onset diabetes, defined as diabetes 
diagnosed more than 12 months before the diagnosis of PNEN in cases, or 12 months prior to the 
interview for controls (17.4% vs. 9.7%, p=0.004) (Table 2). After adjustment for the matching variables, 
non-recent onset diabetes was confirmed to be consistent with the occurrence of PNEN (OR 1.89, 95% 
CI 1.17-3.05, p=0.008). At multivariable analysis the association with non-recent onset diabetes 
remained statistically significant (OR 2.09, 95% CI 243 1.27-3.45, p=0.003) (Table3). At sensitivity 
analysis, a history of diabetes with an onset between 1-3 year and between 3- 5 years, was increasingly 
prevalent in PNEN compared to controls (respectively 3.0% vs 1.1% p=0.07 and 4% vs 0.9% p=0.004). 
At univariable logistic regression analysis this difference remained significant (respectively OR 2.56, 
95% C.I 0.83- 247 7.91 and OR 4.31, 95% C.I 1.43-12.98). For intervals of occurrence of diabetes 
superior to 5 years no statistically significant difference was found between cases and controls 
(respectively 10.7% vs 7.4%, p=0.16) (Table 2). We also performed a separate analysis for “late onset 
diabetes” using as controls either only the 422 hospital controls or only the 181 visitors controls. In the 
first case, the OR resulted to be 2.52 (95%CI 1.08-5.86; p=0.03), while in the second one the OR was 
1.7 (95%CI 0.95-3; p=0.07), most likely due to the lower number of controls reducing the power of the 
analysis. Neither the use of metformin (7.3% vs. 5.1%, p=0.3), nor insulin (4.1% vs. 1.6%, p=0.1), or 
their association together (5.2% vs 3.4%, p=0.4) were statistically different between cases and controls.  
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Past medical history  
With regards to past medical history, the prevalence of acute pancreatitis (3.5% vs. 2.4%, p=0.60), 
peptic ulcer disease (12.3% vs. 10.6%, p=0.59), cholecystectomy (9.0% vs. 8.5%, 260 p=0.92) and 
gastrectomy (1.0% vs. 0.7%, p=0.99) were similar in cases and controls. None of the participants 
reported a medical history of chronic pancreatitis (Table 2). A higher proportion of cases reported a 
history of gallstone disease than controls (19.2% vs. 13.3%) but this did not reach the significance 
threshold (p=0.06). After adjustment for age, sex and enrolment center at multivariable analysis, this 
latter association remained borderline significant (OR 1.52, 95% CI 0.95-2.44, p=0.08) (Table 3).A 
history of allergies was not different in cases and in controls (28.9% vs. 25.0%, p=0.32).  Specifically, 
neither asthma (12.1% vs. 8.6%, p=0.19), eczema (11.1% vs. 7.6%, p=0.17) nor hay fever (15.6% vs. 
14.5%, p=0.79) were more prevalent in PNEN patients than in controls (Table 2).  
 
Non-diabetic medications  
The use of proton pump inhibitors (PPI) (39.2% vs. 39.6%, p=0.97) and aspirin (22.5% vs. 26.5%, p=0.29) 
did not differ among cases and controls respectively (Table 2).  
 
Risk factors for the advanced grades and stages of PNEN  
When stratifying cases for the TNM stage at diagnosis and for the tumor grade, diabetes mellitus was 
statistically more prevalent in patients with G3 tumors (pancreatic neuro endocrine carcinoma; PNEC) 
than with G1 or G2 tumors (40.9% vs. 15.8%, p=0.01). Amongst cases, non-recent onset diabetes was 
associated with a more advanced stage at diagnosis (TNM III-IV vs TNM I-II respectively 23.3% vs. 
11.8%, p=0.05) and with a G3 vs G1-2 tumor (respectively 40.9% vs. 14.9%, p=0.006). The use of 
metformin in combination with insulin was more prevalent in patients with G3 than G1-G2 tumors 
(respectively 23.5% vs. 3.2%, 285 p=0.003) (Table 4). Asthma was more prevalent in G3 cases than in 
G1-2 (30.0% vs. 10.2% 286 p=0.02), and eczema was also more prevalent in G3 cases than in G1-2 but 
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without reaching statistical significance (25.0% vs. 9.6%, p=0.08). Coffee drinking was more prevalent 
in localized disease (TNM 1-2) at diagnosis compared with advanced stage (TNM 3-4) (92.3% vs. 75.9%, 
p=0.003). 
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Table 1 Characteristics of PNENs cases 
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Table 2 Risk factors for PNENs 
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Table 3 Risk Factors for the occurrence of PNENs at the Logistic regression analysis 
 
 
 
Table 4 Factors associated with TNM stage and tumor grade in PNEN patients 
 
 
 
 
 
 
 
Paper IV 
Study design, patients and outcomes 
    PhD Doctoral Thesis 
41 
 
A single-center case-control study between January 2006 to February 2016. 
Incident cases: prospectively recruited patients with histological proved PDAC  
Controls consisted of hospital non-patient visitors not genetically related to cases, or Gastroenterology 
Unit outpatients and inpatients. Both cases and controls demonstrated the will and ability to 
participate providing personal data, clinical and cancer history.Patients enrolled in either group 
provided written informed consent for interviews. The study received local IRB approval at 
Sant’Andrea Hospital. Methods were performed in accordance with the relevant guidelines and 
regulations. 
Exclusion criteria for controls: (a) personal history of IBD, chronic kidney disease or liver cirrhosis, (b) 
referral to our center for family history (FH) of gastrointestinal cancer, (c) referral for NSAID-induced 
ulcer disease, (d) history of neoplasia within 5 years (e)inability to participate or providing personal 
data, clinical and cancer history. For each case enrolled, the first two eligible controls matched for sex 
and age (±2 years) were enrolled and interviewed within 30 days. 
Data collection and exposure definition 
A trained physician through direct patient interview collected data on a standardized questionnaire. 
Clinical, epidemiological, therapeutic and morphological parameters were collected such as sex, age, 
race, tobacco and alcohol intake, body mass index (BMI), family history (FH) of cancer, previous 
pancreatic diseases, history of diabetes, aspirin and statin use, length, type and dosage of their use.  
During the interview, a list of brand and generic medication names for aspirin and statins was provided 
to help facilitate recall. All cases were interviewed within 1 month from diagnosis and data pertaining 
the disease were also recorded. 
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Smoking (ever) was considered a consumption of at least 100 cigarettes or >6 months of smoking. The 
total amount of smoking was evaluated as pack-years, defined as the product of packs smoked per day 
and the total years of smoking. Twenty pack-years was set as cut-off of to define heavy smokers.  
Current smoker was considered as a person currently smoking or who had quit less than 1 year in the 
past while to be considered ex-smokers patient should had quit at least 1 year before the diagnosis or 
the time of interview for controls. 
A consumption of at least 12.5 g (1 unit) of alcohol/month was needed to be considered a drinker. One 
glass of wine, 1 pint of beer, one shot of hard liquor was considered equal to 12.5 g amount of alcohol. 
Heavy drinkers were considered as individuals drinking more than 21 units/week (262.5 g of 
alcohol).(33) 
BMI was calculated as usual adult weight/height2 (kg/m2) with obesity considered as BMI >30 kg/m2. 
Diabetes was recorded as a potential risk factor when diagnosed >1 year before the diagnosis of cancer 
or its first symptoms for cases or before the interview for controls. 
Participants were considered as aspirin or statin users when reporting ever use of the medication for 
at least 3 consecutive months and were subsequently categorized as “high dosage users” (≥300 mg) 
and “low dosage users” (≤160 mg) for aspirin and “low-dosage users” (<20 mg) or “moderate/high 
dosage users” (≥20 mg) for statins. Aspirin or statin users were categorized into different length of 
duration (<60 months and ≥60 months for aspirin, <48 months and ≥48 months for statins) based on 
median value. To avoid possible bias due to cancer symptoms, subjects were asked about risk factors 
present 12 months before diagnosis or presentation symptom. 
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Statistical analysis 
A preliminary power calculation was performed. Considering an exposure of ~20% for aspirin or statins 
as previously recorded in controls, 395 cases and 790 controls were needed to have a 80% power of 
identifying an odds ratio (OR) ≤ 0.62 as single effect of aspirin or statins. This would also allow to detect 
an OR ≤ 0.50 for the combined used of aspirin and statins, based on a 10% combined exposure among 
controls.  
Case-control comparisons were made using Chi-square and Fisher’s exact tests for categorical variables 
and Student’s t-test for continuous variables. Univariate logistic regression analysis was used to 
calculate ORs and their 95% confidence intervals (CI). Multivariable logistic regression models were 
adjusted for potential confounders.  All statistical analysis was performed using MedCalc version 13 
(MedCalc Software, Belgium). All reported P values were 2-sided and considered statistically significant 
when p < 0.05. 
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Results: 
Of 421 PDAC cases seen at the Gastroenterology Department during the study period, 9 (2.1%; 4 males 
and 5 females, mean age 74) were not histologically confirmed. Of the remaining 412, 2 (0.5%) refused 
to participate and 2 (0.5%) were too ill to take part; of the 893 controls recruited in the same 
timeframe, 51 (5.7%) were excluded for matching exclusion criteria, 8 (0.9%) refused to be interviewed 
for privacy concerns, 18 (2.0%) were too ill to take part. This led to a participation rate of 99% for cases 
and 91% for controls; the analysis was therefore conducted on a final population of 408 cases and 816 
matched controls. Respectively 48.7%, 13.4% and 37.9% of the controls, consisted of visitors, 
inpatients and outpatients. Most of the inpatients were hospitalized for diverticulitis or 
gastrointestinal infections; outpatients were visiting for either gastro-esophageal reflux disease, 
irritable bowel syndrome, chronic constipation or dyspepsia. The median age of cases and matched 
controls was 68 years (range 35 to 99); 51.2% were men. 
Almost all cases and controls were Caucasians. 
Risk factors for pancreatic cancer 
Compared with controls, cases had higher mean BMI value, higher proportion of obesity, 1st degree FH 
of PDAC, previous history of diabetes, previous chronic pancreatitis, and were more frequently 
smokers, heavy smokers and heavy drinkers (see Table 1).  
Overall use of aspirin and statins and risk of pancreatic cancer 
Seventy-eight cases (19.1%) and 191 controls (23.4%) reported ever use of aspirin, which was 
associated with a statistically borderline significant reduced PDAC risk (age- and sex-adjusted OR, 0.74; 
95% CI, 0.54–1.02; Table 2). Only 2 of the 78 cases and 5 of the 191 controls (0.5% of both cases and 
controls) were on high-dose aspirin. The median duration of aspirin use was 60 months for both cases 
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and controls, with 20 patients (4.9%) among cases and 33 patients (4.0%) among controls not recalling 
the exact duration of use. A borderline significant protective association was recorded for shorter 
duration of exposure.  
Seventy-four cases (18.1%) and 203 controls (24.9%) reported ever use of statins, which was associated 
with a statistically significant reduced PDAC risk (age- and sex-adjusted OR, 0.64; 95% CI, 0.48–0.88; 
Table 2).  
The median dosage of statins was 20 mg and the median duration of use was 48 months for both cases 
and controls. A higher dosage of statins (for ≥20 mg, OR, 0.43; 95% CI, 0.27–0.71) was associated with 
a stronger protective effect. The most commonly used statin was atorvastatin. Of the 74 cases and the 
203 controls, respectively 11 (2.7%) and 46 (5.6%) could not recall the type of drug, 38 (9.3%) and 69 
(8.5%) could not recall the dosage, and 27 (6.6%) and 48 (5.9%) could not recall the duration of use. 
At multivariable analysis, statins (OR 0.61; 95% CI, 0.43–0.88) but not aspirin (OR, 0.77; 95% CI, 0.53–
1.11) use was associated to a reduced PDAC risk (Table 2).  
To avoid possible bias due to controls selection, a sensitive analysis for control type (visitors or hospital 
patients) was performed. At multivariable analysis, statin use was associated to a reduced risk of PDAC 
both with sensitive analysis restricted to visitors (OR 0.60; 95% CI, 0.40–0.89) or to hospital controls 
(OR 0.59; 95% CI 0.40–0.87), while the use of aspirin was not associated to PDAC risk for either visitors 
(OR, 0.82; 95% CI, 0.55–1.23) nor hospital controls (OR 0.67; 95% CI 0.45–1.01). 
Exclusive and Combined use of Aspirin and Statins and risk of pancreatic cancer 
In order to evaluate the exclusive or combined effect of the two drugs and avoid possible confounding 
effects, we analyzed the use of aspirin excluding patients reporting also the use of statins and vice 
versa (Table 3). An exclusive aspirin use was recorded in 39 (9.6%) of all cases and 95 (11.6%) of all 
controls, and an exclusive statin use was recorded in 35 (8.6%) of cases and 107 (13.1%) of controls. In 
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an age- and sex- adjusted analysis the exclusive use of statins was associated with a stronger risk 
reduction (OR, 0.54; 95% CI, 0.36–0.82) than the exclusive use of aspirin (OR, 0.67; 95% CI, 0.45–1.02). 
The concomitant use of statins and aspirin was reported in 39 cases (9.6%) and 96 controls (11.8%). 
This combined use did not further reduce the risk (OR, 0.67; 95% CI, 0.44–1.01) compared with the use 
of statins alone.  
At logistic regression multivariable analysis adjusted for other potential confounding factors, statin use 
(OR, 0.51; 95% CI, 0.32–0.80) was associated to a reduced risk of PDAC occurrence, while the 
association for aspirin use was of borderline significance (OR, 0.64; 95% CI, 0.40–1.01). The combined 
use of the two drugs did no further reduce the risk compared to the use of statins alone at multivariable 
logistic regression analysis (OR, 0.54; 95% CI, 0.34–0.87). No evidence of interaction between statin 
and aspirin was found when adding an interaction term to the main effects of aspirin and statin in a 
multivariable model adjusted for other potential confounding variables (p = 0.17). 
Association between use of aspirin and statins and risk of pancreatic cancer in subgroups 
To evaluate a potential specific association between the use of the two drugs and the risk of PDAC 
among different subgroups, separate multivariable subgroup analyses were conducted for the 
exclusive use of aspirin and statin according to: gender, smoking habit, obesity, history of diabetes and 
age ≥ or <70 years. Results are shown in Fig. 1.  
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Discussion: 
Paper I has shown as the use of ACEI and STAT was associated with lower rates of dimensional 
progression and overall progression (any) of BD-IPMNs in follow-up. Such effect remained significant 
even at sex, age and insulin adjusted multivariable cox hazard regression analysis. Interestingly the 
lowering of dimensional and any progression in STAT users was in line with the risk reduction of 
pancreas cancer elsewhere described.(19) Anyway, no statistically significant effect has been shown 
on clinically relevant progression.   
The use of ARB use was associated with an increased risk for clinically significant progression at sex 
and age adjusted univariable cox hazard regression analysis, but the data was not confirmed in the 
multivariate model after correction for possible risk factors. Thus, such association has still to be 
confirmed even because the absence of statistical significance, might be related to the absence of 
statistical power for such outcome.  
In opposition to several observational studies on pancreas cancer in the current study, ASA use was 
not significantly associated with a slower progression. On the other hand, recently questioning have 
been risen regarding the real effect of ASA on cancer, since a large trial has shown a higher incidence 
of cancer in patients treated with aspirin arm compared to controls group. (35) 
Takasaki et al. in the only paper addressing such aspect in IPMNs, investigated the effect of aspirin in 
a cohort of BD-IPMNs in follow up, suggesting after a median 5.5 years follow up a possible effect of 
low dose aspirin in slowing MPD dilation over the time (4.8% vs 12.7%, p=0.02). In such study, no 
specific investigation was performed regarding the use of STAT or ACEI/ARB nor their possible 
associations.(36) 
As a matter of facts, it is also still unclear whether the potential anti neoplastic effect of ASA could be 
a long-term rather than immediate effect. (37) As previously suggested by some authors the effect of 
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aspirin might be balanced by confounding drugs such as statins, since often these two drugs are co-
prescribed. (31) 
 So far, Paper I represents the first paper investigating the effects of ASA, ACEI/ARB and STAT on the 
progression os  BD-IPMNs. Although several papers have already suggested an active role of ACEI/ARB 
in inhibiting cancer initiation and progression in several cancer models, none of them investigated the 
exclusive effect of the two classes of drugs, nor the effect of different molecules among the same class 
of drug.(26, 38) 
The main breakthrough of Paper I is the identification of different clinical effects for the exclusive use 
of ACEI and ARB. In fact, in many papers they are generally pooled together, although acting on 
different points of the renin-angiotensin-aldosterone cascade.  
ACEI act on angiotensin I converting enzyme (ACE1), which is an enzyme upstream the entire cascade 
converting circulating angiotensin I into angiotensin II (AngII).  
Ang II is the main effector of the cascade, acting either on Ang II receptor 1 (AT1), which is the target 
of ARB, and on receptor II (AT2), which is not. In addition, Ang II through multiple intermediate 
mediators, such as ang III, ang IV, ang 1-7, acts even on other different pathways, through different 
receptors such as AT2, AT4, MAS. Therefore, while the blocking of ACE1 by ACEI might inhibit the entire 
cascade, the selective blocking of AT1-2 might instead imply escape mechanisms with retrograde 
shifting of the cascade towards other mediators and receptors. The exact activity of such other 
receptors is still matter of debate and has not be fully elucidated, but some of them are implied in the 
regulation of the neovascularization after myocardium infarction through a VEGF pathway, with 
possible activity even on different intracellular kinases. These pathways are important mediators in 
neoplastic initiation and progression and might be at least one of the molecular mechanism justifying 
of our results (Figure3).(39)   
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Beside some limitations, such as the absence of a preliminary power calculation, the retrospective 
design and the absence on correlation with final histology, Paper I displays some strengths such as the 
relatively large sample size, the inclusions of patients from high volume centers assuring high quality 
of data, the investigation of several pharmacological previously uninvestigated factors on a high 
prevalence disease, with potential major implications for health care policies. 
Despite a possible heterogeneity in modalities of data collection among Italian and Swedish cohort, in 
two third of patients the extraction of data from a specific IT system, constantly updated, gave 
clinicians direct access to inpatient’s/outpatient’s clinical charts and prescriptions, therefore 
minimizing possible recall biases.  
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Paper II is the first paper analyzing the effect of potentially chemo-preventive agents on cancer related 
death in a cohort of operated IPMNs. In the past years, huge body of literature has been focusing on 
the role of different clinical features in predicting cancer or invasive IPMNs “recurrence” in the 
remnant pancreas.(11, 12, 40) 
In the current study, heterogeneity of our cohort in terms of resected specimen (ranging from absence 
of dysplasia to invasive IPMNs), is largely counterbalanced by the strict inclusion of patients undergone 
surgery with curative intent. For that purpose, all patients with positive margins for high grade 
dysplasia and/or cancer, synchronous pancreas cancer and/or periampullary tumors, potentially 
influencing prognosis, were excluded from our analysis.  
On the other hand, we do think that such heterogeneity of resected specimens, might be more 
representative of “real world” population undergoing surgery for suspect malignified IPMN. It does 
therefore specifically served our aim of investigating the effect of such drugs on definitive prognosis 
of patients undergone surgery. In the current study, STAT use was associated with 23% reduction of 
cancer related death. Although not statistically significant, it is interesting to note how the data is in 
line with what reported in other epidemiological studies and meta-analysis (19, 31) 
Surprisingly and in contradiction to several observational studies, that have previously shown a 
potential anti-cancer effect, in the current study, ASA was associated to an increased risk of cancer 
related death.(21, 37) The exact molecular mechanism behind that has not been clarified yet and 
deserves further investigations. ASA use maintained its association with cancer related death even 
when corrected for the presence of possible known risk factors for pancreas cancer, such as smoking, 
diabetes overweight/obesity, who might also increase cardiovascular risk and therefore need primary 
or secondary cardiovascular prevention with ASA. Further studies are needed to specifically investigate 
whether such association display  
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a real pathophysiological background or whether it’s the result of the exposure to a common risk factor 
for both pancreas cancer and cardiovascular disease. 
Paper II displays several strengths as well as limitations. Inherent with its design, our study displays as 
main limitation the absence of a preliminary power calculation. The strength of the study is 
represented by the relatively large sample size, the investigation of several clinical factors possibly 
implicated in progression of IPMNs after surgery and, for the first time, the evaluation of 
pharmacological exposures possibly influencing cancer occurrence and prognosis. The inclusions 
criteria were clearly defined and aiming at identifying prognostic factors in a population treated with 
curative intent. Data were extracted by IT system, constantly updated and giving clinicians access to 
inpatient’s/outpatient’s clinical charts and prescriptions, therefore minimizing possible recall biases.  
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Paper III is this largest multicenter study investigating possible risk and protective factors for the 
occurrence of pancreatic neuro endocrine tumors. To the best of our knowledge, there have been six 
published studies to have investigated risk factors for PNEN with heterogeneos results. (34, 41-45) Due 
to the low incidence of such tumors, which would make a longitudinal cohort study highly problematic, 
it is not unexpected that these were all case–control studies.  In the current study,  diabetes mellitus 
was associated with an increased risk of PNEN occurrence, however it is noteworthy that we identify 
the significance of non-recent onset diabetes as a risk factor. Non-recent onset diabetes was confirmed 
to be increasingly consistent with the occurrence of PNEN for intervals superior to 1 year and up to 5 
years. For intervals of onset of diabetes superior to 5 years this association was not anymore 
statistically significant. This might be interpreted on the base of a lack of power of the study when 
considering small subgroups or, alternatively, it could be biologically explained by the trophic influence 
that diabetes plays on cancer. On the other hand, one should also consider that PNEN display a slower 
growing rate compared to PDAC and therefore it might justify a major latency of occurrence of 
symptom diabetes. Differently from what elsewhere suggested(34), no specific difference in cancer 
occurrence was noted between cases and controls with regards to family history of cancer, past 
medical history (other than diabetes) and exposure to environmental factors such as alcohol and 
smoking. 
As the potential role of pharmacological exposures has been reported to possible influence pancreatic 
carcinogenesis (32, 46) we specifically investigated also the role of aspirin, metformin and insulin. 
Although the prevalent use insulin alone was more frequent among cases than in controls (4.1% vs 
1.6%), this difference was not significant as the study was underpowered to assess it. No statistically 
significant differences were detected for the use of aspirin (22.5% vs 26.5, p=0.29), possibly reflecting 
intrinsic biological differences between endocrine and exocrine neoplasia of the pancreas.  
Paper III displays several strengths as well as limitations. The strengths of the study are represented 
by the relatively large sample size keeping in mind the low incidence of this tumor type, the European 
    PhD Doctoral Thesis 
57 
 
multicenter setting (6 countries involved), the preliminary power calculation, the investigation for the 
first time of a large set of factors possibly associated with the risk of PNENs and the conduct of the 
study by face-to-face interview with a standardized questionnaire. The inclusion criteria were clearly 
defined, controls were well matched for age and gender with a 1:3 ratio and all questionnaires were 
administered by trained medical doctors fluent in the local language, who evaluated exposures present 
12 months before diagnosis, to minimize bias due to cancer symptoms. Inherent with a multi-national 
case-control design, our study displays some limitations such as potential recall bias and heterogeneity 
in data from different countries, although the analysis was corrected for center of enrollment. 
Furthermore, the analysis might have been underpowered for some of the investigated factors and 
additional studies might be important to confirm the lack of significant association. Another important 
matter of concern, as for any case-control study, regards the choice of the control population. We 
opted for a mixed control group that we believed to represent the same population as the case group, 
as living in the same catchment area of the corresponding cases, to limit possible bias that could have 
been specific of either hospital controls or visitors.  
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Paper IV 
This is the first study evaluating the possible association between overall, exclusive and combined use 
of both aspirin and statins and PDAC risk at the same time. This is a relevant issue, as both drugs 
together are very frequently co-prescribed. Therefore, one might hypothesize the presence of both a 
possible confounding or a synergistic effect due to the prescription of both drugs. In the present study, 
PDAC risk is inversely associated with the overall statin use, with a dosage-dependent effect while the 
overall aspirin use is not associated to a statistically significant reduced PDAC risk. Statin use displayed 
a risk reduction of 49%, higher than that of aspirin, which was only borderline statistically significant. 
The concomitant use of the two drugs was also associated to a 46% reduced PDAC risk, without 
conferring a stronger risk reduction compared to the use of statins alone.  Furthermore, no synergistic 
effect was shown through the analysis of interaction. Two previous cohort and case-control studies 
evaluated the use of statins and the risk of PDAC. The first study on a female population adjusted the 
analysis for the use of aspirin and NSAIDs, and the second also analysed the use of aspirin, but both 
did not evaluate the association of the two drugs or their exclusive use. (47, 48)  As a difference with 
previous case-control studies evaluating the association between statin use and PDAC risk, Paper IV 
had a preliminary power calculation and the investigation of possible confounding factors such as BMI 
or dosage and duration of drug use.(49, 50)  Our results shown a more consistent association between 
the exclusive use of statins and PDAC risk reduction. The effect was similar for both genders, but limited 
to smokers, elderly subjects, obese and non-diabetic patients.  
Statins might exert a specific protective effect on cigarette-related carcinogenesis, because their 
possible effect of AKT and ERK pathways .(51) 
The reasons for a more important protective effect of statins in non-diabetics are unclear. The 
association between statin use and reduced PDAC risk in subjects aged ≥70 years is probably due to 
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the increased PDAC risk in older subjects that might also have a prolonged drug exposure. Paper IV 
has some strengths:  
1) it is the first specifically aimed at evaluating the association between overall, exclusive and 
combined use of both aspirin and statins  
2) a priori power calculation  
3) the investigations of possible known risk factors, allowing the identification of possible selection 
biases among our population 
4) statin results are consistent with most Bradford Hill criteria for causation.(52) 
As every case control study, even the current one might display as limitation the possible presence of 
recall biases. To reduce the risk of confounding factors, the questionnaire was carefully conducted by 
a trained physician with expertise on pancreatic disorders, asking information regarding risk factors 
exposure as present 1 year before the interview.  
As in any case-control study the choice of the control population is a possible matter of concern. We 
opted for a control group that we believed to represent the same population as the case group, derived 
from the same catchment area seeking medical attention for similar symptoms but with a final 
diagnosis unrelated with the disease of interest, and by hospital non-patient visitors to minimize 
possible selection biases. 
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Conclusions: 
Paper I: Results of this large multi institutional cohort study suggest a possible effect of ACEI and STAT 
on the progression of BD-IPMNs. Such effect has not been confirmed for ASA and ARB. Further studies 
are needed to validate such association and shed light on the possible underlining pathophysiological 
mechanism. 
Paper II: Results of this large single institution cohort study suggest a possible association between 
aspirin use and cancer related death after surgical resection for pancreatic IPMNs. On the contrary no 
specific influence on cancer related death has been reported for statins and ace inhibitors/sartans use. 
Further studies are needed to investigate if this association is the result of an underling 
pathophysiologic mechanism or the result to a common and yet unknown risk factors exposure. 
Paper III: Findings of this large multicenter case-control study suggest that non-recent onset diabetes 
was associated with an increased risk of PNENs occurrence. Our results do not support the view of a 
strict similarity with factors affecting the risk of pancreatic adenocarcinoma such as the use of insulin 
and aspirin. 
Paper IV: Results of the present study suggests that statin use, rather than that of aspirin, particularly 
at higher dosages is associated to a reduced PDAC risk. These findings support a chemo-preventive 
action of statins on PDAC and no apparent synergistic activity of the two medications. 
 
 
 
 
 
 
    PhD Doctoral Thesis 
61 
 
References: 
 
1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting 
cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers 
in the United States. Cancer research. 2014;74(11):2913-21. 
2. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 
2018;67(5):789-804. 
3. Crippa S, Pezzilli R, Bissolati M, Capurso G, Romano L, Brunori MP, et al. Active 
Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous 
Neoplasms Undergoing Non-Operative Management. The American journal of gastroenterology. 
2017;112(7):1153-61. 
4. Del Chiaro M, Ateeb Z, Hansson MR, Rangelova E, Segersvard R, Kartalis N, et al. 
Survival Analysis and Risk for Progression of Intraductal Papillary Mucinous Neoplasia of the Pancreas 
(IPMN) Under Surveillance: A Single-Institution Experience. Annals of surgical oncology. 
2017;24(4):1120-6. 
5. Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. 
Revisions of international consensus Fukuoka guidelines for the management of IPMN of the 
pancreas. Pancreatology : official journal of the International Association of Pancreatology (IAP)  [et 
al]. 2017;17(5):738-53. 
6. Dortch JD, Stauffer JA, Asbun HJ. Pancreatic Resection for Side-Branch Intraductal 
Papillary Mucinous Neoplasm (SB-IPMN): a Contemporary Single-Institution Experience. Journal of 
gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 
2015;19(9):1603-9. 
7. Robles EP, Maire F, Cros J, Vullierme MP, Rebours V, Sauvanet A, et al. Accuracy of 
2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal 
papillary mucinous neoplasms of the pancreas. United European gastroenterology journal. 
2016;4(4):580-6. 
8. Seo N, Byun JH, Kim JH, Kim HJ, Lee SS, Song KB, et al. Validation of the 2012 
International Consensus Guidelines Using Computed Tomography and Magnetic Resonance Imaging: 
Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of 
surgery. 2016;263(3):557-64. 
9. Sahora K, Fernandez-del Castillo C, Dong F, Marchegiani G, Thayer SP, Ferrone CR, et 
al. Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: 
implications of minimal involvement of the main pancreatic duct. Surgery. 2014;156(3):611-21. 
10. Pergolini I, Sahora K, Ferrone CR, Morales-Oyarvide V, Wolpin BM, Mucci LA, et al. 
Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous 
Neoplasm in a Referral Center. Gastroenterology. 2017;153(5):1284-94.e1. 
11. Marchegiani G, Mino-Kenudson M, Ferrone CR, Morales-Oyarvide V, Warshaw AL, 
Lillemoe KD, et al. Patterns of Recurrence After Resection of IPMN: Who, When, and How? Annals of 
surgery. 2015;262(6):1108-14. 
12. Passot G, Lebeau R, Hervieu V, Ponchon T, Pilleul F, Adham M. Recurrences after 
surgical resection of intraductal papillary mucinous neoplasm of the pancreas: a single-center study 
of recurrence predictive factors. Pancreas. 2012;41(1):137-41. 
13. Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ. Changing incidence of pancreatic 
neoplasms: a 16-year review of statewide tumor registry. Pancreas. 2008;37(2):134-8. 
14. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years 
after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases 
in the United States. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 2008;26(18):3063-72. 
    PhD Doctoral Thesis 
62 
 
15. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ. Antihypertensives as novel 
antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor 
blockers in pancreatic ductal adenocarcinoma. Journal of the American College of Surgeons. 
2007;204(5):996-1005; discussion -6. 
16. Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA. Angiotensin 
II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 
1 receptor and ERK1/2 signaling. Journal of gastrointestinal surgery : official journal of the Society for 
Surgery of the Alimentary Tract. 2008;12(1):57-66. 
17. Bang UC, Watanabe T, Bendtsen F. The relationship between the use of statins and 
mortality, severity, and pancreatic cancer in Danish patients with chronic pancreatitis. European 
journal of gastroenterology & hepatology. 2018;30(3):346-51. 
18. Lee HS, Lee SH, Lee HJ, Chung MJ, Park JY, Park SW, et al. Statin Use and Its Impact on 
Survival in Pancreatic Cancer Patients. Medicine. 2016;95(19):e3607. 
19. Archibugi L, Arcidiacono PG, Capurso G. Statin use is associated to a reduced risk of 
pancreatic cancer: A meta-analysis. Digestive and liver disease : official journal of the Italian Society 
of Gastroenterology and the Italian Association for the Study of the Liver. 2018. 
20. Jankowski JAZ, de Caestecker J, Love SB, Reilly G, Watson P, Sanders S, et al. 
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet 
(London, England). 2018;392(10145):400-8. 
21. Patrignani P, Patrono C. Aspirin, platelet inhibition and cancer prevention. Platelets. 
2018:1-7. 
22. Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. 
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. 2015;162(6):1257-70. 
23. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC 
Guidelines for the management of acute coronary syndromes in patients presenting without 
persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in 
Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology 
(ESC). European heart journal. 2016;37(3):267-315. 
24. Patrignani P, Sacco A, Sostres C, Bruno A, Dovizio M, Piazuelo E, et al. Low-Dose Aspirin 
Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of 
Colorectal Cancer. Clinical pharmacology and therapeutics. 2017;102(1):52-61. 
25. Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, et al. Associations between aspirin use 
and the risk of cancers: a meta-analysis of observational studies. BMC cancer. 2018;18(1):288. 
26. Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, et al. Inhibition of renin-
angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. British 
journal of cancer. 2010;103(11):1644-8. 
27. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I 
converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with 
advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. Journal of 
cancer research and clinical oncology. 2009;135(10):1429-35. 
28. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, et al. Reduced risk 
of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer 
investigation. 2011;29(9):585-93. 
29. Laezza C, Malfitano AM, Proto MC, Esposito I, Gazzerro P, Formisano P, et al. Inhibition 
of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate 
antitumor effects of anandamide in human breast cancer cells. Endocrine-related cancer. 
2010;17(2):495-503. 
30. Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer 
epidemiology, biomarkers & prevention : a publication of the American Association for Cancer 
Research, cosponsored by the American Society of Preventive Oncology. 2005;14(8):1897-8. 
    PhD Doctoral Thesis 
63 
 
31. Archibugi L, Piciucchi M, Stigliano S, Valente R, Zerboni G, Barucca V, et al. Exclusive 
and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. 
Scientific reports. 2017;7(1):13024. 
32. Zhang YP, Wan YD, Sun YL, Li J, Zhu RT. Aspirin might reduce the incidence of 
pancreatic cancer: A meta-analysis of observational studies. Scientific reports. 2015;5:15460. 
33. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Light alcohol 
drinking and cancer: a meta-analysis. Annals of oncology : official journal of the European Society for 
Medical Oncology. 2013;24(2):301-8. 
34. Capurso G, Falconi M, Panzuto F, Rinzivillo M, Boninsegna L, Bettini R, et al. Risk 
factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated 
patients. The American journal of gastroenterology. 2009;104(12):3034-41. 
35. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of Aspirin 
on All-Cause Mortality in the Healthy Elderly. The New England journal of medicine. 
2018;379(16):1519-28. 
36. Takasaki Y, Nagata N, Imbe K, Hisada Y, Sekine K, Tajima T, et al. Effect of low-dose 
aspirin use on pancreatic cancer development and morphological changes on imaging in IPMN: A 
long-term cohort study. United European gastroenterology journal. 2017;5(7):1030-6. 
37. Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS, et al. Aspirin for 
the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. 
Preventive Services Task Force. Annals of internal medicine. 2016;164(12):814-25. 
38. Mandilaras V, Bouganim N, Yin H, Asselah J, Azoulay L. The use of drugs acting on the 
renin-angiotensin system and the incidence of pancreatic cancer. British journal of cancer. 
2017;116(1):103-8. 
39. Karnik SS, Unal H, Kemp JR, Tirupula KC, Eguchi S, Vanderheyden PM, et al. 
International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of 
Pathophysiological Angiotensinergic Stimuli [corrected]. Pharmacological reviews. 2015;67(4):754-
819. 
40. Dhar VK, Merchant NB, Patel SH, Edwards MJ, Wima K, Imbus J, et al. Does Surgical 
Margin Impact Recurrence in Noninvasive Intraductal Papillary Mucinous Neoplasms?: A Multi-
institutional Study. Annals of surgery. 2018;268(3):469-78. 
41. Ben Q, Zhong J, Fei J, Chen H, Yv L, Tan J, et al. Risk Factors for Sporadic Pancreatic 
Neuroendocrine Tumors: A Case-Control Study. Scientific reports. 2016;6:36073. 
42. Halfdanarson TR, Bamlet WR, McWilliams RR, Hobday TJ, Burch PA, Rabe KG, et al. Risk 
factors for pancreatic neuroendocrine tumors: a clinic-based case-control study. Pancreas. 
2014;43(8):1219-22. 
43. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Family history of cancer and 
associated risk of developing neuroendocrine tumors: a case-control study. Cancer epidemiology, 
biomarkers & prevention : a publication of the American Association for Cancer Research, 
cosponsored by the American Society of Preventive Oncology. 2008;17(4):959-65. 
44. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Risk factors associated with 
neuroendocrine tumors: A U.S.-based case-control study. International journal of cancer. 
2008;123(4):867-73. 
45. Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G. Risk factors for the occurrence of 
insulinoma: a case-control study. Hepatobiliary & pancreatic diseases international : HBPD INT. 
2013;12(3):324-8. 
46. De Souza A, Khawaja KI, Masud F, Saif MW. Metformin and pancreatic cancer: Is there 
a role? Cancer chemotherapy and pharmacology. 2016;77(2):235-42. 
47. Simon MS, Desai P, Wallace R, Wu C, Howard BV, Martin LW, et al. Prospective 
analysis of association between statins and pancreatic cancer risk in the Women's Health Initiative. 
Cancer causes & control : CCC. 2016;27(3):415-23. 
    PhD Doctoral Thesis 
64 
 
48. Kho PF, Fawcett J, Fritschi L, Risch H, Webb PM, Whiteman DC, et al. Nonsteroidal anti-
inflammatory drugs, statins, and pancreatic cancer risk: a population-based case-control study. 
2016;27(12):1457-64. 
49. Walker EJ, Ko AH, Holly EA, Bracci PM. Statin use and risk of pancreatic cancer: results 
from a large, clinic-based case-control study. Cancer. 2015;121(8):1287-94. 
50. Carey FJ, Little MW, Pugh TF, Ndokera R, Ing H, Clark A, et al. The differential effects of 
statins on the risk of developing pancreatic cancer: a case-control study in two centres in the United 
Kingdom. Digestive diseases and sciences. 2013;58(11):3308-12. 
51. Hermann PC, Sancho P, Canamero M, Martinelli P, Madriles F, Michl P, et al. Nicotine 
promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent 
dedifferentiation of acinar cells in mice. Gastroenterology. 2014;147(5):1119-33.e4. 
52. Hill AB. THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? Proceedings 
of the Royal Society of Medicine. 1965;58:295-300. 
 
Study 1: Presented as oral presentation at UEGW2018 
 
Effect of Aspirin, ACE Inhibitors/Sartans and Statins use on the progression of BD-IPMN in follow 
up: a multicenter study 
Roberto Valente1,2, Stefano Crippa3, Urban Arnelo3, Giuseppe Vanella2, Giulia Zerboni2, Laura 
Zarantonello1,Alessandro Fogliati3, Massimo Falconi3, Gabriele Capurso*2 and  Marco del Chiaro*1  
Pancreatic Disease Unit, Karolinska University Hospital, CLINTEC, Stockholm, Sweden 
Digestive and Liver Disease Unit, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy 
Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific 
Institute, 'Vita-Salute' University, Milan Italy 
 
*authors contribute equally to the writing of manuscript 
 
 
 
 
 
 
 
 
 
 
 
Corresponding author: 
Marco Del Chiaro, MD, PhD, FACS  
Professor of Surgery  
Chief of Surgical Oncology  
Director of the Hepato-Pancreato-Biliary Program 
University of Colorado Anschutz Medical Campus | Department of Surgery 
12631 E. 17th Avenue, C-313 | Aurora, CO 80045 
Email: marco.delchiaro@ucdenver.edu 
Introduction:  
Pancreatic cancer is expected to become the third cause of cancer related death within 2030.(1) In the 
last decades, the spread use of cross-sectional imaging and the progressive quality improvement of 
abdominal imaging, has led to a more frequent detection of pancreatic cystic neoplasm, whose actual 
prevalence is estimated to be around 45%. (2, 3) Intrapapillary mucinous neoplasms (IPMNs) represent 
circa half of these lesions and are increasingly considered as possible precursor lesions of pancreatic 
cancer. (4)   
According to the isolated, combined or absent cystic involvement of the main pancreatic duct are 
divided into main duct (MD), mixed type(MT) and branch duct (BD) IPMNs. (5)  
If patient is fit for surgery, the presence of mixed type or main duct IPMN represents a clear surgical 
indication. A more selective approach has been proposed instead for BD IPMNs, which harbor a lower, 
despite not inexistent, lifetime risk of pancreas cancer occurrence (approximately 8-10%). (3, 6, 7)   
Several authors and different guidelines have suggested a lifelong follow-up with MRI/MRCP and/or 
EUS for all BD-IPMNs patients “potentially fit for surgery”.(2-5) Considering the high prevalence of BD-
IPMNs (around 20%), the relative low incidence of pancreas cancer and the need for a life-long follow-
up, questions  have been risen on  cost-effectiveness of such a strategy for health care systems.  
The long-term follow-up of BD-IPMNs will probably represent in the upcoming future, from a logistic 
and economic point of view, one of the main challenges for the development of wide scale screening 
programs for the early detection and treatment of pancreas cancer.  
So far, no effective chemoprevention is available to slow or prevent the progression of BD-IPMNs. 
Aspirin (ASA), Ace Inibitors/Sartans (ACEI/ARB) and Statins (STAT) are among the most used drugs for 
primary and secondary cardiovascular prevention.  Aspirin, is a selective and irreversibly acetylator of 
prostaglandin (PG)G/H-synthases (COX-1 and COX-2), that blocks the catalytic reaction that converts 
arachidonic acid into PGG2 and PGH2 and therefore thromboxane (TX)A2 resulting in anti-
inflammatory, analgesic, antipyretic and antiplatelet effects. (8) COX-2 expression and platelets 
activation seems to contribute to development, progression and metastatic potential of cancer, 
through locoregional release of a variety of cell growth, pro-angiogenic and pro inflammatory 
mediators,  while PGE2 seems to be implied into immunological escapes from Interferon and/or T-cell-
dependent cancer killing.(9) Beside the well-known cardiovascular protective effect (10), aspirin has 
been recently proved to play a major role in inhibit cancerogenesis, acting on several pathways (mTOR, 
EGFR, 15-PGDH) (11) Observational studies support the idea that aspirin use is associated with a 
significant decrease in the risk of overall and site-specific cancers.(12) 
Angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are 
widely diffused antihypertensive drugs for their property to inhibit the activation of systemic renin–
angiotensin system (RAS).(13) Angiotensin II, which represents a cornerstone in such a cascade, has 
shown to harbor proangiogenic properties by acting on the vascular endothelial growth factor (VEGF), 
MAP Kinases and G-protein cascades with potential major implications on cancer management, as 
suggested for lung, breast and pancreas cancer.(13-15) 
Statins, are inhibitors of the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase and used 
as cholesterol lowering agents in the setting of both primary and secondary cardiovascular prophylaxis. 
Statins seem to act a regulation on several intracellular pathways such as Ras, MEK, mTOR, BCL-2 and 
Rho kinases, that also play a major role in cancer development. Recently their possible role in 
decreasing the incidence of cancer has been suggested in epidemiological studies and meta-analysis. 
(16-18) 
Therefore despite Aspirin (ASA), Ace Inibitors/Sartans (ACEI/ARB) and Statins (STAT) have shown to 
inhibit tumoral growth in several clinical and preclinical models, including pancreatic cancer 
(PDAC),(19-24) their possible role in IPMNs has never been investigated. (25)  
 
Aim: to evaluate the possible effect of ASA, ACEI/ARB and STAT used for cardiovascular prevention on 
the progression of BD-IPMN in follow-up. 
 
Materials and method: Multicenter, retrospective cohort study. Patients were collected at Karolinska 
University Hospital in Stockholm Sweden, Sant’ Andrea Hospital, Sapienza University of Rome, Rome 
Italy and San Raffaele Vita Salute Hospital, Milan Italy.  
Inclusion Criteria:  BD-IPMNs patients without “ab initio” surgical indications and undergoing 
radiological follow-up according to current guidelines at the participating centers. Clinical- and 
radiological characteristics as well as exposure to the target drugs were collected and analyzed in 
relation to the progression of BD-IPMN. 
Data collection: Prospectively collected data about medical history, family history of cancer and 
exposures were extracted by a specific created retrospective database at Sant ’Andrea Hospital and 
San Raffaele Hospital. Eventual missing data were filled as possible by re-contacting patients. A specific 
IT database (®Take Care) with in real time updated inpatient and outpatient clinic charts was consulted 
for data collection in Sweden. 
Exclusion criteria at diagnosis:  
• presence of mural nodules 
• main pancreatic duct (MPD) diameter ≥5 mm  
• cyst diameter ≥40 mm  
Exposures: 
The exposure to several potential risk factors for the development of pancreas cancer were 
considered: 
Smoking habit: participants were considered as being ever smokers when reporting to have smoked 
for a period above 6 months or a quantity superior to 100 cigarettes.  
 
Alcohol drinking: the cut-off to be considered a regular ever drinker was a daily intake of at least 12.5 
g of alcohol for at least one year. Such quantity is approximately equal to either one glass of wine, one 
shot of hard liquor or one pint of beer. Participants were then classified as ever drinkers or nondrinkers. 
 
General risk factors for pancreas cancer:  A 1st degree family history of pancreatic cancer, the presence 
of symptoms, the cyst’s mean diameter and a diagnosis of diabetes were specifically recorded. Recent 
onset diabetes was defined as that which occurrence was in the 12 months prior to diagnosis of BD-
IPMN. 
Target drugs exposure: The previous use of drugs such as aspirin (ASA), ace inhibitors AND/OR Sartans 
(ACEI/ARB), exclusive ace inhibitors (ACEI), exclusive Sartans (ARB), statins (STAT), insulin and 
metformin has been recorded and analyzed. For STAT, ACEI and ARB a further distinct analysis was 
performed sub-dividing different drugs within the same class. For ASA a distinction between low and 
high dose was considered. Considering that many of these drugs are often prescribed together in 
patients displaying high cardiovascular risk profile, beside the evaluation of single class effect, we also 
considered the potential summative effect resulting from the simultaneous treatment with more than 
one drug. We therefore analyzed several possible combinations of the studied drugs. 
Definition of outcomes:  
Definition of outcomes: progression during follow up defined as:  
-dimensional progression: increasing of cyst maximum diameter of at least 2 mm 
between two follow-up imaging 
-clinical significant progression: appearance of mural nodules and/or increasing in MPD 
diameter ≥ 5 mm and/or the occurrence of cancer and/or increasing of cyst maximum 
diameter above 40 mm. 
-any-progression: indiscriminate appearance of either dimensional and/or clinical 
significant progression and increased number of cystic lesions.  
 
Statistical Analysis: Patients exposed and non-exposed to the target drugs or displaying possible risk 
factors for pancreas cancer were compared by chi-square test and fisher test with Yates correction for 
categorical variables; Student’s t test or long Rank test for continuous ones. Significant variables were 
further analyzed by sex and age adjusted univariable and multivariable logistic regression analysis. The 
effect of the target drugs over the time was evaluated through univariable and multivariable Cox 
hazard regression analysis (by enter selection procedure). The 95% confidence interval (95% CI) was 
calculated where possible and all p-values were two-sided and considered statistically significant when 
p<0.05.  A dedicated statistical software (MedCald Mariakerke, Belgium) was used. 
 
Results 
 
Patients’ Characteristics  
A total of 594 patients with BD-IPMN without mural nodules, suspect of main duct involvement and 
cyst dimension above 40 mm were recruited at the three participating centers (62.28% at Karolinska 
University Hospital, 23.73% at Sant ’Andrea Hospital and 13.9% at San Raffaele Hospital). The mean 
age 64.84 years (63.95-65.73; 95% CI), 38.38% were male. During a mean follow-up of 44.78 months 
(42.01-47.54; 95% CI), 46.86% of patients displayed progression (any), 41.32% displayed dimensional 
progression (mean size increasing: 7.77 mm), 7.74% displayed a clinically significant progression. 
Thirty-two-point forty-six percent of patients had a previous use of ASA, 31.9% of STAT and 43.39% of 
ACEI/ARB. Among this last group, 30.86% of patients were exclusive users of ACEI, while 45.67% were 
exclusive users of ARB. Some of the patients were exposed to multiple drugs belonging to the same 
class and some to association of the different classes of drugs. Patients characteristics and a more 
detailed report of drug use are summarized in Table 1. 
 
Past medical history:  
Multifocal of BD IPMN (73.3% vs 56.8% p=0.03), a history of diabetes (31.8% vs 16.5%; p=0.01) and 
especially newly onset diabetes (18.2% vs 4.8% p=0.06) were all factors significantly associated to 
higher rates of clinically relevant progression Table 2. 
 
Drug exposures:  
Insulin use was significantly associated to higher rates of both dimensional and clinically significant 
progression (respectively: 12.3% vs 6.8%, p=0.02 and 22.7% vs 7.9%, p=0.0009). At sex and age 
adjusted univariable Cox proportional hazard regression analysis insulin was confirmed to be 
associated to an increased risk of clinically significant progression: HR= 3.07 (95%CI: 1.49 to 6.30; 
p=0.002). 
At sex and age adjusted univariable Cox proportional hazard regression analysis the exclusive use of 
ACEI was confirmed to be associated to a decreased risk of dimensional progression: HR= 0.65 (0.45-
0.94; 95%CI; p=0.02) and any progression: HR= 0.64 (0.45-0.90; 95%CI; p= 0.01). The exclusive use of 
ARB was instead confirmed to be associated to an increased risk of clinically significant progression: 
HR= 1.94 (95%CI: 1.00-3.76; p=0.04) Figure 1b. 
At sex and age adjusted univariable Cox proportional hazard regression analysis the use of statins was 
significantly associated to decreased risk of dimensional progression (HR= 0.72; 0.54-0.97 95%CI; 
p=0.03) Table 2. 
We performed several models of sex and age adjusted multivariable Cox proportional hazard 
regression analysis. In a first model the use of ACEI (HR=0.70; 95% CI 048.1.01; p=0.06) and STAT (HR= 
0.67; 95%CI 0.49-0.93; p=0.01) was associated to a decreased risk to display dimensional progression, 
while the use of Insulin was associated to a statistically significant higher risk of dimensional 
progression (HR 1.65; 95% CI 1.09-2.51; p=0.01.  
In a second model, the use of ACEI (HR=0.69; 95%CI 0.48-0.98, p=0.04) and STAT (HR= 0.72=0.53- 0.76; 
95% CI, p=0.03) was associated to a decreased risk of (any) progression, while the use of Insulin was 
associated to an increased risk of (any) progression Insulin (HR= 1.49; 95% CI 0.99-2-24; p=0.05).  
In a third model the use of Insulin (HR=2.97; 95% CI 1.34-6.55; p=0.006) but not ARB (HR 1.41; 95% CI 
0.69-2.87; p=0.34) was statistically associated to clinically relevant progression Figure 1c.   
 
Discussion: 
The increasing of pancreatic IPMNs detection will probably represent in the next future the only 
possibility to address pancreas cancer at early or ideally pre-invasive stage. Technical improving and 
spreading of cross sectional imaging has led to increased detection of such lesions. If, from an 
oncological point of view, MD-IPMNs and MT-IPMNs are the most challenging, because have a risk of 
pancreatic cancer respectively in up to 91% (26-28) and 70% (29)of cases, from a decisional point of 
view, they are not. In fact, whenever the patient is fit for surgery, he/she encounter a surgical 
indication.(2, 5) The situation is more complex for BD-IPMNs that display 15%  risk of progression at 3-
5 years (2) and harbor 8-10% lifetime risk for pancreas cancer. (7) In BD-IPMNs, which represent by 
far, the majority of IPMN lesions in the general population, a more conservative approach has been 
suggested though lifelong follow up with MRI/MRCP and/or EUS until the patient is fit for surgery. (3, 
4) The economic counterpart of such strategy will unavoidably imply an excess of costs for health care 
systems that will probably be economically not sustainable.  In the next future, two possible strategies 
might overcome the problem: on one hand a better detection of the lesions at risk for progression. 
This will allow the optimizing of resources by continuing/intensifying follow up in a more targeted way. 
The other possible strategy will be the application of possible chemoprevention, able to slow down 
and, ideally, to stop the progression on IPMNs. While the first strategy has been addressed by several 
authors and guidelines and is still largely matter of debate, the second aspect has poorly been 
investigated so far. 
Takasaki et al. in the only paper on the issue, investigated the effect of aspirin in a cohort of BD-IPMNs 
in follow up suggesting ,after a median 5.5 years follow-up, a possible effect of low dose aspirin in 
slowing MPD dilation over the time (4.8% vs 12.7%, p=0.02). In such study, no specific investigation 
was performed regarding the use of STAT or ACEI/ARB nor their possible associations.(25) 
 So far, the current study represents the first paper investigating such pharmacological exposures on 
BD-IPMNs. In addition, although several papers suggested an active role of ACEI/ARB in inhibiting 
cancer initiation and progression in several cancer models, none of them investigated the exclusive 
effect of the two classes of drugs, nor the effect of different molecules among the same class of 
drug.(13, 30) 
In the current study, the use of ACEI and STAT was associated with lower rates of dimensional 
progression and overall progression (any). Such effect remained significant even after correction for 
other possible risk factors for pancreas cancer (such as diabetes, smoking, first degree family history 
of pancreas cancer), some of which in possible overlap as risk factors also for cardiovascular disease. 
Interestingly the lowering of dimensional and any progression in STAT users was in line with the risk 
reduction of pancreas cancer elsewhere described.(23) Anyway no significantly effect has been shown 
on clinically relevant progression.   
The use of ARB use was associated with an increased risk for clinically significant progression at sex 
and age adjusted cox hazard regression analysis, but the data was not confirmed in the multivariate 
model after correction for possible risk factors. Thus, such association has still to be confirmed even 
because the absence of statistical significance, might be related to the absence of statistical power for 
such outcome.  
The main breakthrough of such work is the identification of different clinical effects for the exclusive 
use of ACEI and ARB, generally pooled together when considering their clinical effect, although acting 
on different point of the renin-angiotensin-aldosterone cascade.  
In fact, ACEI act on angiotensin I converting enzyme (ACE1), which is an enzyme upstream the entire 
cascade and converting circulating angiotensin I into angiotensin II (AngII).  
Ang II is then the main effector of the cascade, acting either on Ang II receptor 1 (AT1), which is the 
target of ARB, and on receptor II (AT2), which is not. In addition, AngII through multiple intermediate 
mediators, such as ang III, ang IV, ang 1-7 acts even on other different pathways, through different 
receptors such as AT2, AT4, MAS. Therefore, while the blocking of ACE1 by ACEI might inhibit the entire 
cascade, the selective blocking of AT1, might instead imply escape mechanisms with retrograde 
shifting of the cascade towards other mediators and receptors. The exact activity of such other 
receptors is still matter of debate and has not be fully elucidated, but some of them are implied in the 
regulation of the neovascularization of myocardium infarction through a VEGF pathway, with possible 
activity even on different intracellular kinases. These pathways are important mediators in neoplastic 
initiation and progression and might be at least one of the molecular mechanism justifying of our 
results (Figure3).(31)   
In opposition to several observational studies on pancreas cancer, in the current study ASA use was 
not significantly associated with a slower progression. On the other hand, questioning have been risen 
regarding the real effect of ASA on cancer, since recently a large trial shown a higher incidence of 
cancer in patients treated with aspirin arm compared to controls group. (32) 
It is also unclear whether the potential anti neoplastic effect of ASA could be a long-term rather than 
immediate effect. (33)As previously suggested by some authors the effect of aspirin might be balanced 
by confounding drugs such as statins, since often these two drugs are co-prescribed. (18) 
Beside some limitations, such as the absence of a preliminary power calculation, the retrospective 
design and the absence on correlation with final histology, this study displays some strengths such as 
the relatively large sample size, the inclusions of patients from high volume centers assuring high 
quality of data, the investigation of several pharmacological, previously uninvestigated, factors on a 
high prevalence disease, with potential major implications for health care policies. 
Despite a possible heterogeneity in modalities of data collection among Italian and Swedish cohort, in 
two third of patients the extraction of data from a specific IT system, constantly updated, gave 
clinicians direct access to inpatient’s/outpatient’s clinical charts and prescriptions, therefore 
minimizing possible recall biases.  
In conclusion the results of this large multi institutional cohort study suggest a possible effect of ACEI 
and STAT on the progression of BD-IPMNs. Such effect has not been confirmed for ASA and ARB. 
Further studies are needed to validate such association and shed light on the possible underlining 
pathophysiological mechanism. 
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Table 1 Characteristics of BD-IPMN patients in follow up. *ASA: Aspirin users (ever);** ACE: Ace Inhibitors only users 
(ever);§ ARB: Sartans only users (ever);§§ STAT: Statins users (ever);# ACEI/ARB: Ace Inhibitors AND/OR Sartans users 
(ever);## plus : concomitant use 
Characteristic N (%)- (95% CI) 
Patients 594 
Number of male 228/594 (38.38) 
Mean Age (years) 64.84 (63.95–65.73; 95% CI) 
Mean follow-up (months) 44.78 (42.01–47.54; 95% CI) 
Smoking 156/579 (26.94) 
1st degree family history of PDAC  27/582 (4.63) 
Diabetes  102/579 (17.61) 
Alcohol (ever) 136/579 (23.48) 
Recent onset diabetes 10/102 (9.80) 
Mean Cyst Diameter (mm) 15.1 (14.42-15.85; 95% CI) 
Multifocal Disease 344/592 (58.10) 
Symptomatic  104/592 (17.56) 
Progression (any) 277/591 (46.86) 
Dimensional Progression 243/588 (41.32) 
Mean dimensional increase (mm) 7.77 (6.82–8.72; 95% CI) 
Clinically significant progression 46/594 (7.74) 
ASA  
Low dose (<160mg/die) 
186/573 (32.46) 
170/186 (91.39) 
ACEI/ARB:  
ACEI:  
          -Enalapril 
          -Perindopril 
          -Captopril 
          -Lisinopril 
          -Ramipril 
          - Others 
           
ARB: 
        -Telmisartan 
        -Olmesartan 
        -Combisartan 
        -Valsartan 
        -Candesartan 
        -Irbesartan 
        -Losartan 
         
 
UNSPECIFIED: 
Multiple ARB 
ACE plus ARB 
243/560 (43.39) 
75/243 (30.86) 
70/110 (63.63) 
4/110 (3.63) 
1/110 (0.90) 
3/110 (2.72) 
30/110 (27.27) 
2/110 (1.81) 
 
              111/243 (45.67) 
6/156 (3–84) 
6/156 (3.84) 
2/156 (1.28) 
6/156 (3.84) 
56/156 (35.89) 
16/156 (10.25) 
64/156 (41.02) 
 
 
22/243 (9.05) 
10/243 (4.11) 
35/243 (14.40) 
 
ASA plus ACEI/ARB plus STAT 
ASA plus ACEI/ARB  
ASA plus STAT 
ASA plus ARB plus STAT 
ASA plus ARB  
ARB plus STAT 
 
82/558 (14.69) 
122/559 (21.82) 
114/571 (19.96) 
47/536 (8.76) 
71/537 (13.22) 
81/537 (15.08) 
STAT 
Simvastatin 
Atorvastatin 
Pravastatin 
Rosuvastatin 
Multiple 
Unknown  
183/594 (30.80) 
112/208 (53.84) 
56/208 (26.92) 
5/208(2.40) 
17/208 (8.17) 
25/208 (12.01) 
18/208 (8.65) 
 
Features Progression (any): Yes/No Progression (dimension): 
Yes/No 
Significant progression:Yes/No 
Acute pancreatitis 13 (4.7) vs 14 (4.5) p=0.88  8 (3.3) vs 19 (5.5) p=0.21  2 (4.4) vs 25 (4.6) p=1.0 
1st degree FH PDAC 16 (5.9) vs 11 (3.6) p=0.20  15 (6.2) vs 12 (3.6) p=0.13  1 (2.3) vs 26 (4.8) p=0.71 
Multifocal  166 (60.4) vs 176 (56.2) p=0.31  151 (62.4) vs 188 (54.8) p=0.06  33 (73.3) vs 310 (56.8) p=0.03 
Smoking 67 (24.8) vs 88 (28.9) p=0.27  58 (24.2) vs 97 (29.0) p=0.22  13 (30.2) vs 142 (26.5) p=0.59 
Alcohol 59 (21.9) vs 76 (24.9) p=0.38  51 (21.4) vs 84 (25.1) p=0.31  11 (25.6) vs 124 (23.2) p=0.72 
Diabetes 49 (17.9) vs 52 (17.3) p=0.84  44 (18.2) vs 57 (17.2) p=0.76  14 (31.8) vs 88 (16.5) p=0.01 
New Onset Diabetes 6 (7.9) vs 4 (4.0) p=0.26  5 (7.7) vs 5 (4.5) p=0.50  2 (18.2) vs 8 (4.8) p=0.06 
Insulin  30 (11.2) vs 21 (7.1) p=0.09  29 (12.3) vs 22 (6.8) p=0.02  10 (22.7) vs 41 (7.9) p=0.0009 
Metformin  25 (9.3) vs 37 (12.5) p=0.21  22 (9.3) vs 41 (12.6) p=0.21  3 (6.8) vs 60 (11.5) p=0.34 
ASA  
Low dose ASA 
86 (32.2) vs 98 (32.5) p=0.95 
78 (92.9) vs 90 (96.8) p=0.23 
 75 (32.1) vs 108 (32.5) p=0.90 
68 (91.9) vs 100 (97.1) p=0.12 
 17 (39.5) vs 168 (31.8) p=0.29 
16 (100.0) vs 153 (94.4) p=0.33 
ACEI /ARB 116 (44.4) vs 124 (42.0) p=0.56  103 (44.8) vs 136 (42.0) p=0.51  27 (62.8) vs 215 (41.7) p=0.007 
ACEI  
Enalapril 
Perindopril 
Captopril 
Lisinopril 
Ramipril 
41 (16.6) vs 68 (23.6) p=0.04 
29 (29.0) vs 41 (36.0) p=0.27 
0 (0) vs 4 (3.4) p=0.12 
1 (1.0) vs 0 (0) p=0.46 
1(1.0) vs 3 (2.7) p=0.62 
10 (10.0) vs 19 (16.5) p=0.22 
37 (16.8) vs 72 (23.0) p=0.08 
 26 (28.6) vs 44 (36.1) p=0.25 
 0 (0) vs 4 (3.2) p=0.13 
 1 (1.1) vs 0 (0) p=0.42 
 1 (1.1) vs 3 (2.5) p=0.63 
 9 (9.9) vs 20 (16.3) p=0.17 
7 (18.4) vs 103 (20.6) p=0.74 
 4 (19.0) vs 66 (34.0) p=0.16 
 0 (0) vs 4 (2.0) p=1.0 
 0 (0) vs 1 (0.5) p=1.0 
 0 (0) vs 4 (2.1) p=1.0 
 2 (9.5) vs 28 (14.4) p=0.74 
ARB  
Telmisartan 
Olmesartan 
Combisartan 
Valsartan 
Candesartan 
Irbesartan 
Losartan 
80 (32.4) vs 65 (22.6) p=0.01 
4 (3.9) vs 2 (1.7) p=0.42 
1 (1.0) vs 5 (4.3) p=0.21 
2 (2.0) vs 0 (0) p=0.21 
5 (5.0) vs 1 (0.9) p= 0.10 
24 (24.0) vs 31 (27.7) p=0.54 
10 (10.1) vs 6 (5.3) p=0.18 
43 (44.3)vs 21 (18.8);p=0.0001 
 74 (33.6) vs 70 (22.4) p=0.0039 
 3 (3.2) vs 3 (2.4) p=0.70 
 1 (1.1) vs 5 (4.0) p=0.24 
 2 (2.2) vs 0 (0) p=0.17 
 5 (5.4) vs 1 (0.8) p=0.08 
 23 (25.3) vs 32 (26.7) p=0.82 
 9 (10.0) vs 7 (5.8) p=0.25 
 40 (44.9) vs 23 (19.3) p=0.0001 
 17 (44.7) vs 128 (25.7) p=0.01 
 0 (0) vs 6 (3.0) p=1.0 
 0 (0) vs 6 (3.0) p=1.0 
 0 (0) vs 2 (1.0) p=1.0 
 1 (4.8) vs 5 (2.6) p=0.46 
 4 (19.0) vs 51 (26.6) p=0.60 
 5 (23.8) vs 11 (5.7) p=0.01 
 9 (42.9) vs 55 (29.1) p=0.19 
STAT  
Simvastatine 
81 (30.3) vs 101 (33.4) p=0.42 
54 (21.3) vs 57 (19.9) p=0.68 
 67 (28.6) vs 114 (34.2) p=0.15 
 44 (19.7) vs 66 (21.0) p=0.71 
 20 (46.5) vs 162 (30.6) p=0.03 
 14 (34.1) vs 97 (19.4) p=0.02 
 Table 2: Association between patient’s features/exposure and the progression of the IPMN at Chi-square/ 
Fisher test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Atorvastatine 
Pravastatine 
Rosuvastatine 
19 (7.5) vs 36 (12.6) p=0.05 
4 (1.6) vs 1 (0.3) p=0.13 
6 (2.3) vs 11 (3.8) p=0.33 
 17 (7.6) vs 37 (11.8) p=0.11 
 3 (1.3) vs 2 (0.6) p=0.65 
 6 (2.6) vs 11 (3.4) p=0.60 
 5 (12.2) vs 50 (10.0) p=0.59 
 1 (2.4) vs 4 (0.8) p=0.32 
 1 (2.4) vs 16 (3.1) p=1.0 
ASA plus ACEI/ARB 57 (21.8) vs 63 (21.4) p=0.90  52 (22.6) vs 68 (21.1) p=0.66  14 (32.6) vs 107 (20.8) p=0.07 
  ASA plus STAT 46 (17.2) vs 67 (22.3) p=0.12  41 (17.5) vs 72 (21.8) p=0.21  13 (30.2) vs 100 (19.0) p=0.07 
ACEI/ARB plus STAT  61 (23.4) vs 66 (22.4) p=0.79  53 (23.0) vs 73 (22.6) p=0.90  17 (39.5) vs 110 (21.4) p=0.006 
ASA plus ACEI/ARB 
plus STAT 
35 (13.4) vs 46 (15.7) p=0.44  32 (13.9) vs 49 (15.2) p=0.66  11 (25.6) vs 70 (13.6) p=0.03 
ASA plus ARB plus 
STAT 
24 (9.7) vs 22 (7.7) p=0.40  22 (10) vs 24 (7.7) p=0.35  7 (18.4) vs 39 (7.8) p=0.02 
 
ASA plus ARB  39 (15.8) vs 31 (10.8) p=0.08  36 (16.4) vs 34 (10.9) p=0.06  9 (23.7) vs 61 (12.2) p=0.04 
ARB plus STAT 45 (18.2) vs 35 (12.2) p=0.05  40 (18.2) vs 39 (12.5) p=0.06  12 (31.6) vs 68 (13.7) p=0.002 
Figure 1 a) Sex and age adjusted univariable Cox proportional hazard regression analysis for drug exposure 
 
 
Figure 1 b) Sex and age adjusted univariable Cox proportional hazard regression analysis for the exclusive use of ACEI and 
ARB 
 
 
 Figure 2 a) Sex and age adjusted multivariable Cox proportional hazard regression analysis for pharmacological exposure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The renin angiotensin aldosterone axis and its blockers.  
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Introduction: pancreas cancer is expected to become the 2nd leading cause of cancer related 
death within 2030.(1) Its precursor lesions, intrapapillary mucinous neoplasms (IPMNs), are 
increasingly recognized because of the spread use of cross sectional imaging and have been 
reported to be as prevalent as 20% in general population.(2, 3)  
IPMNs harboring high-grade dysplasia/cancer represent a target for surgery but the long term 
their post-surgical prognosis is still largely impacted by rates of locoregional and distant 
recurrences.(3)  
Several authors have identified possible risk factors for recurrence after surgery in IPMNs such 
as family history for pancreas cancer and the grade of dysplasia in the resected specimen. (4-
6) So far, no specific chemoprevention has been shown to prevent or slow down post-surgical 
recurrence and therefore cancer related death in operated IPMNs patients.  
Ace inhibitors/sartans (ACEI/ARB), statins (STAT) and Aspirin (ASA), widely used in the setting 
of primary and secondary cardiovascular prevention, seem also to play a role in modulating 
incidence and prognosis of different type of tumors.(7-9)  
Angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) 
are inhibitors at different levels of the renin–angiotensin aldosterone cascade displaying 
powerful anti-hypertensive properties. (9, 10) Beside its cardiovascular action, angiotensin II 
has been suggested to possibly influence the activity of important pro-angiogenetic regulators 
such as vascular endothelial growth factor (VEGF), MAP Kinases and several intracellular G-
protein. This might therefore eventually result even in potential secondary effect on cancer 
growth, as suggested for different clinical models in lung, breast and pancreas cancer. (8-14) 
The inhibitors of the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, also 
known as statins (STAT) and employed as cholesterol lowering agents, have been associated 
to a possible decreased incidence of cancer in several epidemiological studies and meta-
analysis, possibly because their ability to act on intracellular kinase pathways (Ras, MEK, 
mTOR, BCL-2 and Rho). (8) 
Aspirin, is a selective and irreversible inhibitor of COX-1 and COX-2. Beside its well-known anti-
inflammatory, analgesic, antipyretic and antiplatelet effects, aspirin seems also to inhibit 
cancer spread and progression by modulating cell growth, angiogenesis and inflammation, 
especially in colorectal cancer. (15, 16) Several intracellular molecular pathways, such as 
mTOR, EGFR, 15-PGDH, have been suggested to explain aspirin pleiotropic effects (17). In 
several observational studies aspirin seems to be associated with an overall lower risk of 
cancer occurrence and mortality(12). As a matter of facts, anyway recent evidences 
questioned about the existence of a real chemo-preventive effect in the first 10 year of 
treatment, suggesting that aspirin might display its chemo preventive effect on colorectal 
cancer from 10 to 19 years after the initiation of therapy. (12) In addition, a recent trial from 
the ASPREE group published on the New England Journal of Medicine, has highlighted as 
aspirin use is associated to overall increased risk of cancer mortality. Such increase in cancer 
related mortality was anyway not confined to any specific cancer location or pathologic 
type.(18)  
Although the exact mechanism has not been elucidated so far, clinical and preclinical models 
have increasingly suggested a possible action of ACEI/ARB and STAT in inhibiting cancer 
development and spreading while the real chemo preventive effect of ASA, that used to be 
given for granted, has recently questioned and deserves further studies to be confirmed.  
Interestingly, although several studies have been focusing on pancreas cancer(8, 10, 19, 20), 
none of them has specifically investigated the effect of such drugs on the prognosis of IPMNs 
considered its precursor lesions. More specifically no study has investigated possible effects 
of such drugs to influence the rate of cancer related death after surgery with curative intent. 
Aim: to evaluate the effect of aspirin, ace inhibitors/sartans and statins alone or in association, 
on cancer related death in a cohort of operated IPMNs patients 
Materials and Methods:  
Study design  
A single-center hospital-based retrospective cohort study on prospectively collected patients 
with surgically resected IPMNs of the pancreas. Ethical committee approval was obtained 
(EPN 2015/1544-31/4). Demographics, hereditary factors, clinical and pharmacological history 
were collected and analyzed.  
Cohort and Population’s Characteristics  
Consecutive cases of histologically verified IPMNs who had undergone surgery for radiological 
suspect of high grade IPMNs according to the European Guidelines for the management of 
cystic tumors of the pancreas (from October 2011).(2) The date of surgery was considered as 
date of diagnosis. All patients were discussed in a multidisciplinary conference before surgery. 
 Definition of the exposure: Patients were investigated for ever use of aspirin ace inhibitors, 
sartans and statins used alone or in combination as well as for exposure to known risk factors 
for pancreas cancer. Data regarding demographics, known risk factors for pancreatic cancer 
(hereditary, smoking, alcohol, overweight/obesity) as well as final pathological assessment 
(degree of dysplasia, presence of cancer, TNM, specific histological phenotype), and exposure 
to the target drugs was retrospectively collected. A specific Swedish electronic database 
(®Take Care) with in time updated inpatient and outpatient clinic charts was consulted for 
data collection. 
Outcome definition: Overall survival was defined as the interval of time between surgery and 
the date of analysis if patient was alive or between diagnosis and cancer related death in case 
he/she died during follow-up due to metastatic disease or locoregional recurrence.  
All patients in which death was not related to cancer, were excluded from survival analysis as 
a censored data, to specifically analyze the possible effect of investigated factors/drugs on 
cancer related survival.  
Inclusions criteria:  
Consecutive patients who have undergone surgery at Karolinska University Hospital because 
suspect malignified IPMN according to the European Guidelines for the Management of 
Pancreatic Cystic Neoplasms.  
Exclusion criteria:  
- The presence of a synchronous pancreatic cancer, cholangiocarcinoma or high grade 
neuroendocrine tumor which could influence the final prognosis. 
- The presence of surgical margins at final histology showing cancer or high-grade 
dysplasia (Figure 1) 
Statistical analysis 
Categorical variables were analyzed through chi-square, continuous variable through Students 
t-test. Statistically significant variables were further analyzed in sex and age adjusted 
univariate and multivariate logistic regression analysis. Sex and age adjusted univariable and 
multivariable logistic regression analysis was used to evaluate the possible association 
between cancer related death and known risk factors for pancreas cancer and sex and age 
adjusted univariable and multivariable cox hazard regression analysis was used to identify 
associations between pharmacological exposures and cancer related death. The 95% 
confidence interval (CI) was calculated. All p-values were two-sided and a p<0.05 was 
considered statistically significant. A statistical software package was used for data analysis 
(MedCalc Mariakerke, Belgium). 
Results: 
Patient characteristics 
Between 2008 and 2017, 274 IPMN patients were operated at Pancreatic Disease Unit, 
Karolinska University Hospital for suspect malignified IPMN. Two hundred ten, mean age 
70.55 years (67.60-73.50; 95% CI), 47.61% male, were included in the final analysis. Inclusion 
criteria are summarized in Figure1 and patients’ characteristics are summarized in Table 1.  
Clinical known risk factors for pancreas cancer: 
Fifty patients (23.80%) were smokers and among them 66% displayed active smoking. First-
degree family history of pancreatic cancer was present in 3.8% of patients.  Diabetes was 
present in 19.52% of patients and in 2.43% diabetes was of early onset (diagnosed within the 
latest 12 months before surgery).  Multifocal disease was present in 43.8% of patients, 
preoperatively increased levels of Ca19.9 in 32.66%, while 34.05% of patients had a mean 
diameter of mean cyst above 40 mm. Mean MPD diameter was 7.64 (6.88-8.39; 95% CI). 
Significantly higher percentage of patients with preoperative jaundice, increased Ca19.9 and 
cyst diameter above 40 mm died for cancer (respectively: 36.4 vs 9.8%, p=0.0005; 76.2% vs 
27.6%, p<0.0001; 62.5% vs 30.0%, p=0.05). Table 2 
At sex and age adjusted univariable logistic regression analysis preoperative jaundice and 
preoperative increased level of Ca19.9 were associated with increased risk of cancer related 
death (respectively OR =4.99, 95% CI 1.80-13.87, p=0.02 and OR= 8.75, 95% CI 2.96-25.87, 
p=0.001. Table 3a  
At sex and age adjusted multivariable logistic regression analysis, preoperative increased level 
of Ca19.9 remained consistent with increased risk of cancer related death OR=7.31, 95% CI 
2.40-22.21, p=0.0004. Table 3b 
A previous or current use (ever use) of aspirin, ace inhibitors/sartans and statins was present 
respectively in 29.18%, 51.90% and 36.84% of cases.  
ASA ever users displayed significantly higher rates of cancer related death 50.0% vs 27.4% p= 
0.03. Sex and age adjusted univariable cox hazard regression analysis ASA users displayed a 
borderline significantly higher risk of cancer related death HR 2.11 (0.90-4.94, 95% CI, p=0.08). 
The risk of cancer related death was not statistically significant different among exclusive STAT 
and exclusive ACEI/ARB users (respectively HR= 0.77, 95% CI 0.32-1.89, p=0.58 and HR= 1.18, 
95% CI 0.49-2.82, p=0.69) or their combinations. (Table and Figure 2a)  
At multivariable cox hazard regression analysis adjusted for sex, age, clinical factors associated 
with both pancreas cancer and cardiovascular risk (such as smoking, diabetes, first degree 
family history, overweight/obesity and elevated Ca19.9) ASA users were confirmed to have 
higher risk of cancer related death (HR=2.70, 95% CI 1.10-6.59, p=0.02). Figure 2b 
Discussion: 
This is the first paper analyzing the effect of potentially chemo-preventive agents on cancer 
related death in a cohort of operated IPMNs. In the past years, huge body of literature has 
been focusing on the role of different clinical features in predicting cancer or invasive IPMNs 
“recurrence” in the remnant pancreas.(4-6, 21)  A first interesting point to underline is the 
choice of the main outcome, which in our case was cancer related death instead of “IPMN 
recurrence”.   
In fact, being IPMNs a field defect in which by definition the whole gland is involved, when 
considering post-surgical outcomes, it does seem more appropriate to use as a primary 
outcome cancer related death instead of ”recurrence”, since the latter would imply post-
surgical absence of residual disease, which is namely incorrect in the case of IPMNs. (21)    
This also in the light that pancreas cancer recurrence is associated to cancer death in virtually 
almost 100% of cases. In the current study, heterogeneity of our cohort in terms of resected 
specimen (ranging from absence of dysplasia to invasive IPMNs), is largely counterbalanced 
by the strict inclusion of patients undergone surgery with curative intent. For that purpose, all 
patients with positive margins for high grade dysplasia and/or cancer, synchronous pancreas 
cancer and/or periampullary tumors, potentially influencing prognosis, were excluded from 
our analysis.  
On the other hand, we do think that such heterogeneity of resected specimens, might be more 
representative of “real world” population undergoing surgery for suspect malignified IPMN. 
Therefore, it did specifically serve our aim of investigating the effect of such drugs on definitive 
prognosis of patients undergone surgery. In the current study, STAT use was associated with 
23% reduction of cancer related death. Although not statistically significant, it is interesting to 
note how the data is in line with what reported in other epidemiological studies and meta-
analysis. (8, 19) In addition, the absence of statistically significance, might be related to the 
absence of statistical power for such outcome.  
The current paper shows no statistically significant effect of ACEI/ARB in influencing cancer 
related death, both when pooling together the use of ACEI and/or ARB and when considered 
it separately, as exclusive use of ACEI or ARB (data not shown). 
Surprisingly, and in contradiction to several observational studies, that have previously shown 
a potential anti-cancer effect(7), in the current study, ASA was associated to an increased risk 
of cancer related death. On the other hand, a recent trial has questioned these previously 
ascertained knowledges, by showing in a large cohort of patients undergone circa 5 years 
follow up, an increased incidence of cancer in aspirin arm compared to controls group. (18) 
In addition, during the last years, several papers suggested that the potential benefits of ASA 
might represent a long-term effect, visible after at least 10 years of exposure to the drug.(12)  
In a large case control study, Archibugi et al.(19) reported have shown that the combined use 
of ASA and STAT was not superior to the exclusive use of STAT in reducing the risk of pancreatic 
cancer. Therefore, the association between ASA use and pancreas cancer occurrence‘s 
reduction, might also be secondary to overlaps with other drugs such as STAT which seldom 
have been investigated separately as potential protective/risk factor. 
In this respect, in the present study, the association between ASA use and STAT use was not 
significantly associated with higher risk of cancer related death as shown in table 2a. 
The exact molecular mechanism behind that has not been clarified yet and deserves further 
investigations. ASA use maintained its association with cancer related death, even when 
corrected for the presence of possible known risk factors for pancreas cancer, such as 
smoking, diabetes overweight/obesity, who might also increase cardiovascular risk and 
therefore need primary or secondary cardiovascular prevention with ASA. Further studies are 
needed to specifically investigate whether such association display a real pathophysiological 
background or whether it’s the result of the exposure to a common risk factor for both 
pancreas cancer and cardiovascular disease.  
In the current study the presence of a pre-operative elevated value of Ca19.9 was the only 
factor in sex and age adjusted logistic and cox hazard regression multivariable analysis 
associated with an increased risk of cancer related death. 
This is not surprising and is in line with what recommended in the European evidence based 
guidelines for the management of cystic tumors, which identified in increased Ca19.9 levels a 
possible predictor of cancer occurrence.(3)  
The present study displays several strengths as well as limitations. Inherent with its design, 
our study displays as main limitation the absence of a preliminary power calculation. The 
strength of the study is represented by the relatively large sample size, the investigation of 
several clinical factors possibly implicated in progression of IPMNs after surgery and, for the 
first time, the evaluation of pharmacological exposures possibly influencing cancer occurrence 
and prognosis. The inclusions criteria were clearly defined and aiming at identifying prognostic 
factors in a population treated with curative intent. Data were extracted by IT system, 
constantly updated and giving clinicians access to inpatient’s/outpatient’s clinical charts and 
prescriptions, therefore minimizing possible recall biases.  
In conclusion the results of this large single institution cohort study suggest a possible 
association between aspirin use and cancer related death after surgical resection for 
pancreatic IPMNs. On the contrary no specific influence on cancer related death has been 
reported for statins and ace inhibitors/sartans use. Further studies are needed to investigate 
if this association is the result of an underling pathophysiologic mechanism or the result to a 
common and yet unknown risk factors exposure. 
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 Figure 1: Patients’ inclusion flow chart 
 
 
 
 
 
 
 
 
 
 
 
 Table 1 Patients demographic, disease morphology and operative characteristics 
Characteristic N/mean (%; 95%CI) 
Patients 210 
Male  100/210 (47.61) 
Age 70.55 (67.60-73.50; 95% CI) 
Mean OS (months) 37.60 (33.76-41.43; 95%CI) 
Dead 
Cancer related death 
51/210 (24.24) 
22/210 (10.47) 
Mean BMI 25.73 (25.12-26.38; 95% CI) 
Obesity 18/210 (8.57) 
Overweight  41/210 (19.52) 
Smokers 50/210 (23.80) 
Current smokers 33/50 (66.0) 
1st degree FH PDAC  8/210(3.80) 
Diabetes  41/210 (19.52) 
Recent Onset Diabetes                   1/41 (2.43) 
Jaundice                  26/210 (12.38) 
Abdominal pain 42/210 (20.0) 
Weight loss 32/210 (15.23) 
Acute pancreatitis 23/210 (10.95) 
Incidental diagnosis 100/209 (47.84) 
Multifocal  92/210 (43.80) 
Mean MPD diameter (mm) 7.64 (6.88-8.39; 95% CI) 
MPD diameter 5-9.9 mm 89/210 (42.38) 
MPD diameter ≥10 mm 50/210 (23.80) 
Max Cystic Size (mm) 33.93 (30.23-37.62; 95%CI) 
Cyst Size ≥4 cm in BD-IPMNs 47/138 (34.05) 
Mural nodules  16/209 (7.65)  
Increased Ca19.9 65/199 (32.66) 
Pancreaticoduodenectomy  97/210 (46.19) 
Distal Pancreatectomy 66/210 (31.42) 
Total Pancreatectomy 39/210 (18.57) 
Atypical resections 8/210 (3.80) 
Margin status: 
No dysplasia 
Low grade of dysplasia 
NA (total pancreatectomy) 
 
64/171 (37.42) 
107/171 (62.57) 
39/210 (18.57) 
ASA 
ACEI/ARB 
STAT 
ASA plus ACEI/ARB 
ASA plus STAT 
ACEI/ARB plus STAT 
ASA plus ACEI/ARB plus STAT 
61/209 (29.18) 
109/210 (51.90) 
77/209 (36.84) 
46/209 (22.00) 
42/208 (20.19) 
58/209 (27.75) 
32/208 (15.38) 
Final histology: 
Cancer 
IPMN with high grade dysplasia 
IPMN with low grade dysplasia 
 
60/210 (28.57) 
44/210 (20.95) 
106/210 (50.47) 
 
 
Table 2 IPMNs features and patient’s exposure possibly associated to cancer relater death at fisher 
or chi square test 
Features/exposures Cancer related death vs alive patient p value 
Smoking 5 (22.7) vs 37 (22.6) 0.98 
1st degree FH PDAC      0 (0) vs 8 (4.9) 0.29 
Diabetes  4 (18.2) vs 32 (19.5) 0.88 
Preoperative Jaundice 8 (36.4) vs 16 (9.8) 0.0005 
Abdominal pain 4 (18.2) vs 35 (21.3) 0.73 
Weight loss 5 (22.7) vs 23 (14.0) 0.28 
Incidental diagnosis 7 (31.8) vs 79 (48.5) 0.14 
Head location 10 (45.5) vs 48 (29.3) 0.12 
Preoperative Increased Ca19.9 (≥37 UI/L) 16 (76.2) vs 43 (27.6)             <0.0001 
Multifocal IPMNs 6 (27.3) vs 76 (46.3) 0.09 
Positive Margin for dysplasia 12 (85.70) vs 87 (63.00) 0.09 
Preoperative presence of mural nodules 1 (4.5) vs 14 (8.6) 0.51 
maximum diameter 5-9.9 mm 10 (45.5) vs 71 (43.3) 0.84 
maximum diameter ≥10 mm 6 (27.3) vs 37 (22.6) 0.62 
Preoperative Cyst Size ≥4 cm  5 (62.5) vs 33 (30.0) 0.05 
ASA use (ever) 11 (50.0) vs 45 (27.4) 0.03  
STAT use (ever) 8 (36.4) vs 62 (38.0) 0.87 
ACEI use (ever) 7 (31.8) vs 33 (20.1) 0.21 
ARB use (ever) 4 (18.2) vs 41 (25.0) 0.48 
ACE/ARB use (ever) 13 (59.1) vs 82 (50.0) 0.42 
ASA plus STAT use (ever) 6 (27.3) vs 34 (20.9) 0.49 
ASA plus ACEI/ARB use (ever) 6 (27.3) vs 36 (22.0) 0.57 
ASA plus ACEI/ARB plus STAT use (ever) 5 (22.7) vs 26 (16.0) 0.42 
ACEI/ARB plus STAT use (ever) 6 (27.3) vs 47 (28.8) 0.87 
 
 
Table 3 Sex and age adjusted univariate and multivariable logistic regression analysis for the 
assessment of possible associations between clinical features and the occurrence of cancer related 
death. 
 
Clinical features Univariable OR (95%CI) Multivariable OR (95%CI) 
Jaundice 4.99 (1.80-13.87); p=0.02 2.57 (0.82-8.04); p=0.10 
Increased Ca19.9 (≥37 UI/L) 8.75 (2.96-25.87); p=0.001 7.31 (2.40-22.21); p=0.0004 
Preoperative Cyst Size ≥4 cm 4.43 (0.96-20.30); p=0.05  
Figure 2a Sex and age adjusted univariable cox hazard regression analysis for the assessment of 
possible associations between pharmacological exposure and the occurrence of cancer related death 
 
 
Figure 2b Multivariable cox hazard regression analysis for the assessment of possible associations 
between aspirin exposure and the occurrence of cancer related death, adjusted for sex, age, clinical 
factors associated with pancreas cancer (smoking, diabetes, first degree family history, 
overweight/obesity, elevated Ca19.9)  
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Abstract
Pancreatic neuroendocrine neoplasms (PNENs) represent 10% of all pancreatic 
tumors by prevalence. Their incidence has reportedly increased over recent decades 
in parallel with that of pancreatic adenocarcinoma. PNENs are relatively rare, and 
of the few institutions that have published potential risk factors, findings have been 
heterogeneous. Our objective was to investigate the association between potential 
risk and protective factors for the occurrence of sporadic PNENs across a European 
population from several institutions. A multinational European case–control study was 
conducted to examine the association of selected environmental, family and medical 
exposure factors using a standardized questionnaire in face-to-face interviews. A ratio 
of 1:3 cases to controls were sex and age matched at each study site. Adjusted univariate 
and multivariate logistic regression analysis were performed for statistically significant 
factors. The following results were obtained: In 201 cases and 603 controls, non-recent 
onset diabetes (OR 2.09, CI 1.27–3.46) was associated with an increased occurrence 
of PNENs. The prevalence of non-recent onset diabetes was higher both in cases with 
metastatic disease (TNM stage III–IV) or advanced grade (G3) at the time of diagnosis. 
The use of metformin in combination with insulin was also associated with a more 
aggressive phenotype. Drinking coffee was more frequent in cases with localized disease 
at diagnosis. Our study concluded that non-recent onset diabetes was associated with 
an increased occurrence of PNENs and the combination of metformin and insulin was 
consistent with a more aggressive PNEN phenotype. In contrast to previous studies, 
smoking, alcohol and first-degree family history of cancer were not associated with 
PNEN occurrence. Endocrine-Related Cancer  
(2017) 24, 405–414
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Introduction
Pancreatic neuroendocrine neoplasms (PNENs) are a group 
of tumors which originate from endocrine cells within 
the pancreas gland. PNENs have heterogeneous clinical 
behavior owing to their hormone functional status, 
cellular characteristics and the extent of metastatic disease. 
While representing only 1–2% of pancreatic neoplasms by 
incidence (Fitzgerald et al. 2008, Yao et al. 2008), PNENs 
may account for as much as 10% by prevalence (Yao et al. 
2008). Such discrepancy is due in part to the relatively 
indolent clinical course of many PNENs compared to 
pancreatic adenocarcinoma. PNENs are rare tumors but 
their incidence has reportedly increased in recent decades, 
particularly that of non-functioning tumors (Lepage et al. 
2004, Fitzgerald  et  al. 2008, Yao  et  al. 2008). To a lesser 
degree, investigators have also identified a modest 
increase in the incidence of pancreatic adenocarcinoma 
(Fitzgerald et al. 2008).
The increased reported incidence of both endocrine 
and exocrine pancreatic tumors is likely due to rising 
population lifespan and the wider availability of high-
resolution cross-sectional imaging (Del Chiaro et al. 2013, 
Ellison et al. 2014), but additionally raises the possibility 
of changing exposure to factors which may alter the risk 
of pancreatic neoplasia.
There are a small number of case–control studies 
that have investigated potential risk factors for the 
occurrence of PNENs (Hassan et al. 2008b, Capurso et al. 
2009, Zhan et al. 2013, Halfdanarson et al. 2014, Ben et al. 
2016). These studies recruited participants from a single 
institution or geographical region, and were recently 
summarized in a meta-analysis that found personal history 
of diabetes mellitus and family history of cancer to be 
associated with an increased risk of PNEN (Haugvik et al. 
2015). The association of PNENs with smoking and alcohol 
drinking was less clear, and only heavy smoking and heavy 
alcohol consumption reached statistical significance. The 
included studies differed in their design and population 
definitions, with a considerable heterogeneity limiting 
the significance of the meta-analysis. Moreover, these 
studies had some specific methodological limitations, 
such as the absence of a power calculation and exposures 
were often recorded at the time of diagnosis or treatment, 
rather than considering the exposure history prior to 
diagnosis. The latter raises the possibility of a bias due to 
cancer symptoms (e.g. weight loss, new onset diabetes) 
or lifestyle modifications such as changes in smoking 
behavior and alcohol consumption.
It appears that there is overlap in risk factors, 
such as smoking and alcohol, for the occurrence of 
PNENs and pancreatic adenocarcinoma; however, a 
number of other factors that have been associated with 
the occurrence of pancreatic cancer have not, to our 
knowledge, been investigated for PNENs. For example, 
the use of medications such as aspirin, and the association 
with allergy and atopy that have been reported to be 
protective against pancreatic adenocarcinoma occurrence 
(Streicher et al. 2014, Gomez-Rubio et al. 2017).
For these reasons, we conducted a multicenter 
European study aimed at assessing the association between 
a large number of potential risk or protective factors for 
the development of sporadic PNENs.
Materials and methods
Study design and population
A collaborative multicenter hospital-based case–control 
study was conducted in six European countries: Italy, 
Norway, Sweden, Slovenia, United Kingdom and 
Germany as part of the ‘Pancreas 2000’ educational 
project (www.pancreas2000.org), upon local hospital 
ethical committee approval.
A standardized questionnaire, including questions 
about demographics and potential risk factors, such as 
family history of cancer, environmental factors, previous 
use of drugs and other medical history features was 
administered to patients by a trained medical doctor. 
Each questionnaire took ~15 min to be completed during 
a face-to-face interview, after gaining participant consent.
The cases were prevalent sporadic PNEN patients 
diagnosed within 24 months from the beginning of the 
study (January 2013) and new incident cases of sporadic 
PNENs diagnosed from January 2013 to December 2015 
that were recruited at the participating centers.
The inclusion criterion was to have a histological 
or cytological diagnosis of PNEN. The date of the 
confirmatory pathological report was accepted as the date 
of diagnosis.
Exclusion criteria were the presence of an inherited 
form of PNEN such as those associated with multiple 
endocrine neoplasia-type 1 (MEN1), von Hipple-Lindau 
disease (VHL), neurofibromatosis type 1 (NF1), tuberous 
sclerosis (TSC) or an inability to participate, such 
as dementia.
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According to the absence or presence of a clinical 
syndrome due to hormonal hypersecretion, cases were 
classified as non-functioning or functioning tumors 
(gastrinoma, insulinoma, glucagonoma). For example, 
the Zollinger Ellison Syndrome was clinically suspected 
in the presence of a PNEN associated with peptic disease 
and its complications and diarrhea, insulinomas in 
the presence of severe hypoglycemia with associated 
neurological symptoms (varying from confusion to coma), 
glucagonoma in the presence of rash, glucose intolerance 
and weight loss. In any case, the syndrome was confirmed 
with a specific laboratory workup according to guidelines 
(Jensen et al. 2012, Falconi et al. 2016).
Cases were classified according to the European 
Neuroendocrine Tumor Society (ENETs) and the 2010 
World Health Organization classifications (Rindi  et  al. 
2010, Solcia et al. 2002, Falconi et al. 2016).
Eligible controls were either individuals seen in the 
participating hospitals’ outpatient clinic for a non-specific, 
non-organic gastrointestinal disorder (bloating, aspecific 
dyspeptic symptoms, eructation) or visitors attending 
the same network of referring hospitals, matched by 
country, sex and age (+/− 5 years). Visitors and hospital 
outpatients’ clinic belonged to the same catchment area 
of cases. Specific exclusion criteria for controls were the 
following: (1) the presence of any genetic syndrome 
associated with the occurrence of PNENs; (2) a history of 
active cancer (diagnosed within 5 years); (3) any biological 
relation of a participating PNEN case in this study; 
(4) a history of any chronic inflammatory condition (e.g. 
chronic obstructive pulmonary disease, liver cirrhosis, 
inflammatory bowel disease, end stage kidney disease); 
and (5) undergoing evaluation of a possible familial cancer 
syndrome. Controls were included in the same country 
and interviewed within 6 months of the inclusion of the 
matched corresponding case.
Exposure definitions
Subjects were questioned about risk factors that 
were present at least 12  months before diagnosis or 
presentation of symptoms, in order to avoid potential 
bias due to lifestyle modifications, cancer symptoms or 
cancer treatments.
Subjects were considered ever smokers if they 
reported a cumulative lifetime smoking history greater 
than 6 months or 100 cigarettes smoked. A quantification 
of the smoking habit for cases and controls was performed 
considering the number of pack-years (pack-year = number 
of packs per day × years of smoking), with 20 pack-
years being the lower limit to qualify a participant a 
heavy smoker.
A daily intake of at least 12.5 g of alcohol, equivalent 
to one glass of wine, one pint of beer or one shot of hard 
liquor, for at least one year, was considered the cut-off to be 
a regular ever alcohol drinker. Because of possible different 
drinking habits within different European countries, the 
weekly alcohol amount was also sub-analyzed according 
to low (1–7 weekly units assumption), medium (8–14 weekly 
units), medium-high (14–20  weekly units) and heavy 
alcohol consumption (≥21 weekly units). Coffee drinking 
was also recorded as ever drinking (at least one cup per 
day) or heavy coffee drinking (>5 cups per day).
Height and weight were recorded from which body 
mass index (BMI) (kg/m2) was calculated. A history of 
chronic pancreatitis, acute pancreatitis, peptic ulcer 
disease, biliary stones and previous surgery were 
specifically recorded. Additionally, a diagnosis of 
diabetes was documented and subdivided for type and 
onset. For cases, recent onset diabetes was defined as 
that which was diagnosed in 12  months prior to the 
PNEN diagnosis, and for controls, a diagnosis of diabetes 
12 months prior to the date of recruitment was required. 
Sensitivity analysis was also performed for different 
intervals of the onset of diabetes, (inferior to 1  year, 
between 1 and 3 years, between 3 and 5 years and above 
5  years, respectively). Another sensitivity analysis was 
also conducted considering incident/prevalent cases 
and hospitals controls/visitors controls compared to 
respective cases.
As atopy and allergy have been associated with a 
reduced risk of pancreatic cancer (Gomez-Rubio  et  al. 
2017), cases and controls were interrogated about a 
history of allergy, with specific enquiry for eczema, 
hay fever and asthma. The use of aspirin, proton pump 
inhibitors, metformin and insulin were recorded. Subjects 
were interrogated about 1st and 2nd degree family history 
of cancer, and the total number of siblings and children 
was recorded.
Statistical analysis
An a priori power calculation was performed. We estimated 
sample size based on the differences reported in the 
frequencies of exposure in cases and controls according 
to a previous study (Capurso et al. 2009), and considering 
a ratio 1:3, with a statistical power equal to 80% and an 
alpha error equal to 0.05.
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According to Capurso and coworkers (Capurso et al. 
2009) the reported prevalence in cases and controls 
was, respectively, 53% vs 32% for 1st degree family 
history of cancer, 10% vs 2% for diabetes and 14% 
vs 3% for heavy alcohol consumption. Therefore, 
the sample size’s estimate of cases and controls, 
to show true differences whether existing, were, 
respectively, 64 cases and 191 controls for 1st degree 
family history of cancer, 117 cases and 350 controls 
for diabetes, and 85 cases and 253 controls for heavy 
alcohol consumption.
We therefore estimated that a total of 200 cases and 
600 controls across participating centers to be an adequate 
sample size to reveal differences in the prevalence of most 
risk factors analyzed among cases and controls, where 
these exist.
Characteristics of cases and controls were compared 
by chi-square test for categorical variables or Student’s 
t-test for continuous variables. Significant variables were 
analyzed by logistic regression analysis adjusted for sex, age 
and enrollment center. A multivariable logistic regression 
analysis, adjusted for sex, age and enrollment center was 
also performed with an enter selection procedure for 
statistically significant risk factors. A dedicated statistical 
software package (MedCalc, Mariakerke, Belgium) was 
used for data analysis. Ninety-five percent confidence 
interval (95%) was calculated where possible. All P 
values were two sided, and a P < 0.05 was considered 
statistically significant.
Results
Characteristics of cases and controls
A total of 201 cases and 603 sex- and age-matched controls 
were enrolled among the six centers (Italy, Norway, 
Sweden, United Kingdom, Slovenia and Germany) as 
shown in Table 1. The mean age was 59.6 years in cases 
(CI 57.7–61.4) and 59.5 years in controls (CI 58.4–60.55), 
and 51% of cases and controls were male.
Among the 201 PNEN cases, 154 (76.6%) had a non-
functioning tumor. Of the 47 functioning PNENs, 26 
(55.3%) had an insulinoma, 9 (19.1%) a gastrinoma, 7 
(14.9%) a glucagonoma and 5 (10.6%) other functioning 
tumors. The majority were G1 (44.8%) or G2 (43.3%) 
PNENs, and were equally distributed among different 
disease stages (Table 1). Of the 201 PNEN cases, 80 (38%) 
cases were incident and 121 (62%) prevalent. Of the 603 
controls, 422 (70%) were hospital outpatients controls 
and 181 (30%) visitors.
Risk factors for the occurrence of PNEN
Family history of cancer The proportion of subjects 
who had a 1st degree family history of cancer was similar 
both in cases and in controls (51.1% vs 45.3% P = 0.17, 
respectively), while 2nd degree family history was slightly 
more prevalent in cases (36.8% vs 30.2% P = 0.09). A 1st 
degree family history of specific cancer sites was also not 
significantly different (Table  2). No cases or controls 
reported a family history of neuroendocrine tumor (NET). 
At multiple regression analysis, 2nd degree family history 
of any cancer was, however, associated with an increased 
risk of PNEN (Tables 2 and 3).
Body mass index Mean BMI was not significantly 
different among cases and controls (26.8 kg/m2 (CI 26.0–
27.5) and 26.4 kg/m2 (CI 26.4–26.8), P = 0.10. Similarly, 
while the overall prevalence of obesity was more frequent 
Table 1 Characteristics of PNENs cases.
 Cases N (%)
Total 201 
Referral center  
 Italy 62 (30.8)
 Norway 44 (21.9)
 Sweden 40 (19.9)
 Slovenia 24 (11.9)
 United Kingdom 20 (10.0)
 Germany 11 (5.5)
Sex  
 Male 103 (51.2)
Age (years)  
 Mean ± s.d. 59.6 ± 13.1
Race Caucasians 196 (97.5)
Tumor type  
 Functioning 47 (23.3)
 Non-functioning 154 (76.7)
Functioning only (n = 47)  
 Insulinomas 26 (55.3)
 Gastrinomas 9 (19.1)
 Glucagonomas 7 (14.9)
 Other 5 (10.6)
Tumor grade  
 G1 90 (44.8) 
 G2 87 (43.3)
 G3 22 (10.9)
 Unknown 2 (1.0)
Tumor stage  
 Stage I 51 (25.4)
 Stage II 53 (26.4)
 Stage III 47 (23.4)
 Stage IV 43 (21.4)
 Unknown 7 (3.5)
Tumor site  
 Head 75 (37.3)
 Body or tail 120 (59.7)
 Unknown 6 (3.0)
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Table 2 Risk factors for PNENs.
 Cases N (%) Controls N (%) P value OR* (95% CI)
Total 201 603   
Family history*     
 1st degree FH of any cancer 103 (51.1) 272 (45.3) 0.17 1.32 (0.94–1.83)
 2nd degree FH of any cancer 74 (36.8) 181 (30.2) 0.09 1.51 (1.05–2.17)
 1st degree FH pancreatic cancer 6 (3.0) 13 (2.2) 0.69 1.42 (0.52–3.84)
 1st degree FH esophageal 2 (1.0) 4 (0.7) 0.99 1.58 (0.28–8.79)
 1st degree FH gastric cancer 7 (3.5) 26 (4.3) 0.75 0.77 (0.32–1.85)
 1st degree FH colorectal cancer 18 (9.0) 57 (9.5) 0.92 0.99 (0.56–1.75)
 1st degree FH breast cancer 20 (10.0) 51 (8.3) 0.62 1.25 (0.72–2.18)
 1st degree FH lung cancer 17 (8.5) 48 (8.0) 0.95 1.12 (0.62–2.00)
 1st degree FH NETs – –   
 1st degree FH hematological cancer 12 (6.0) 30 (5.0) 0.72 1.28 (0.63–2.57)
 1st degree FH hepatobiliary cancer 4 (2.0) 17 (2.8) 0.69 0.45 (0.12–1.66)
 1st degree FH sarcoma – 3 (0.5) 0.73 –
Number of siblings     
 Mean ± s.d. 2.1 ± 1.7 2.5 ± 2.0 0.05  
BMI     
 Underweight 5 (2.5) 10 (1.6)  1.68 (0.55–5.04)
 Normal weight 82 (41.0) 243 (40.2) P-trend** 1.00 (0.71–1.39)
 Overweight 63 (31.5) 240 (39.8) 0.44 0.75 (0.52–1.10)
 Obese 51 (25.5) 110 (18.2)  1.36 (0.88–2.08)
Smoking     
 Never smoke 89 (44.5) 279 (46.5)  0.86 (0.62–1.20)
 <20 pack-years 60 (30.0) 176 (29.3) P-trend 1.07 (0.75–1.53)
 ≥20 pack-years 51 (25.5) 144 (24.0) 0.59 1.15 (0.78–1.69)
 Unknown 1 (0.5) 3 (0.5)  1.00
Alcohol intake     
 Never drink 49 (24.4) 173 (29.2)  0.77 (0.53–1.12)
 <21 units/week 145 (72.1) 394 (66.6) P-trend** 1.29 (0.90–1.85)
 ≥21 units/week 7 (3.4) 25 (4.2) 0.33 0.88 (0.37–2.11)
Coffee     
 Never drink 30 (15.2) 73 (12.2)  1.37 (0.83–2.14)
 ≤4 cups/day 135 (68.2) 411 (68.7) P-trend** 0.94 (0.66–1.34)
 >4 cups/day 33 (18.8) 114 (19.2) 0.24 0.86 (0.55–1.35)
 Unknown 3 (1.4) 5 (0.8)  1.00
Diabetes     
 No 164 (81.6) 529 (87.7) 0.03 1.00
 Recent onset (<1 year) 1 (0.5) 10 (1.6) 0.4 0.24 (0.03–1.88)
 No-recent onset (≥1 year) 35 (17.4) 58 (9.7) 0.004 1.89 (1.17–3.05)
 Unknown 1 (0.5) 6 (1.0)  1.00
 Diabetes (≥1 year, <3 years) 6 (3.0) 7 (1.1) 0.07 2.56 (0.83–7.91)
 Diabetes (≥3 year, <5 years) 8 (4.0) 6 (0.9) 0.0045 4.31 (1.43–12.98)
 Diabetes (≥5 years) 21 (10.7) 45 (7.4) 0.16 1.47 (0.84–2.56)
Diabetes treatment     
 Metformin (no insulin) 13 (7.3) 29 (5.1) 0.3 1.35 (0.68–2.66)
 Insulin 7 (4.1) 9 (1.6) 0.1 1.63 (0.86–3.08)
 Metformin and insulin 9 (5.2) 19 (3.4) 0.4 1.48 (0.65–3.35)
Past medical history     
 Acute pancreatitis 7 (3.5) 15 (2.5) 0.60 1.42 (0.56–3.60)
 Chronic pancreatitis – – –  
 Peptic ulcer 24 (12.3) 64 (10.6) 0.59 1.25 (0.75–2.07)
 Cholecystectomy 18 (9.0) 51 (8.5) 0.92 1.07 (0.61–1.90)
 Gastrectomy 2 (1.0) 4 (0.7) 0.99 1.56 (0.28–8.65)
 Gallstone disease 34 (19.2) 77 (13.3) 0.06 1.53 (0.97–2.42)
 Asthma 24 (12.1) 52 (8.6) 0.19 1.47 (0.87–2.47)
 Eczema 22 (11.1) 46 (7.6) 0.17 1.52 (0.88–2.62)
 Hay fever 31 (15.6) 87 (14.5) 0.79 1.17 (0.74–1.84)
 Any allergy 58 (28.9) 151 (25.0) 0.32 1.26 (0.88–1.82)
 Use of aspirin 45 (22.5) 160 (26.5) 0.29 0.79 (0.53–1.18)
 Use of proton pump inhibitors 78 (39.2) 239 (39.6) 0.97 1.04 (0.74–1.45)
*OR adjusted for sex, age and center of enrollment; **P value based on the Mantel–Haenszel test for trend excluding missing category.
FH, family history; NET, neuroendocrine tumor.
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in cases than controls (25.5% vs 18.2%), this was not 
significant (P = 0.44).
At regression analysis after adjustment for matching 
variables, there remained no significant association with 
obesity (OR 1.36, 95% CI 0.88–2.08, P = 0.15) (Table 3).
Cigarette smoking, alcohol intake and coffee 
drinking The proportion of smokers (55.5% vs 53.5%, 
P = 0.59), heavy smokers (25.5% vs 24.0%, P = 0.59), 
alcohol drinkers (75.6% vs 70.8%, P = 0.33), heavy alcohol 
drinkers (3.4% vs 4.2%, P = 0.33), coffee drinkers (84.8% 
vs 87.8%, P = 0.24) and heavy coffee drinkers (18.8% vs 
19.2%, P = 0.24) did not significantly differ between cases 
and controls (Table 2).
History of diabetes mellitus A history of diabetes 
mellitus was more prevalent in cases than in controls 
(18.4% vs 12.3%, P = 0.03). This difference was greater on 
analysis of non-recent onset diabetes, defined as diabetes 
diagnosed more than 12  months before the diagnosis 
of PNEN in cases, or 12  months prior to the interview 
for controls (17.4% vs 9.7%, P = 0.004) (Table  2). After 
adjustment for the matching variables, non-recent onset 
diabetes was confirmed to be consistent with the occur-
rence of PNEN (OR 1.89, 95% CI 1.17–3.05, P = 0.008). 
At multivariable analysis, the association with non-recent 
onset diabetes remained statistically significant (OR 2.09, 
95% CI 1.27–3.45, P = 0.003) (Table  3). At sensitivity 
analysis, a history of diabetes with an onset between 
1–3  year and 3–5  years was increasingly prevalent in 
PNEN compared to controls (3.0% vs 1.1% P = 0.07 and 
4% vs 0.9% P = 0.004, respectively). At univariable logistic 
regression analysis, this difference remained significant 
(OR 2.56, 95% CI 0.83–7.91 and OR 4.31, 95% CI 1.43–
12.98, respectively). For intervals of occurrence of diabetes 
superior to 5 years, no statistically significant difference 
was found between cases and controls (10.7% vs 7.4%, 
P = 0.16, respectively) (Table  2). We also performed a 
separate analysis for ‘late onset diabetes’ using as controls 
either only the 422 hospital controls or only the 181 
visitors controls. In the first case, the OR resulted to be 
2.52 (95% CI 1.08–5.86; P = 0.03), while in the second one, 
the OR was 1.7 (95% CI 0.95–3; P = 0.07), most likely due 
to the lower number of controls reducing the power of 
the analysis.
The use of metformin (7.3% vs 5.1%, P = 0.3) and 
insulin (4.1% vs 1.6%, P = 0.1) or their association together 
(5.2% vs 3.4%, P = 0.4) was not statistically different 
between cases and controls.
Past medical history With regard to past medical 
history, the prevalence of acute pancreatitis (3.5% vs 
2.4%, P = 0.60), peptic ulcer disease (12.3% vs 10.6%, 
P = 0.59), cholecystectomy (9.0% vs 8.5%, P = 0.92) and 
gastrectomy (1.0% vs 0.7%, P = 0.99) were similar in 
cases and controls. None of the participants reported a 
medical history of chronic pancreatitis (Table 2). A higher 
proportion of cases reported a history of gallstone disease 
than controls (19.2% vs 13.3%) but this did not reach 
the significance threshold (P = 0.06). After adjustment for 
age, sex and enrollment center at multivariable analysis, 
this latter association remained borderline significant 
(OR 1.52, 95% CI 0.95–2.44, P = 0.08) (Table 3).
Non-diabetic medications The use of proton pump 
inhibitors (PPI) (39.2% vs 39.6%, P = 0.97) and aspirin 
(22.5% vs 26.5%, P = 0.29) did not differ among cases and 
controls, respectively (Table 2).
Allergies A history of allergies was not different 
in cases and in controls (28.9% vs 25.0%, P = 0.32). 
Specifically, asthma (12.1% vs 8.6%, P = 0.19), eczema 
(11.1% vs 7.6%, P = 0.17) and hay fever (15.6% vs 14.5%, 
Table 3 Risk factors for the occurrence of PNENs at the Logistic regression analysis.
Risk factor Univariate*OR (95% CI) P value Multivariable* OR (95% CI) P value
Diabetes     
 No 1.00  1.00  
 Early onset (≤1 year) 0.24 (0.03–1.88) 0.17   
 Late onset (>1 year) 1.89 (1.17–3.05) 0.008 2.09 (1.27–3.45) 0.003
2nd degree FH of any cancer     
 1.51 (1.05–2.17) 0.02 1.53 (1.03–2.27) 0.03
Gallstone disease     
 No 1.00    
 Yes 1.48 (0.93–2.35) 0.08 1.52 (0.95–2.44) 0.08
Adjusted for sex, age, underweight, 1st degree family history for esophageal cancer and center of enrollment.
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P = 0.79) were not more prevalent in PNEN patients than 
in controls (Table 2).
Risk factors for the advanced grades and stages of PNEN
When stratifying cases for the TNM stage at diagnosis and 
for the tumor grade, diabetes mellitus was statistically 
more prevalent in patients with G3 tumors (pancreatic 
neuroendocrine carcinoma; PNEC) than with G1 or G2 
tumors (40.9% vs 15.8%, P = 0.01). Among cases, non-recent 
onset diabetes was associated with a more advanced stage 
at diagnosis (TNM III–IV vs TNM I–II, respectively, 23.3% 
vs 11.8%, P = 0.05) and with a G3 vs G1–2 tumor (40.9% 
vs 14.9%, P = 0.006, respectively). The use of metformin in 
combination with insulin was more prevalent in patients 
with G3 than G1–G2 tumors (23.5% vs 3.2%, P = 0.003, 
respectively) (Table 4). Asthma was more prevalent in G3 
cases than in G1–2 (30.0% vs 10.2% P = 0.02), and eczema 
was also more prevalent in G3 cases than in G1–2 but 
without reaching statistical significance (25.0% vs 9.6%, 
P = 0.08). Coffee drinking was more prevalent in localized 
disease (TNM 1–2) at diagnosis compared with advanced 
stage (TNM 3–4) (92.3% vs 75.9%, P = 0.003).
Discussion
The present study was designed to recruit cases of PNEN 
from multiple sites across Europe using a standardized 
questionnaire in a face-to-face interview setting. To 
further strengthen our method, we incorporated a 
preliminary power calculation based on results from 
a similar previous study. To the best of our knowledge, 
there have been six published studies to have investigated 
risk factors for PNEN. Due to the low incidence of such 
tumors, which would make a longitudinal cohort study 
highly problematic, it is not unexpected that these were 
all case–control studies. Three were conducted in the USA, 
one in Europe and two in China (Hassan  et  al. 2008a,b 
Capurso et al. 2009, Zhan et al. 2013, Halfdanarson et al. 
2014, Ben et al. 2016). Collective analysis of these studies 
has been limited by the various data collection methods 
employed, the selection of investigated exposures 
(and differing definitions), in addition to the disparate 
population pools, all of which lead to substantial 
heterogeneity (Haugvik et al. 2015). One study from China 
exclusively investigated a cohort of insulinomas, with 
the exclusion of non-functioning endocrine tumors; the 
latter represent the majority of PNEN cases, accounting 
for 60 to 90% of cases (Falconi  et  al. 2016). Another 
study from China investigated a cohort of PNEN cases in 
which 63% had functioning tumors, and 84% had early-
stage disease (Ben  et  al. 2016). The results of this study 
may have limited applicability to other populations, as 
the majority of PNENs arising in Western populations are 
non-functioning and would typically present with more 
advanced disease (Panzuto et al. 2011).
The two publications from the USA reported different 
risk factors in the same population, from a retrospective 
analysis of a large hospital database of NETs (Hassan et al. 
2008a,b). None of the reported studies sought to investigate 
potentially protective factors against the occurrence of 
PNENs. Two meta-analyses have summarized the results 
of the previous primary studies and reached similar 
conclusions: Diabetes mellitus and family history of 
cancer are risk factors for the occurrence of PNENs, 
while the role of environmental factors was unclear and 
warranted further investigation (Haugvik  et  al. 2015, 
Leoncini et al. 2016).
Our study affirms an increased risk of PNEN occurrence 
with diabetes mellitus; however, it is noteworthy that we 
identify the significance of non-recent onset diabetes 
as a risk factor. Four studies previously identified an 
association between PNEN and diabetes (Hassan  et  al. 
2008b, Capurso  et  al. 2009, Halfdanarson  et  al. 2014, 
Table 4 Factors associated with TNM stage and tumor grade in PNEN patients.
 TNM Stage 1–2 N (%) TNM Stage 3–4 N (%) P value OR (95% CI)
Late-onset diabetes (≥1 year) 12 (11.8) 21 (23.3) 0.05 1.98 (0.83–4.74)
Coffee drinking 96 (92.3) 66 (75.9) 0.003 0.14 (0.05–0.4)
 G1–G2 N (%) G3 N (%) P value OR (95% CI)
Diabetes 28 (15.8) 9 (40.9) 0.01 4.28 (1.41–12.93)
Late-onset diabetes (≥1 year) 26 (14.9) 9 (40.9) 0.006 5.43 (1.66–17.72)
Metformin plus insulin use 5 (3.2) 4 (23.5) 0.003 9.71 (1.86–50.74)
Allergic factors    
 Asthma 18 (10.2) 6 (30.0) 0.02 3.96 (1.91–13.21)
 Eczema 17 (9.6) 5 (25.0) 0.08 3.06 (0.92–10.19)
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Ben  et  al. 2016); however, in contrast to the current 
study, this association was for recent onset diabetes, 
which can represent an epiphenomenon of the disease 
as suggested elsewhere for pancreatic adenocarcinoma 
(Pannala et al. 2008).
Given that beta cells typically express low levels 
of cytoprotective antioxidant enzymes (Tiedge  et  al. 
1997) and because oxidative stress contributes to both 
the pathogenesis of diabetes (Rolo & Palmeira 2006) 
and can potentiate somatic mutations, it would not 
be unexpected for long-standing diabetes to have an 
association with oncogenic transformation of islet cells. 
Indeed, PNEN proliferation, tumor invasion and disease 
stage have been found to be associated with expression 
of mTOR (mechanistic/mammalian target of rapamycin) 
and its effectors (Capurso  et  al. 2015), a cytoplasmic 
kinase that is activated by both glucose and insulin 
(Blagosklonny 2013).
As the relation between diabetes and carcinogenesis 
is complex and still not clear, we sought to specifically 
investigate the timing of onset of diabetes in respect to the 
clinical presentation of the cancer. We therefore analyzed 
risk factors present at least 12 months before diagnosis, 
minimizing the overlap between risk factors and cancer-
related symptoms, which could include cancer-induced 
endocrine insufficiency. With such premises, our results 
support the view that long-standing diabetes is a risk 
factor for PNEN rather than sign of disease. In order to 
further analyze possible overlaps between diabetes as a 
risk factors and diabetes as a cancer-related symptom, 
we performed a further sensitivity analysis, investigating 
several different intervals of time between the onset of 
diabetes and the diagnosis of cancer. Non-recent onset 
diabetes was confirmed to be increasingly consistent with 
the occurrence of PNEN for intervals superior to 1 year and 
up to 5 years. For intervals of onset of diabetes superior 
to 5 years, this association was not anymore statistically 
significant. This might be interpreted on the base of a lack 
of power of the study when considering small subgroups 
or, alternatively, it could be biologically explained by the 
trophic influence that diabetes plays on cancer. On the 
other hand, one should also take into account that PNEN 
displays a slower growing rate compared to PDAC, and 
therefore it might justify a major latency of occurrence of 
symptom diabetes.
As the potential role of anti-diabetic drugs (metformin 
and insulin) in influencing pancreatic carcinogenesis has 
been reported (De Souza et al. 2016), we also specifically 
investigated the role of such drugs in our multinational 
cohort. Although the prevalent use of insulin alone 
was more frequent among cases than in controls 
(4.1% vs 1.6%), this difference was not significant as the 
study was underpowered to assess it.
Another noteworthy finding of the present study 
was the increased proportion of gallstone disease among 
PNEN cases compared to controls. However, this did not 
reach statistical significance, and we therefore cannot 
conclude that this was anything more than a chance 
observation. The apparent proportional increase among 
cases, however, may reflect the universal use of abdominal 
imaging in those diagnosed with PNEN, as compared to 
occult gallstones in controls. It may be that our study 
was underpowered to detect a true association between 
PNEN and biliary calculi, as the latter have been found to 
be associated with ‘malignant neoplasm of the pancreas’ 
(ICD-Oncology C25.0–C25.9) as a single entity, using a 
large combined US cancer registry with population-based 
controls (Nogueira et al. 2014).
In the present study, the rate of family history of 
cancer was not different between cases and controls. 
This finding was in contrast with previous studies on this 
topic. However, study design issues and/or selection bias 
in previous studies may account for this difference. For 
example, three of these reports (Hassan  et  al. 2008a,b, 
Zhan et al. 2013) did not exclude PNEN cases with genetic 
syndromes (i.e. MEN1 or VHL). Of particular note, 25% 
of PNEN cases had a genetic syndrome in the study by 
Zhan and coworkers, and therefore a higher proportion 
of family history of any cancer would be expected 
(Zhan  et  al. 2013). Halfdanarson and coworkers studied 
only sporadic cases, but excluded insulinomas and poorly 
differenced PNECs which may have affected results in this 
regard (Halfdanarson  et  al. 2014). In the present study, 
controls had a significantly higher number of siblings 
compared with cases, potentially biasing the probability 
of cancer family history in the control study arm. On the 
other hand, we found an association between 2nd degree 
family history of cancer and risk of PNEN, thus suggesting 
that some kind of hereditary component might exist in 
these patients.
Environmental factors such as smoking and 
alcohol, even in high doses, did not increase the risk of 
developing a PNEN in our study. This result is in keeping 
with the study by Hassan and coworkers (Hassan  et  al. 
2008b) but in contrast with others (Capurso 2009, 
Halfdanarson et al. 2014, Zhan et al. 2013). A recent meta-
analysis highlighted that the role of smoking and alcohol 
might be less relevant in PNENs than in pancreatic 
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adenocarcinoma (Haugvik  et  al. 2015). To explore 
potential environmental factors that might alter the risk 
of PNEN occurrence, we investigated for the first time a 
number of factors associated with a lower incidence of 
pancreatic adenocarcinoma, such as the use of aspirin and 
a personal history of allergies. No statistically significant 
differences were detected, possibly reflecting intrinsic 
biological differences between endocrine and exocrine 
neoplasia of the pancreas. Furthermore, as the power 
of the present study was based on risk factors for which 
there were previous data, and this was not the case for 
previously uninvestigated exposures, a type II error may 
have occurred.
Finally, we investigated the possible prognostic 
relevance of the investigated factors, analyzing their 
distribution in PNEN patients according to their stage 
of disease at diagnosis (TNM stages III or IV compared 
with I and II) or with their grade assessed by proliferative 
activity (G1 and G2 compared to G3). Interestingly, the 
prevalence of non-recent onset diabetes was higher both 
in cases with metastatic disease (TNM stage III–IV) and 
advanced grade (G3) at the time of diagnosis (Table  4). 
Drinking coffee was more frequent in cases with localized 
disease at diagnosis. The use of metformin in combination 
with insulin was also associated with a more aggressive 
phenotype. Therefore, diabetes and use of insulin might 
also exert a proliferative effect on tumor progression, as 
reported for other cancer types (Vigneri et al. 2016).
The present study displays several strengths as well as 
limitations. The strengths of the study are represented by 
the relatively large sample size keeping in mind the low 
incidence of this tumor type, the European multicenter 
setting (6 countries involved), the preliminary power 
calculation, the investigation for the first time of a large 
set of factors possibly associated with the risk of PNENs 
and the conduct of the study by face-to-face interview 
with a standardized questionnaire. The inclusion criteria 
were clearly defined: controls were well matched for 
age and gender with a 1:3 ratio, and all questionnaires 
were administered by trained medical doctors fluent in 
the local language, who evaluated exposures present 
12  months before diagnosis, to minimize bias due to 
cancer symptoms. Inherent with a multinational case-
control design, our study displays some limitations such 
as potential recall bias and heterogeneity in data from 
different countries, although the analysis was corrected 
for centere of enrollment. Furthermore, the analysis might 
have been underpowered for some of the investigated 
factors, and additional studies might be important to 
confirm the lack of significant association.
Another important matter of concern, as for any 
case-control study, regards the choice of the control 
population. We opted for a mixed control group that 
we believed to represent the same population as the 
case group, as living in the same catchment area of the 
corresponding cases, to limit possible bias that could 
have been specific of either hospital controls or visitors. 
Interestingly, ‘late onset diabetes’ seemed to be associated 
with an increased risk of PNEN with both kind of controls 
used in separate analyses.
In conclusion, the findings of this large multicenter 
case-control study suggest that non-recent onset diabetes 
was associated with an increased risk of PNENs occurrence. 
Our results do not support the view of a strict similarity with 
factors affecting the risk of pancreatic adenocarcinoma.
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Exclusive and Combined Use of 
Statins and Aspirin and the Risk of 
Pancreatic Cancer: a Case-Control 
Study
Livia Archibugi1, Matteo Piciucchi1, Serena Stigliano1, Roberto Valente1, Giulia Zerboni1,  
Viola Barucca1, Michele Milella2, Patrick Maisonneuve3, Gianfranco Delle Fave1 &  
Gabriele Capurso1
Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma 
(PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential 
combined or confounding effect of the two at the same time. We aimed to investigate the association 
between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental 
factors, family and medical history were screened in a case-control study. PDAC cases were matched to 
controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95% confidence 
intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 
816 matched controls, overall statin (OR 0.61; 95%CI,0.43–0.88), but not aspirin use was associated to 
reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95%CI,0.32–0.80) and exclusive 
aspirin users (OR 0.64; 95%CI,0.40–1.01) had reduced PDAC risk. Concomitant statin and aspirin 
use did not further reduce the risk compared with statin use alone and no interaction was evident. 
Statin protective association was dose-dependent, and consistent in most subgroups, being stronger 
in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is 
associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related mortality1 and is estimated to 
become the 2nd within 20302. PDAC 5-year survival rate is only 6%1 as only 20% of patients are eligible for surgery3, 
and chemo/radiotherapy marginally improve survival in advanced disease4. Screening is advised only for high 
risk individuals in experimental settings5.
Prevention might, therefore, play a key role in terms of modifiable lifestyle risk factors such as smoking and/or 
alcohol drinking, overweight, obesity and diet6. Evidence regarding potential chemopreventive drugs for PDAC 
is instead limited.
Aspirin is a nonsteroidal anti-inflammatory drug (NSAID), irreversible inhibitor of the cyclooxygenase 1/2, 
widely prescribed for its anti-inflammatory, antipyretic, analgesic and anti-platelet activities. Its chemopreventive 
role is well recognized for many cancer types7 particularly colorectal cancer (CRC)8,9.
Preclinical studies demonstrated that aspirin has a role in inhibiting different signaling pathways involved 
in the carcinogenesis of several cancers including PDAC, such as mTOR, NFkB and Wnt, resulting in enhanced 
DNA mismatch repair mechanisms, apoptosis, angiogenesis and tumour progression inhibition10–12. However, its 
role in clinical studies on PDAC is less clear, and the most recent meta-analysis on cohort and case-control studies, 
showed an overall protective effect of aspirin with an odds ratio (OR) of 0.77, although with high heterogeneity13.
Statins are 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors commonly prescribed 
for the treatment of hypercholesterolemia and for cardiovascular primary and secondary prevention14. The meva-
lonate pathway involved in their action has a role on multiple signaling cascades such as Ras, MEK, mTOR, 
BCL-2 and Rho kinases15–17, that play role in carcinogenesis and tumour progression. Statin antineoplastic effect 
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is also related with an immunomodulatory and anti-inflammatory activity and with angiogenesis inhibition18,19. 
Their clinical role as chemopreventive agents is still controversial, although a few meta-analyses showed a risk 
reduction associated with their use, mostly for gastrointestinal tract tumours20–22. The latest meta-analysis on 
the association between statin use and PDAC risk showed no pooled effect23. However, since then, other large 
case-control studies were published24,25, recording a reduced PDAC risk associated with statin use.
As aspirin and statins are often co-prescribed, mostly for cardiovascular disease prevention or treatment, one 
might hypothesize that in studies investigating aspirin, at least a part of the observed effect might be due to the 
use of statins and vice versa. An investigation on the use of both these drugs, alone and in combination, has been 
conducted by Hoffmeister et al. in a case-control study on CRC. The authors reported a stronger risk reduction 
for statin exclusive use than for that of aspirin, while the combination of the two drugs did not further increase 
the effect of statins, unless for prolonged uses26.
As studies on the possible chemopreventive activity of both aspirin and statins on PDAC gathered heterogene-
ous results, the analysis of their potential combined or confounding effect in this tumour type seems particularly 
important. However, there are no studies examining the association of both these two drugs at the same time with 
PDAC risk.
Therefore, the primary aim of the study was to examine the association between overall and exclusive aspirin 
and statin use and their combined use with the risk of PDAC. In addition, we conducted subanalyses to explore 
whether the association was stronger in specific subgroups.
Materials and Methods
Study design and population. A single-center case-control study was conducted from January 2006 to 
February 2016. Patients enrolled in either group provided written informed consent for interviews. The study 
received local IRB approval at Sant’Andrea Hospital. Methods were performed in accordance with the relevant 
guidelines and regulations.
Incident cases were prospectively recruited at the gastroenterology department and had PDAC histological 
diagnosis. Controls consisted of hospital non-patient visitors not genetically related to cases, as well as outpa-
tients and inpatients from the gastroenterology department. Both cases and controls demonstrated the will and 
ability to participate providing personal data, clinical and cancer history. Exclusion criteria for controls in order 
to reduce the risk of recruitment bias were: (a) personal history of inflammatory bowel disease, chronic kidney 
disease or liver cirrhosis, (b) referral to our center for family history (FH) of gastrointestinal cancer, (c) referral 
to our center or hospitalization for NSAID-induced ulcer disease, (d) personal history of neoplasia in the last 5 
years.
We used a frequency matching oversampling controls with a 2:1 ratio. For each case enrolled, the first two 
eligible controls of the same sex and age (±2 years) were enrolled and interviewed within 30 days.
Data collection and exposure definition. Data were recorded on a standardized form by a trained phy-
sician through direct patient interview; no proxies were interviewed.
The following clinical, epidemiological, therapeutic and morphological parameters were collected: sex, age, 
race, tobacco and alcohol intake, body mass index (BMI), FH of cancer, previous pancreatic diseases, history of 
diabetes, aspirin and statin use, length, type and dosage of their use. During the interview, a list of brand and 
generic medication names for aspirin and statins was provided to help facilitate recall. All cases were interviewed 
within 1 month from diagnosis and data pertaining the disease were also recorded.
For ever smokers, a consumption of at least 100 cigarettes or >6 months of smoking were needed to be consid-
ered a smoker. The total amount of smoking was evaluated as pack-years, defined as the product of packs smoked 
per day and the total years of smoking. A cut-off of 20 pack-years was set to define heavy smokers. Current 
smokers were considered as smokers who were currently smoking or who had quit less than 1 year in the past. 
Ex-smokers were classified as smokers who had quit at least 1 year before the diagnosis of the disease, or its first 
presentation symptom for cases, or the time of interview for controls.
For ever drinkers, a consumption of at least 12.5 g (1 unit) of alcohol/month was needed to be considered a 
drinker. One glass of wine, 1 pint or can of beer, one shot of hard liquor were each considered approximatively 
equal to 12.5 g of alcohol. A cut-off of 21 units/week (262.5 g of alcohol) was set to define heavy drinkers.
This cut-off was used because in a meta-analysis of 156 studies, drinking was reported as a risk factor for many 
cancers at a dose of both 25 and 50 g/day, and population studies in Italy suggest that 94% of subjects report either 
being teetotallers or consuming ≤4 alcoholic drinks daily27,28.
BMI was calculated as usual adult weight/height2 (kg/m2) with obesity considered as BMI >30 kg/m2. Diabetes 
was recorded as a potential risk factor when diagnosed >1 year before the diagnosis of cancer or its first symp-
toms for cases or before the interview for controls.
Aspirin or statin use was defined as the ever use of the medication for at least three consecutive months.
Aspirin users were categorized in “high dosage users” (≥300 mg) and “low dosage users” (≤160 mg)29. Statin 
users were categorized in “low-dosage users” (<20 mg) and “moderate/high dosage users” (≥20 mg) based on 
median value.
Aspirin or statin users were categorized into different length of duration (<60 months and ≥60 months for 
aspirin, <48 months and ≥48 months for statins) based on median value.
To avoid possible bias due to cancer symptoms (i.e., weight loss, etc.) or subsequent cancer therapies, subjects 
were asked about risk factors that were present 12 months before diagnosis or presentation symptoms.
Statistical analysis. A power calculation was performed ahead: considering an exposure of ~20% for aspirin 
or statins as previously recorded in 200 controls, to have a 80% power of identifying an odds ratio (OR) ≤ 0.62 as 
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single effect of aspirin or statins, 395 cases and 790 controls were needed. This number would also allow to detect 
an OR ≤ 0.50 for the combined used of aspirin and statins, based on a 10% combined exposure among controls.
A descriptive analysis was conducted to show the characteristics of PDAC patients at time of diagnosis. 
Case-control comparisons were made using Chi-square and Fisher’s exact tests where appropriate, for categorical 
variables and Student’s t-test for continuous variables.
Logistic regression was used to calculate ORs and their 95% confidence intervals (CI). Multivariable logistic 
regression models were adjusted for potential confounders: age at diagnosis (for cases) or interview (for controls) 
(5-year age groups), gender, BMI, smoking history, drinking habits, diabetes history, chronic pancreatitis history, 
FH of PDAC.
All statistical analysis were performed using MedCalc version 13 (MedCalc Software, Belgium). All reported 
P values are 2-sided. P values < 0.05 were considered statistically significant.
The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist for 
case-control studies was checked for items that should be included in the report.
Results
Of 421 PDAC cases seen at the Gastroenterology Department during the study period, 9 (2.1%; 4 males and 
5 females, mean age 74) were not histologically confirmed. Of the remaining 412, 2 (0.5%) refused to partici-
pate and 2 (0.5%) were too ill to take part; of the 893 controls recruited in the same timeframe, 51 (5.7%) were 
excluded for matching exclusion criteria, 8 (0.9%) refused to be interviewed for privacy concerns, 18 (2.0%) were 
too ill to take part. This led to a participation rate of 99% for cases and 91% for controls; the analysis was therefore 
conducted on a final population of 408 cases and 816 matched controls. Respectively 48.7%, 13.4% and 37.9% of 
the controls, consisted of visitors, inpatients and outpatients. Most of the inpatients were hospitalized for divertic-
ulitis or gastrointestinal infections; outpatients were visiting for either gastro-esophageal reflux disease, irritable 
bowel syndrome, chronic constipation or dyspepsia.
The median age of cases and matched controls was 68 years (range 35 to 99); 51.2% were men.
Almost all cases and controls were Caucasians.
Risk factors for pancreatic cancer. Compared with controls, cases had higher mean BMI value, higher 
proportion of obesity, 1st degree FH of PDAC, previous history of diabetes, previous chronic pancreatitis, and 
were more frequently smokers, heavy smokers and heavy drinkers (see Table 1).
Overall use of aspirin and statins and risk of pancreatic cancer. Seventy-eight cases (19.1%) and 
191 controls (23.4%) reported ever use of aspirin, which was associated with a statistically borderline significant 
reduced PDAC risk (age- and sex-adjusted OR, 0.74; 95% CI, 0.54–1.02; Table 2). Only 2 of the 78 cases and 5 of 
the 191 controls (0.5% of both cases and controls) were on high-dose aspirin. The median duration of aspirin use 
Figure 1. Subgroup analysis of the association between the exclusive use of either statins or aspirin and 
pancreatic cancer risk. Subgroup estimates are adjusted for age, sex, body mass index, first degree family history 
of pancreatic cancer, history of diabetes >1 year and smoking habit. OR: Odds Ratio, CI: Confidence Interval.
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was 60 months for both cases and controls, with 20 patients (4.9%) among cases and 33 patients (4.0%) among 
controls not recalling the exact duration of use. A borderline significant protective association was recorded for 
shorter duration of exposure.
Seventy-four cases (18.1%) and 203 controls (24.9%) reported ever use of statins, which was associated with a 
statistically significant reduced PDAC risk (age- and sex-adjusted OR, 0.64; 95% CI, 0.48–0.88; Table 2). The median 
dosage of statins was 20 mg and the median duration of use was 48 months for both cases and controls. A higher dos-
age of statins (for ≥20 mg, OR, 0.43; 95% CI, 0.27–0.71) was associated with a stronger protective effect. The most 
commonly used statin was atorvastatin. Of the 74 cases and the 203 controls, respectively 11 (2.7%) and 46 (5.6%) 
could not recall the type of drug, 38 (9.3%) and 69 (8.5%) could not recall the dosage, and 27 (6.6%) and 48 (5.9%) 
could not recall the duration of use.
At multivariable analysis, statins (OR 0.61; 95% CI, 0.43–0.88) but not aspirin (OR, 0.77; 95% CI, 0.53–1.11) 
use was associated to a reduced PDAC risk (Table 2). OR and 95% CI for all other risk factors for this first multi-
variable analysis model are reported in Supplementary Table 1.
In order to avoid possible bias due to controls selection, a sensitive analysis for control type (visitors or hospi-
tal patients) was performed. At multivariable analysis, statin use was associated to a reduced risk of PDAC both 
with sensitive analysis restricted to visitors (OR 0.60; 95% CI, 0.40–0.89) or to hospital controls (OR 0.59; 95% 
CI 0.40–0.87), while the use of aspirin was not associated to PDAC risk for either visitors (OR, 0.82; 95% CI, 
0.55–1.23) nor hospital controls (OR 0.67; 95% CI 0.45–1.01).
Exclusive and Combined use of Aspirin and Statins and risk of pancreatic cancer. In order to 
evaluate the exclusive or combined effect of the two drugs and avoid possible confounding effects, we analyzed 
the use of aspirin excluding patients reporting also the use of statins and vice versa (Table 3). An exclusive aspirin 
use was recorded in 39 (9.6%) of all cases and 95 (11.6%) of all controls, and an exclusive statin use was recorded 
in 35 (8.6%) of cases and 107 (13.1%) of controls. In an age- and sex- adjusted analysis the exclusive use of statins 
was associated with a stronger risk reduction (OR, 0.54; 95% CI, 0.36–0.82) than the exclusive use of aspirin 
(OR, 0.67; 95% CI, 0.45–1.02). The concomitant use of statins and aspirin was reported in 39 cases (9.6%) and 96 
controls (11.8%). This combined use did not further reduce the risk (OR, 0.67; 95% CI, 0.44–1.01) compared with 
the use of statins alone.
At multivariable analysis adjusted for other potential confounding factors, statin use (OR, 0.51; 95% CI, 0.32–
0.80) was associated to a reduced risk of PDAC occurrence, while the association for aspirin use was of borderline 
significance (OR, 0.64; 95% CI, 0.40–1.01). Also at multivariable analysis the combined use of the two drugs did no 
further reduce the risk compared to the use of statins alone (OR, 0.54; 95% CI, 0.34–0.87). We found no evidence 
Cases (408)
Controls 
(816)
Age and sex adjusted1 
OR (95% CI) P value
Multivariable analysis2 
OR (95% CI) P value
Age 68.1 ± 11.6 67.9 ± 11.9 1.00 (0.99–1.01) 0.67 1.00 (0.99–1.02) 0.48
Male gender 209 (51.2%) 418 (51.2%) 1.00 (0.79–1.27) 0.99 0.77 (0.54–1.10) 0.16
1st degree FH of any cancer 218 (53.4%) 403 (49.4%) 1.22 (0.95–1.57) 0.12 —
2nd degree FH of any cancer 30 (7.4%) 54 (6.6%) 1.29 (0.79–2.11) 0.31 —
1st degree FH of PDAC 32 (7.8%) 23 (2.8%) 3.02 (1.73–5.26) 0.0001 3.26 (1.79–5.92) 0.0001
2nd degree FH of PDAC 5 (1.2%) 6 (0.7%) 1.83 (0.55–6.09) 0.33 2.17 (0.59–7.97) 0.24
BMI (mean ± Std.dev.) 26.8 ± 4.9 25.9 ± 4.1 1.05 (1.02–1.08) 0.001 1.04 (1.01–1.08) 0.009
BMI >30 79 (19.4%) 120 (14.7%) 1.47 (1.07–2.02) 0.02 —
History of diabetes 72 (17.6%) 79 (9.7%) 2.03 (1.43–2.88) <0.0001 1.84 (1.25–2.71) 0.002
Chronic pancreatitis 15 (3.7%) 2 (0.2%) 15.9 (3.60–70.0) <0.0001 14.7 (3.18–67.6) 0.0006
Cigarette smoking3
  Never smoker 155 (38.0%) 416 (51.0%) 1.00 1.00
  Ever smoker 253 (62.0%) 400 (49.0%) 1.80 (1.39–2.32) <0.0001 —
  <20 Pack-years 75 (18.4%) 171 (21.0%) 1.24 (0.89–1.74) 0.21 1.27 (0.88–1.84) 0.19
  ≥20 Pack-years 153 (37.5%) 229 (28.1%) 1.92 (1.43–2.57) 0.0001 1.93 (1.40–2.66) <0.0001
Alcohol drinking4,5
  Never drinker 203 (49.8%) 446 (54.7%) 1.00 1.00
  Ever drinker 173 (42.4%) 370 (45.3%) 0.99 (0.77–1.29) 0.96 —
  <21 alcohol units/week 116 (28.4%) 312 (38.2%) 0.81 (0.61–1.07) 0.14 0.90 (0.66–1.21) 0.47
  ≥21 alcohol units/week 49 (12.0%) 57 (7.0%) 1.81 (1.17–2.80) 0.008 1.55 (0.96–2.49) 0.07
Table 1. Characteristics of pancreatic cancer cases and controls by selected variables of family history, chronic 
conditions, and lifestyle. FH: Family History, PDAC: Pancreatic Ductal AdenoCarcinoma, BMI: Body Mass 
Index, OR: Odds Ratio, CI: Confidence Intervals. 1Odds Ratios adjusted for age (5-year age groups) and gender. 
2Odds ratios adjusted for age (5-year age groups), sex, body mass index (continuous scale), family history of 
pancreatic cancer (first and second degree relatives), history of chronic pancreatitis, history of diabetes >1 year, 
smoking and drinking habits. 3Exact amount and duration not recalled by 25 (6.1%) cases and 0 controls. 4Exact 
amount and duration not recalled by 32 (7.8%) cases and 0 controls. 5Unknown units/week for 8 (2.0%) cases 
and 1 (0.1%) control.
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of interaction between statin and aspirin (P = 0.17), when adding an interaction term to the main effects of aspirin 
and statin in a multivariable model adjusted for other potential confounding variables (Supplementary Table 2).
Association between use of aspirin and statins and risk of pancreatic cancer in subgroups. To 
evaluate a potential specific association between aspirin and statin use and the risk of PDAC among different sub-
groups, separate multivariable subgroup analyses were conducted for the exclusive use of the two drugs according 
to: gender, smoking habit, obesity, history of diabetes and age ≥ or <70 years. Results are shown in Fig. 1.
Discussion
This is the first study evaluating the possible association between overall, exclusive and combined use of both 
aspirin and statins and PDAC risk at the same time. This is a relevant issue, as both drugs together are very fre-
quently prescribed in elderlies for cardiovascular prevention and treatment30.
Therefore, one might hypothesize that both a confounding effect, for which only one of the two co-prescribed 
drugs is protective, or a synergistic effect, for which the activity of the combination of the two drugs is superior to 
their exclusive use, might occur.
In the present study, PDAC risk is inversely associated with the overall statin use, with a dosage-dependent 
effect. The overall aspirin use is not associated to a statistically significant reduced PDAC risk at multivariable 
Cases (408) Controls (816)
Age and sex adjusted1 
OR (95% CI) P value
Multivariable analysis2 
OR (95% CI) P value
Aspirin use3,4
Never 330 (80.9%) 625 (76.6%) 1.00
Ever 78 (19.1%) 191 (23.4%) 0.74 (0.54–1.02) 0.06 0.77 (0.53–1.11) 0.16
Low-dose (≤160 mg) 68 (16.7%) 154 (18.9%) 0.80 (0.58–1.12) 0.20
High-dose (≥300 mg) 2 (0.5%) 5 (0.6%) 0.72 (0.14–3.76) 0.70
<60 months 25 (6.1%) 73 (9.0%) 0.62 (0.38–1.01) 0.05
≥60 months 33 (8.1%) 85 (10.4%) 0.70 (0.45–1.09) 0.11
Statin use5–7
Never 334 (81.9%) 613 (75.1%) 1.00
Ever 74 (18.1%) 203 (24.9%) 0.64 (0.48–0.88) 0.005 0.61 (0.43–0.88) 0.007
Atorvastatin 29 (7.1%) 85 (10.4%) 0.60 (0.38–0.94) 0.03
Simvastatin 23 (5.6%) 45 (5.5%) 0.92 (0.54–1.56) 0.76
Other forms* 11 (2.7%) 27 (3.3%) 0.72 (0.35–1.48) 0.37
<20 mg 14 (3.4%) 44 (5.4%) 0.56 (0.30–1.05) 0.07
≥20 mg 22 (5.4%) 90 (11.0%) 0.43 (0.27–0.71) 0.0008
<48 months 25 (6.1%) 84 (10.3%) 0.53 (0.33–0.84) 0.008
≥48 months 22 (5.4%) 71 (8.7%) 0.55 (0.33–0.90) 0.02
Table 2. Overall aspirin and statin use among pancreatic cancer cases and controls. OR: Odds Ratio, CI: 
Confidence Interval. *Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin. 1Odds Ratios adjusted for age (5-year 
age groups) and gender. 2Odds ratios adjusted for age (5-year age groups), sex, body mass index (continuous 
scale), family history of pancreatic cancer (first and second degree relatives), history of chronic pancreatitis, 
history of diabetes >1 year, smoking and drinking habits. 3Unknown dose for 8 (2%) cases and 32 (3.9%) 
controls. 4Unknown duration for 20 (4.9%) cases and 33 (4%) controls. 5Unknown type for 11 (2.7%) cases 
and 46 (5.6%) controls. 6Unknown dose for 38 (9.3%) cases and 69 (8.5%) controls. 7Unknown duration for 27 
(6.6%) cases and 48 (5.9%) controls.
Cases (408) Controls (816)
Age and sex adjusted1 
OR (95% CI) P value
Multivariable analysis2 
OR (95% CI) P value
Exclusive or combined use
Neither aspirin 
nor statins 295 (72.3%) 518 (63.5%) 1.00 1.00
Aspirin only 39 (9.6%) 95 (11.6%) 0.67 (0.45–1.02) 0.06 0.64 (0.40–1.01) 0.06
Statins only 35 (8.6%) 107 (13.1%) 0.54 (0.36–0.82) 0.004 0.51 (0.32–0.80) 0.004
Aspirin and 
Statins 39 (9.6%) 96 (11.8%) 0.67 (0.44–1.01) 0.06 0.54 (0.34–0.87) 0.01
Table 3. Exclusive and combined aspirin and statin use among pancreatic cancer cases and controls. OR: Odds 
Ratio, CI: Confidence Interval. 1Odds Ratios adjusted for age (5-year age groups) and gender. 2Odds ratios 
adjusted for age (5-year age groups), sex, body mass index (continuous scale), family history of pancreatic 
cancer (first and second degree relatives), history of chronic pancreatitis, history of diabetes >1 year, smoking 
and drinking habits.
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analysis (Table 2). Both exclusive aspirin and statin use were related to a reduced PDAC risk, with statin use show-
ing a risk reduction of 49%, higher than that of aspirin, which was only borderline statistically significant. The 
concomitant use of the two drugs was also associated to a 46% reduced PDAC risk, without conferring a stronger 
risk reduction compared to the use of statins alone, therefore we might speculate that the main protective effect 
of the combined use is due to statins. Furthermore, the analysis of interaction did not suggest a synergistic effect 
(Supplementary Table 2).
A protective association with the use of statins has been described mostly in case-control studies and not in 
cohort studies before. Two recent cohort31 and case-control studies32 evaluated the use of statins and the risk 
of PDAC. The first study on a female population adjusted the analysis for the use of aspirin and NSAIDs, and 
the second also analysed the use of aspirin, but both did not evaluate the association of the two drugs or their 
exclusive use. Two other large case-control studies24,25 evaluating the association between statin use and PDAC 
risk instead showed a risk reduction similar to that of the present study. However, in none of those previous 
publications, a priori power calculation was performed. Walker et al.24 reported a reduced PDAC risk in overall 
statin users with OR = 0.66 and, in a subgroup analysis only in men and mostly for prolonged use. Carey et al.25, 
described a reduced risk only in male smokers. However, in this latter study, OR were not adjusted for BMI and 
dosage and duration of drug use were not recorded. Compared to those previous studies, our results show a more 
consistent association between the exclusive use of statins and PDAC risk reduction, which was similar for both 
genders, but limited to smokers, elderly subjects, obese and non-diabetic patients (Fig. 1). Statins might exert a 
specific protective effect on cigarette-related carcinogenesis, as they have also been found to be protective against 
lung cancer33. Moreover, nicotine-mediated pancreatic carcinogenesis in animal models relies on the activation of 
AKT and ERK34, and statins have been reported to negatively regulate such signaling pathways in PDAC models 
and in other cancers35,36. The reasons for a more important protective effect of statins in non-diabetics are unclear. 
Chen et al., evaluated a cohort of diabetic patients, in whom statin use was associated to a reduced risk37. A more 
complex relation between statins and diabetes might be due to their pro-diabetogenic effect38. Moreover, although 
we considered only patients with a history of diabetes >1 year, in order to avoid PDAC causing, rather than being 
caused by diabetes, one cannot exclude that in some patients the onset of diabetes, although >1 year, might still 
be due to PDAC occurrence39.
As far as regards the more significant association between statin use and reduced PDAC risk in subjects aged ≥70 
years, this can be explained by the obvious increased PDAC risk in older subjects. Furthermore, an older age is 
usually associated to prolonged drug exposure.
There are many published studies on the preventive effect of aspirin on PDAC occurrence, with heterogeneous 
results7,40–42 but, to our knowledge, no significant results were reported for specific subgroups. In our study aspi-
rin was protective only in females and non-smokers. These results are in contrast with those of a previous large 
cohort study conducted on nurses by Schernhammer et al.41, where aspirin intake was a risk factor for PDAC, 
directly related to the number of tablets taken. The results of our multivariable analyses (Tables 2 and 3) and of 
the subgroup analysis for the exclusive use of the two drugs (Fig. 1), suggest an inconsistent effect of aspirin, pos-
sibly supporting the hypothesis that at least a part of the previously reported association between aspirin use and 
reduced PDAC risk is due to concomitant statin use.
However, as in our population there was a very low proportion of high-dosage aspirin users, we cannot 
exclude a stronger protective effect for higher dosages of aspirin, although in previous studies also low-dose 
aspirin showed protective effect40.
Among the different statin types, atorvastatin was the most frequently prescribed in the present study, and was 
associated to a reduced risk of PDAC. The chemopreventive effect of atorvastatin has already been described in 
in vivo studies35,43, while previous cohort or case-control studies showed heterogeneous results between different 
statins23,24,31. This could therefore be only due to atorvastatin being the most frequently prescribed type of statins.
The present study has some strengths: 1) it is the first specifically aimed at evaluating the association between 
overall, exclusive and combined use of both aspirin and statins and PDAC risk, as they both seem to have chemo-
preventive properties and are very often prescribed together; 2) it is one of the few studies on this topic with an a 
priori power calculation; 3) as expected, an increased PDAC risk for patients with multiple 1st degree FH of neo-
plasia, 1st degree FH of PDAC, increased BMI, previous history of diabetes, chronic pancreatitis, smoking habit 
was seen, suggesting the absence of biases and the genuineness of our population; 4) statin results are consistent 
with most Bradford Hill criteria for causation44 as the association is strong, a biological gradient is evident as 
higher dosages lower the risk and the association is plausible in terms of mechanisms and coherent with in vitro 
studies. A clear temporal relation was instead not evident. Of course, as this is a case-control study, causation of 
an effect cannot be observed and we can only report an association with risk, useful to generate hypotheses that 
need validation.
There are, however, some limitations. First, as for any case-control study, the risk of recall bias has to be taken 
into account, although when interviewed, patients were provided with a list of brand and dosages in order to 
reduce this risk. Furthermore, both the rate of non-participants and the rate of patients not recalling data about 
their drug use are similar among cases and controls. In order to reduce the risk of confounding factors, the ques-
tionnaire was carefully conducted by a trained physician with expertise on pancreatic disorders, asking informa-
tion regarding risk factors exposure as present 1 year before the interview. As in any case-control study the choice 
of the control population is a possible matter of concern. We opted for a control group that we believed to repre-
sent the same population as the case group, derived from the same catchment area, and being composed both of 
patients seen for similar symptoms by the same doctors in the same clinics but with a final diagnosis unrelated with 
the disease of interest, and by hospital non-patient visitors; this, therefore, was unlikely to cause a specific bias45. 
To explore the possibility of a potential selection bias among hospital controls, who might have been less likely to 
use aspirin being selected in a Gastroenterology setting, we performed a sensitivity analysis comparing the effect 
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of aspirin and statins in the two different control groups (visitors and hospital controls) separately with findings 
suggesting a consistent effect of statins but not of aspirin.
Furthermore, our control group seems to be representative of the general Italian population in terms of envi-
ronmental risk factors and exposure to the drugs of interest46,47 and to populations used for other case-control 
studies on PDAC48. Also, as the study was not powered for the exclusive use analyses or subgroup analysis, these 
results have to be taken carefully into account as they might not be conclusive. For example, in a post-hoc cal-
culation limited to the 653 smokers (253 cases and 400 controls), the statistical power of the study dropped to 
67% for detecting an OR = 0.62 (as per protocol) considering the actual aspirin exposure (26%) measured among 
control smokers.
Furthermore, one cannot exclude that the observed reduced PDAC risk associated with statin use and to a 
lesser extent of aspirin, is a surrogate for other uninvestigated factors such as a healthier lifestyle. At any rate, the 
current analyses were corrected for most known risk factors associated with PDAC risk (see Table 1), but residual 
confounding due to other factors such as diet, antioxidants use, physical activity or different indication for statin 
use cannot be excluded. Notably, a recent meta-analysis showed no association between serum cholesterol levels 
and PDAC risk49.
The biological mechanisms through which statins might prevent PDAC are not completely clarified. 
Interestingly, the importance of statins has been recently proved in retrospective studies also in terms of pro-
longing survival in operated PDAC patients50–52, suggesting again an effect of this class of drugs on this tumour. 
In this context, the development of randomized controlled trials investigating the effect of statins in an adjuvant 
setting, in patients undergoing resection for PDAC could prove interesting. Moreover, as the statistical power of 
such studies might be limited by the very low rate of survival of PDAC patients, further studies on the possible 
chemopreventive effect of statins in individuals with an increased risk of developing PDAC, such as patients with 
genetic syndromes at high risk of PDAC5, and patients diagnosed with pancreatic pre-neoplastic lesions such as 
Intraductal Papillary Mucinous Neoplasia (IPMNs)53 might be of interest.
In conclusion, the present study suggests that statin use, rather than that of aspirin, in particular at higher dos-
ages is associated to a reduced PDAC risk. These findings support a chemopreventive action of statins on PDAC 
and no apparent synergistic activity of the two medications.
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